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Abstract 
Arsenic is an environmental toxin which increases skin cancer risk for exposed 
populations worldwide, however the biomolecular mechanism is yet to be fully 
elucidated. Genomewide epigenetic repatterning occurs with arsenic exposure – a 
process which is associated with altered gene expression and activity of epigenetic 
regulators. Whether this mechanism is a direct, or indirect, consequence of arsenic 
toxicity, and whether dysregulated maintenance of the epigenetic landscape drives 
arsenic-induced cancer, are questions which remain unanswered. SIRT1 is a lysine 
deacetylase with a well-characterised role in mediating cellular adaptation to 
metabolic stress; in part, by regulating activation of the tumour suppressor p53, 
and also by maintaining patterns of gene expression by regulating the activity of 
chromatin remodelling complexes. SIRT1 is overexpressed in numerous cancer 
subtypes, therefore the primary hypothesis guiding this thesis was that aberrant 
SIRT1 activity mediates the epigenetic events which initiate and promote arsenic-
induced skin cancer. The overarching aim for this study was to characterise the 
response of SIRT1 and its targeting microRNA, miR-34a in cultured human 
keratinocytes when exposed to arsenic over an extended time frame.  
For the first part of this investigation, wild-type (primary) and p53-mutated (HaCaT) 
keratinocytes were used as an in vitro model to determine the role of the 
p53/SIRT1/miR-34a axis during cell death signalling. Using a SIRT1 siRNA targeting 
pool, and with a targeted SIRT1:miR-34a binding site block, this study found that 
microRNA biogenesis and maturation is dysregulated in HaCaT keratinocytes, 
causing overexpression of microRNA regulatory targets. Consequently, inhibition of 
the miR-34a target, SIRT1, was effective in overcoming apoptotic resistance in the 
HaCaT cell line by restoring p53 transcriptional activation. 
Second, the role of SIRT1 in arsenic-induced transformation of cultured 
keratinocytes was determined by exposing primary keratinocytes to 0.5 µM 
arsenite in culture medium for 10 weeks. By analysing these cells for changes in 
gene expression, chromatin condensation and DNA methylation, this investigation 
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determined that arsenic-induced acetylation of H4K16 in keratinocytes was 
associated with remodelling of the pri-miR-34a promoter and up-regulation of miR-
34a expression, which was sustained by DNA hypomethylation with extended 
arsenic exposure. SIRT1 initially accumulated in arsenic-exposed cells, however this 
effect was transient, indicating that arsenic not only inhibits SIRT1 activity, but also 
down-regulates expression over time. Finally, although arsenic treated primary 
keratinocytes display epigenetic changes consistent with dysregulation of SIRT1 
activity and expression, these cells were unable to escape senescence during 
sustained exposure to arsenic in vitro.  
These data reveal that dysregulation of the p53/SIRT1/miR-34a axis contributes 
significantly to keratinocyte carcinogenesis by blocking efficient cell death 
signalling. Consequently, treatment of skin cancers may be enhanced by using SIRT1 
inhibitors as an adjuvant to pro-apoptotic chemotherapy. Although skin cancer-
inducing concentrations of arsenic altered epigenetic patterns of miR-34a gene 
regulation by interfering with SIRT1 activity and expression in cultured human 
keratinocytes, extended exposure was insufficient to induce transformation in the 
absence of a second hit such as those provided by characteristic UV-induced p53 
mutations. 
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1.1 CARCINOGENESIS 1.1.1 Skin Cancer in Australia 
Cancer incidence in Australia almost doubled between the years 1991 and 2009, 
with the greatest contributors being cancers of the prostate, bowel, breast and 
melanoma of the skin. For all cancers combined, age-standardised mortality 
decreased by 17% during this time frame, however prognosis is sub-type specific, as 
only small gains in 5-year survival have been achieved for mesothelioma, and 
cancers of the brain, pancreas and lung (1).  
Although basal and squamous cell carcinomas of the skin are the most frequently 
diagnosed cancers in Australia, incidence data from non-melanoma skin cancer 
(NMSC) is not included as part of the aforementioned analyses. Cancer diagnosis 
information is collected by law as part of the national cancer registry, however 
unlike all other cancers, basal and squamous cell carcinoma diagnoses are not 
notifiable under this system. Thus the health and economic burden of NMSC is 
frequently underrepresented in reports documenting cancer statistics and data 
trends over time. Although mortality from NMSC is comparatively low 
(~2.8/100,000 individuals), treatment is painful and disfiguring, and consequently 
represents a significant health burden (2). 
Despite concerted efforts to reduce the incidence of skin cancer by sun protective 
measures with public education programs (3), squamous cell carcinoma (SCC) and 
basal cell carcinoma (BCC) continue to be the most common cancer diagnoses (2), 
with approximately 2% of the Australian population affected by non-melanoma skin 
cancer (NMSC) (4). Although not as lethal as melanoma, the cost of treatment for 
NMSC is predicted to increase substantially (22% by the year 2015) – particularly for 
individuals over 70 - each year and therefore is anticipated to become a significant 
public health burden during this time frame (estimated at more than $700 million 
by 2015) (5).  
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For those diagnosed with premalignant lesions, recurrence rates are high (4). 
Surgical excision is the current gold standard management strategy for all intra-
epidermal keratinocyte dysplasias. As the majority of lesions occur in the head and 
neck area, treatment options are limited and commonly disfiguring (6), and 
therefore development of an effective chemopreventative strategy is an attractive 
prospect for health care practitioners and skin cancer patients. 
In order to reduce the disease burden due to non-melanoma skin cancer, both 
incidence and prognosis needs to be addressed. This can be achieved by reducing 
modifiable risk factors (behaviour- and lifestyle-related) and by developing more 
efficient targeted treatment regimes. 
1.1.2 Carcinogenic Transformation 
Carcinogenesis is a complex multistep process during which cells undergo 
progressive functional changes, progressing from initiation to a malignant 
phenotype which is capable of escaping its site of origin and populating alternative 
regions of the body. During this process, patterns of gene expression are disrupted 
as a result of altered signal transduction activity, epigenetic changes, and gene 
mutations (7-9). Two of the more critical stages in carcinogenic transformation are 
the ability to successfully adopt genetic changes acquired during initiation (7); and 
the ability to manifest phenotypic changes which promote metastatic dissemination 
(epithelial-mesenchymal transition) (10). The consequence of these changes is a 
shift to a cellular phenotype which bears the hallmarks of cancer – replicative 
immortality, sustained proliferative signalling, self-sufficient growth/abnormal 
responses to regulatory signals, apoptotic resistance, inflammation, angiogenesis, 
tissue invasion, and metastasis (11, 12). Recently, the search for novel biomarkers 
and therapeutic targets has led to an overhaul of these categories to include 
evasion of immune surveillance, disrupted cellular energetics, genomic instability 
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and mitogenic dysfunction as emerging and/or enabling characteristics of 
carcinogenesis (12-14).  
The tumour microenvironment has a unique role to play in providing a selective 
pressure which promotes growth and transformation of mutated cells (15). Driven 
by persistent exposure to endogenous and external stress, tumour cells are forced 
to adapt to chronic inflammation, replicative and mitotic stress, oxidative stress 
and/or hypoxia, metabolic and proteotoxic stress, and genetic instability (16)  
Many of these changes are facilitated by alterations to the epigenome, with 
epigenetic repatterning contributing to tumour cell heterogeneity and reinforcing 
the neoplastic phenotype by silencing tumour suppressors (17), increasing 
epithelial/mesenchymal plasticity and reducing chromosomal stability (18, 19). 
Additionally, impaired maintenance of epigenetic imprinting is associated with 
increased cancer risk (20). Epigenetic dysregulation in cancer is an important 
biomarker for tumour progression and therapeutic resistance, and will be discussed 
further later in this chapter.  
1.1.3 The DNA Damage Response 
The imperative to maintain genomic integrity has driven eukaryotic cells to develop 
a complex and integrated system for detecting and repairing lesions in its sequence. 
These lesions occur most frequently during cell division, as the unravelling of its 
secondary structure leaves DNA vulnerable to both endogenous replication errors 
and also to environmental insult.  
The cell reacts to inconsistencies in the DNA sequence by mounting a coordinated 
series of actions which facilitate repair of lesions in the genome by pausing 
replication and recruiting DNA repair complexes. Sustained genotoxic stress or 
irreparable damage triggers cell cycle arrest and stimulates proapoptotic cell death, 
preventing mutations from being perpetuated in daughter colonies (21, 22). As 
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such, the DNA damage response classically modulates the activity of four cellular 
processes – control of cell cycle transitions (checkpoints), gene regulation, DNA 
repair, and apoptosis (23, 24).  
The ability to detect, and to coordinate an effective response to DNA damage is 
considered to be an important barrier to carcinogenesis (23-28). Disrupted 
expression and/or function of intermediates in the DNA damage response are 
associated with many, if not all, cancers. Consequently, these regulatory 
components have pharmaceutical potential as antineoplastic targets. This review 
will focus on effectors of the DNA damage response, and in particular the DNA 
damage effector p53 and its role as a tumour suppressor. 
Figure 1:1 Acute Transient vs Chronic Adaptive Stress Signalling 
Acute DNA damage pauses the cell cycle at the G1 phase, stimulating DNA repair through the 
ATR/Nbs1/SMC1 pathway before resuming growth and division. Extended genotoxic damage arrests 
the cell cycle at the G2M phase and coactivates proapoptotic signaling via p53  
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Key: BRCA1/2: breast cancer susceptibility protein 1&2; 53BP1 – p53-binding protein 1; FANCD2: 
Fanconi anaemia protein 2; ATM: ataxia-telangiectasia-mutated protein; ATR: ATM and Rad3-related 
protein; Nbs1: Nijmegen Breakage Syndrome protein 1; Mdm2 – murine double minute protein 2; 
Chk1&2 – checkpoint kinases 1&2; SMC1: structural maintenance of chromosome 1; Cdc25: cell 
division cycle 25; CDK1-4 cyclin-dependent kinases 1-4; GADD45 – growth arrest and DNA damage-
inducible protein 45; G1 – growth phase 1; G2 – growth phase 2; S - synthesis; M - mitosis 
1.1.3.1 Effectors of the DNA Damage Response 
Effectors of the DNA damage response are transcription factors, DNA repair 
proteins, chromatin remodelling factors, cyclin-dependent kinases and the Cdc25 
family of phosphatases (29-32). Short-term damage pauses the cell cycle at the G1 
checkpoint by activating Cdc25A and Cdc25C signalling cascades and allowing DNA 
repair complexes to operate (33). With sustained DNA damage, p53-mediated 
transcriptional targets (p21, 14-3-3σ, GADD45α) are up-regulated, arresting 
proliferation by blocking the cell cycle at G1S and G2M phases and sensitising the 
cell to apoptotic signalling [Figure 1:1]. Although both mechanisms are interrelated, 
adaptive changes induced by p53-mediated responses are more commonly 
disrupted during neoplastic progression, culminating in apoptotic resistance and 
loss of cell cycle control (34). Consequently, activation and/or restoration of the 
DNA damage response is a key chemotherapeutic strategy for most cancers (35). 
1.1.4 Tumour Suppressor Protein p53 
The tumour suppressor p53 is a transcription factor which has a central role in 
mediating cellular responses to genotoxic stress and hyperproliferative signalling 
(36), leading to a functional reputation as the ‘guardian of the genome’.  
6 | 
Chapter 1 
Figure 1:2 p53-Mediated Stress Responses 
Nuclear accumulation of p53 increases transcription of downstream target genes – including cell 
cycle checkpoint regulators, DNA repair genes, cell death, and senescence genes (22, 23, 37, 38) 
Canonical p53 responses regulate a diverse range of cellular processes which inhibit 
the perpetuation of mutated genomic material and thus tumour growth by 
triggering cell cycle arrest, coordinating DNA repair, initiating differentiation or 
senescence, and inducing cell death signalling and apoptosis (35) [Figure 1:2].  
More recently, p53 activity has been implicated in wider spectrum of stress 
responses which contribute to tumour suppression, including oxidative stress, 
nutrient deprivation, hypoxia, ribonucleotide depletion, replicative stress and 
telomere attrition (39). Thus p53 transactivation is important for modulating 
additional cellular processes such as autophagy, metabolic reprogramming, 
invasion and metastasis, and regulation of stemness – all of which become impaired 
during tumorigenesis. 
1.1.4.1 Transactivation 
p53 has a sequence-specific DNA binding domain with a consensus double stranded 
DNA sequence consisting of two tandem copies of a decameric motif separated by a 
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0–13 bp spacer RRRC(A/T)\(T/A)GYYY, where R represents purines, and Y represents 
pyrimidines (40, 41). P53 binds its response element as a homotetramer, which 
induces transactivation of target genes by generating a conformational shift in their 
gene promoter (42). p53-targeting genes have a variety of recognition sequences 
which influence the affinity and kinetics of gene transactivation and consequently 
p53 produces a wide range of transcriptional responses (43). Binding sites that 
conform to the consensus sequence form a strong protein-DNA complex and rapid 
transcriptional activation, however p53 binding sites which deviate from the 
consensus with a TC/GA/TG/CA/GC/GG/CC/CG core or mismatches in the flanking 
triplet sequences produce transcriptional repression in their target genes (44, 45).  
1.1.4.2 Posttranslational Modifications 
The outcome of p53-dependent signalling is dependent on the quality and duration 
of the initiating stimulus (46, 47). Post-translational p53 modifications drive 
transcriptional activation by promoting conformational stabilisation, 
tetramerisation and nuclear translocation (36, 46, 48) [Figure 3]. Amongst these, 
modifications to p53 lysine residues (acetylation and methylation, in particular) 
extend the half-life of p53 protein by inhibiting MDM2 and Pirh2-mediated 
ubiquitinylation (49, 50), and promote DNA binding by enhancing the affinity of p53 
for its response element (51, 52).  
DNA damage transducers stabilise cellular p53 by interfering with p53-MDM2 
binding, after which the protein undergoes further posttranslational modifications 
which lead to both direct and indirect cellular actions (50). Activation of the DNA 
damage response pathway phosphorylates key serine residues (15, 20, 30 and 33) 
in the p53 activation domain (C-terminal regulatory domain) (37). Outcomes of p53 
targeting by DNA damage response mediators are further directed by acetylation 
and deacetylation of lysine residues in the DNA-binding domain, tetramerisation, 
and C-terminal regulatory domains (51, 53) [Figure 1:3]. 
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Figure 1:3 Posttranslational Regulatory Control of p53 
P53 activity is regulated via phosphorylation and acetylation by genotoxic stress response mediators (32, 54). Maintenance of basal p53 expression and activity is 
controlled by deacetylation and ubiquitin-mediated proteolytic breakdown (46, 47, 55), as well as methylation of lysine residues in the regulatory domain (56-58).  
Key: ATM - ataxia-telangiectasia-mutated protein; ATR - ATM and Rad3-related protein; Mdm2 - murine double minute protein 2; TAF1/ERK2 - extracellular signal-
regulated kinase 2; Chk1&2 - checkpoint kinases 1&2; CDK1/2 - cyclin-dependent kinases 1&2; DNA-PK – DNA protein kinase; JNK – c-Jun N terminal kinase; PKC – protein 
kinase C; CBP/p300 - CREB-binding protein; PCAF - CBP/p300-associated factor; TRAF - Tip60/MOF-associated factor; Tip60 - Tat interacting protein; SIRT1 - silent 
information regulator2 protein 1 
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Lysine acetylation is a posttranslational modification which plays a key regulatory 
role in cellular processes dependent on signal transduction and gene transcription. 
Proteins which target p53 lysine residues are ubiquitous and have substrates with 
multiple cellular functions, including chromosomal remodelling, cell cycle control, 
DNA damage and repair, cytoskeletal remodelling, RNA splicing/ribosomal activity 
and signal transduction (59, 60). Of these, p300/CREB-binding protein (CBP), hMOF, 
and TIP60 are well characterised lysine acetyltransferases (KACs), and target 
residues in the p53 C-terminal and DNA binding domains, increasing p53-mediated 
functional activity (61). Conversely, deacetylation of C-terminal residues by lysine 
deacetylases (KDACs) down-regulates p53 transactivation and suppresses p53-
mediated cellular responses, such as cell growth and apoptosis (55, 62). 
Posttranslational lysine acetylation provides an additional qualitative level of 
regulatory control over p53-mediated responses by introducing a spectrum of 
conformational states and DNA binding affinities. These enable p53 to be 
differentially directed to p53 target genes, and to generate a suite of physiological 
outcomes according to the residue(s) modified (54), and the initiating stimulus 
(63)[Figure 1:3]. Partial acetylation by KACs at lysine residues 164, 373 and 382 
promotes cellular survival by upregulating DNA repair enzymes and triggering cell 
cycle arrest (64-66). Further acetylation at lysine 120 alters the DNA binding 
characteristics of p53, switching the cellular outcome from survival to apoptosis 
(67). Modulation of p53 acetylation status, therefore, is considered to be critical to 
a cell’s capacity to cope with environmental toxicity whilst maintaining genomic 
integrity, and generates different outcomes (survival, differentiation, senescence or 
apoptosis) relating to the stressor of interest. 
1.1.4.3 TP53 Mutations in Cancer 
The p53-dependent DNA damage response is considered to be an important barrier 
to tumorigenesis (68), and functional loss of its intermediates is a feature of the 
neoplastic phenotype. Impaired p53 activity and expression is considered to be 
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necessary for the progression of all human malignancies and may occur via 
numerous routes. These include disturbances in upstream pathway regulation, 
increased MDM2 expression, or TP53 mutation (34). TP53 is mutated in ~ 50% of 
cancers with inactivating mutations to its core DNA-binding domain or with 
destabilizing mutations to its tetramerisation domain (69-72). Additionally, loss of 
heterozygosity in the TP53 gene may generate partial loss of function and genomic 
instability. Consequently, cancers with mutations to TP53 are frequently 
accompanied by the loss of the second allele as a result of p53 haploinsufficiency 
(73).  
Carcinogenic TP53 mutations generate a diverse range of alterations which affect 
p53 protein conformation, DNA binding affinity, tetramerisation, and protein-
protein interactions (69, 70). The physiological outcome of these mutations are to 
a) generate a gain or loss of function phenotype – both of which contribute to
tumorigenesis (74-78); and b) decrease genome-wide DNA stability and increase 
the rate of sporadic mutations (79). In cells with heterozygous p53 mutations, 
mutant p53 can have a dominant-negative effect on any non-mutated functional 
p53 within the cell by forming functionally inactive aggregates which inhibit DNA 
binding (80-82). Consequently, mutant forms of p53 contribute to tumour 
aggressiveness and resistance to chemotherapy (83).  
Pharmaceutical p53 activation is an emerging strategy for enhancing the efficacy of 
chemotherapy. This approach exploits p53-specific functional differences between 
cells with wild-type p53 and those with p53-inactivating mutations.  Early results 
from clinical trials indicate that a combinatorial approach is required for 
chemotherapy to effectively overcome p53 inactivating mutations  
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Table 1:1 p53-Mediated Therapeutic Approaches 
P53 Expression  Strategy/Description Drug 
Downregulated Recombinant p53 
Adenovirus 
Gendicine 
Advexin 
SCH 58500, SCH 529074 
 Nuclear Export 
Protein CRM1 
Inhibitors 
Leptomycin B, Leptomycin A, Kasuzamycins 
 MDM2 E3 Ligase 
Inhibitors 
HLI 198 series 
 Mdm2/MdmX 
Binding Blockers 
Nutlin 3a/RG 7112 
Benzodiazepines 
NSC 162908 [RITA] 
MI series of Spiro-oxindoles 
Quinolinols 
Inactive/ 
Partially active 
Conformation 
Restoration 
Peptide Inhibitors: C369-383; C61-382; CDB3 
  CDB3 (Molecular chaperone) 
  WR-1065, WR-2721 [amifostine] 
  PRIMA-1/PRIMAMET 
  MIRA-1 
  PhiKan083 
  CP-31398 
  Ellipticine, NSC 176327, 9-hydroxy-ellipticine [9HE] 
Gain of Function SIRT1 Inhibitors JJ78:12 series 
  Sirtinol 
  Tenovins 1 & 6 
[Taken from (84-90)]. 
 
Current strategies developed to overcome dominant-negative and gain-of-function 
effects of p53 include stimulation of p53 degradation pathways, siRNA-mediated 
ablation of mutant p53 protein, blocking co-association with effector proteins, and 
reactivation of mutant p53 by restoration of wild-type function (82, 91, 92)[Table 
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1:1]. Importantly, the efficacy of these approaches is highly variable because the 
dominant-negative effect of mutant p53 depends on its propensity to inactivate 
circulating wild-type p53, and this is directly related to the site of mutation (93, 94).  
Figure 1:4 p53-Based Cyclotherapy 
Pretreatment with a p53 activating drug halts the cell cycle in G1/G2 in normal cells carrying wild-
type p53, whereas p53-mutant cancer cells continue cycling into S and M phase. S-phase or M-phase 
chemotherapy then specifically targets p53-mutant cancer cells to induce apoptosis, whilst having 
no effect on cell cycle-arrested normal cells (95).  
Cyclotherapy is an alternative therapeutic strategy which exploits p53-based 
phenotypic differences in cancers expressing mutant p53. Cyclotherapy enhances 
the specificity of anti-mitotic chemotherapy by reducing toxicity in normal tissue 
and thereby improving chemotherapeutic dose tolerance for the patient. Here, the 
p53 activator treatment is optimised to induce a cytoprotective, but not cytotoxic, 
response. To achieve this, a pretreating dose of p53 activator is used to induce G1 
arrest in normal cells whilst leaving cancer cells with mutated p53 unaffected 
[Figure 1:4] (89, 95, 96). 
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For p53-directed chemotherapy to be successful, the strategy employed is 
specifically tailored to the phenotypic characteristics generated by the mutation. 
Traditional pharmaceutical techniques exploit the increased rate of replication as a 
way of targeting cancer cells. However, normal cells which are rapidly dividing are 
also susceptible to the toxic effects of mitotic poisons, and thus unpleasant side 
effects are commonly experienced by patients during chemotherapy. Additionally, 
treatments which target tumour cells during division can have off-target effects 
which can cause resistance and induce secondary mutagenic outcomes. Therefore 
alternative techniques which exploit cancer-cell specific differences in order to 
enhance the efficacy of traditional regimens and reduce the risk of resistance and 
recurrence are attractive foci in the field of cancer therapies. 
 1.2 EPIGENETICS 1.2.1 Processes and Mechanisms 
The human genome contains information which is encoded in the DNA sequence 
and is directly transferred to daughter cell lines during division, whereas the 
epigenome relates to the way cells express encoded genetic information and may, 
or may not, be heritable. Epigenetics is an overarching term which broadly 
encompasses DNA methylation, histone posttranslational modifications, chromatin 
remodelling, and the activity of small non-coding RNAs. The principal unifying tenet 
proposed by epigenetic regulation is that combinations of covalent modifications 
cause a structural rearrangement of chromosomal regions so as to register, signal 
or perpetuate altered activity states (97). As such, epigenetics describes 
information which is not directly encoded by the nucleotide sequence and which 
confers defined and gene-specific regulatory outcomes. These processes allows 
cells to respond and adapt to changes in their environment by altering the pattern 
of gene expression, and are now considered to have critical roles in both the 
prevention, and pathogenesis of disease (98). 
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1.2.1.1 DNA Methylation 
Human DNA is most commonly methylated by the activity of DNA 
methyltransferase enzymes, which catalyse the addition of a methyl group to the 5-
carbon of cytosines, particularly those within CpG dinucleotides. Imprinted genomic 
methylation patterns are established at the time of implantation by DNA 
methyltransferases 3a and 3b (DNMT3a & b) and maintained between parent to 
daughter cell lines by DNA methyltransferase 1 (DNMT1) during replication (99). 
CpG islands are genomic regions of ~ 0.2-1 kb rich in CpG dinucleotides. Of the 
~28,000 CpG islands in human haploid cells, approximately 40-50% span the 
promoter and first exon region of genes. In normal cells, the majority of CpG 
dinucleotides are methylated, whereas CpG islands are predominantly 
unmethylated with the exception of inactivated X chromosomes, imprinted genes, 
repetitive and transposable elements (100). These established methylation patterns 
are responsible for regulation of cell type-specific gene expression, and the 
methylation status of regions associated with CpG islands in gene promoters 
inversely correlates with gene expression (101). 
1.2.1.2 Histone Modifications and Chromatin Remodelling 
Nucleosomes form the core structural component of chromatin, each containing 
147bp of DNA wrapped around an octamer of the core histone proteins H3, H4, 
H2A and H2B. Basic residues within histone H4 tails interact with acidic patches on 
adjacent H2A histones, coiling nucleosomes into 1.67 left-handed superhelical turns 
(102). Nucleosomal coiling regulates the degree of chromatin condensation and 
influences gene transcription – looser packing (euchromatin) is associated with 
gene transcription, whereas tighter packing (heterochromatin) silences gene 
transcription (103).  
Modifications to histone N-terminal residues (phosphorylation, acetylation, 
methylation, sumoylation, ADP ribosylation, ubiquitination, deimination and proline 
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isomerisation) influence chromatin dynamics during metabolic processes such as 
DNA repair and replication, and regulate gene transcription by controlling 
accessibility of binding sites for transcription factors (104, 105)[Table 1:1].  
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Table 1:2 Functional Properties of Histone Posttranslational Modifications 
Histone Modification Residues Outcome Ref 
H3 Phosphorylation T3, T11, T32 Chromatin condensation 
S10, S28 Transcriptional activation (106) 
Acetylation K4, K9, K14, K18, K23, K27 Transcriptional activation (106, 107) 
K14, K18, K23, K56 DNA repair (108) 
Methylation K4, R17, K79 Transcriptional activation (109) 
K4 Maintenance of DNA methylation patterns (110) 
K4, K9, K27 Transcriptional repression (106, 109) 
H4 Phosphorylation S1  Chromatin condensation 
Acetylation K5, K8, K12, K16 Transcriptional activation (106) 
K5, K8, K12, K16 DNA repair (108) 
Deacetylation K16 Maintenance of telomeric chromatin (111) 
Methylation R3 Transcriptional activation (106) 
K20, K59 Transcriptional repression (108) 
H2A Phosphorylation S1, T119 Mitosis (112) 
S129, S139 DNA repair (108) 
Acetylation K4, K5, K7 Transcriptional activation (113) 
Ubiquitination K119 Mitotic & Meiotic Growth (108) 
K119 Transcriptional repression (106) 
H2B Phosphorylation S14 Chromatin condensation, apoptosis (113) 
S33 Transcriptional activation 
Acetylation K5, K11, K12, K15, K16, K20 Transcriptional activation (109, 113) 
Ubiquitination K123 Mitotic & Meiotic Growth (108) 
K120 Transcriptional activation (106) 
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Nucleosomal positioning at gene promoters is influenced by acetylation of histone 
H3 at lysine 9 (H3K9), which is directly associated with transcription factor 
accessibility and gene expression levels (114), whereas di- and trimethylation of 
H3K9 (H3K9me2, H3K9me3) promotes binding of heterochromatin protein 1 and is 
associated with transcriptional repression and heterochromatin formation (115, 
116). In general, H4K20me3 and H3K27me3 marks are associated with increased 
chromatin packing and gene silencing; and H3K4me3 and H3K36me3 marks are 
associated with looser chromatin structures and active gene transcription (102, 
107, 109).  
1.2.1.3 Epigenetic Regulation of Gene Transcription  
Cytosine methylation and histone posttranslational modifications contribute 
directly to the control of gene expression and the maintenance of genomic 
integrity. These processes are directly regulated by epigenetic modifiers (histone 
writers, readers, and editors) (117), DNA methylators, and chromatin remodellers, 
which function together to integrate the activity of signal transduction signalling 
intermediates with transcriptional activation (118). 
Epigenetic readers (trans-acting factors) influence local chromatin structure of 
inducible genes through nucleosomal positioning or by modifying histone residues 
at the posttranslational level. These proteins operate by targeting specific histone 
motifs (chromodomains or bromodomains) near gene promoters (119-121). 
Chromodomain acting factors preferentially target methylated lysine residues and 
maintain patterns of histone methylation (histone demethylases, KDMs) (122), 
whereas bromodomain-targeting effector proteins target acetylated lysine residues 
(histone acetyltransferases, KATs) (123, 124) [Figure 1:5]. Current evidence suggests 
that trans-acting factors work cooperatively to maintain DNA methylation and 
histone patterns. 
DNA methyltransferases form part of multi-protein chromatin remodeling 
complexes (Polycomb repressor group complexes, PRG) which include a variety of 
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epigenetic readers, including methyl CpG binding proteins, histone 
methyltransferases, and acetyltransferases (125). These PRGs are recruited to the 
chromatin of target genes which bear specific epigenetic patterns, and 
consequently, pro-carcinogenic changes in DNA methylation are dynamically linked 
to altered histone posttranslational modifications (126, 127). Furthermore, 
temporal models of gene silencing indicate that shifts in the pattern of histone 
acetylation provide the primary initiating event which precedes CpG island 
methylation (128). 
Patterns of transcriptional activation and repression are regulated by a synergistic 
relationship between DNA methylation patterns and histone modifications. 
Regulation by DNA methylation or histone modification is dynamic, with specific 
combinations of epigenetic marks establishing transcriptional behaviour. DNA 
methylation is thought to silence gene transcription by restricting transcription 
factor binding and/or altering regional chromatin packing by increasing affinity for 
methyl-CpG binding proteins. Studies investigating the temporal order of epigenetic 
events associated with transcriptional silencing suggest that repressive histone 
marks are acquired at specific loci prior to changes in DNA methylation (129, 130). 
Less clear is how these histone marks drive patterns of CpG dinucleotide 
methylation. Since chromatin decondensation is required for cis-acting factors such 
as DNMTs to associate with DNA, it is likely that local nucleosomal remodelling 
facilitates accessibility of DNMTs to promoter CpGs. Nucleosomal remodelling 
factors are recruited to CpG islands by Methyl CpG Binding proteins (MeCPs), which 
co-associate at gene promoters with histone modifying enzymes as part of 
Polycomb group repressor complexes (125). 
1.2.1.4 Functional Roles of Epigenetic Regulators 
The chromatin of developmental genes is facultatively silenced by condensation, 
and becomes poised for transcriptional activation during differentiation. ATP-driven 
nucleosomal remodelling factors such as SWI/SNF actively affect higher order 
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chromatin structure by regulating nucleosomal positioning across regions of the 
chromosome (131) [Figure 1:5].  
 
 
Figure 1:5 Chromatin Remodelling 
The histones of tightly packed heterochromatin bear an abundance of trimethylated lysine residues 
at lysine 9 for H3 and lysine 20 for H4. ATP-dependent remodelling enzymes such as SWI/SNF 
release condensed chromatin from its higher order structure during mitosis and differentiation, 
generating bivalent domains by methylating lysines 4 and 27 of H3. The chromatin of inducible genes 
is trimethylated at lysines 4 and 9 of H3 and exists in a poised, but inactive state. Removal of 
trimethylated marks by histone demethylase activity and acetylation of lysines by histone 
acetyltransferases exposes gene promoter sequences during transcriptional activation. 
 
These remodeller proteins are vital during active rearrangement of chromatin 
structure during DNA replication; chromosome segregation during meiosis; 
regulation of transcriptional repression and initiation; and DNA repair and 
recombination (132). Regionally acting histone modifiers are unable to penetrate 
the highly condensed chromatin of silenced genes without this initial remodelling 
process. Consequently, inducible genes exist in a transcriptionally ‘poised’ and 
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inactive state generated by a bivalent pattern of histone marks which facilitates 
regional access to epigenetic readers. 
These remodeller proteins are vital during active rearrangement of chromatin 
structure during DNA replication; chromosome segregation during meiosis; 
regulation of transcriptional repression and initiation; and DNA repair and 
recombination (132). Regionally acting histone modifiers are unable to penetrate 
the highly condensed chromatin of silenced genes without this initial remodelling 
process. Consequently, inducible genes exist in a transcriptionally ‘poised’ and 
inactive state generated by a bivalent pattern of histone marks which facilitates 
regional access to epigenetic readers.Reestablishment of histone marks during 
replication is particularly important for maintaining epigenetic patterns of gene 
silencing. Genes are replicated according to their chromosomal position, such that 
housekeeping genes are constitutively localised in pericentromeric regions, and 
replicate early, whereas inducible genes tend to replicate late (133). DNMTs and 
HDACs are recruited at replication foci during the S phase of the cell cycle (134), 
and consequently, tissue-specific and stress-responsive genes are more susceptible 
to processes which impair maintenance CpG methylation and which alter 
posttranslational histone modifications during growth and proliferation (135, 136). 
1.2.1.5 MicroRNAs 
MicroRNAs (miRNAs) are small non-coding RNAs which regulate gene expression at 
the post transcriptional level and are derived from genomic sequences coding for 
stem-loop precursors. MicroRNA-mediated interference is facilitated by 
complementary base pairing to target mRNAs, mostly at the 3’ UTR region. 
MicroRNAs have documented roles in the regulation of cell proliferation and 
metabolism, developmental timing, cell death, hematopoiesis and neuronal 
development (137, 138).  
With the exception of those within the Alu repeats transcribed by polymerase III 
(Pol III), most miRNA genes are derived from primary miRNA transcripts (pri-
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miRNAs) produced by Pol II and containing a 5′ cap and a poly(A) tail (139). The 
primary sequence is cleaved within the nucleus by a multiprotein complex 
composed of the RNAse III enzyme Drosha and the double-stranded RNA-binding 
domain (dsRBD) protein DGCR8/Pasha into a 70-nt hairpin precursor (pre-miRNA) 
(140). Following cytoplasmic export by the Exportin-5 (141, 142), pre-miRNAs are 
processed into mature 22-nt miRNA:miRNA* duplexes by the RNAse Dicer (143). 
The miRNA strand of this duplex is incorporated into an RNA-induced silencing 
complex (RISC), which guides the complex to its mRNA targets and contains the 
endonuclease Argonaute2 in its catalytic core (144, 145).  
Both the regulation and processing of miRNAs are linked via Drosha and Dicer 
activity regulators; and cis-acting modifications and trans-acting proteins which 
control enzyme activity and the stability of mature microRNAs (146)[Figure 1:6].  
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Figure 1:6 Regulation and Processing of microRNAs 
Following transcription, primary sequences are cleaved into precursor microRNAs by Drosha and translocated from the nucleus to the cytoplasm by Exportin 5. Precursor 
sequences are further cleaved into ~22 nucleotide duplexes by Dicer, following which the mature microRNA is incorporated into a RISC complex by Argonaute. Control of 
microRNA maturation is mediated by regulation of Drosha and Dicer RNase activity and expression (147, 148). These processes are directly or indirectly modulated by p53 
(149, 150). 
Key: RISC - RNA-induced silencing complex; ADAR - adenosine deaminase acting on RNA enzymes; DGCR8 - DiGeorge syndrome critical region gene 8; ERα - estrogen 
receptor alpha; hnRNP A1 - heterogeneous nuclear riboprotein A1; KSRP - KH-type splicing regulatory protein; SMADs - signal transducers of TGF; NF90/NF45 – nuclear 
factors 90 & 45; TUT4 - terminal uridylyl transferase; XPO5 – Exportin 5; ERK1/2 – Extracellular signal regulated protein kinases 1 & 2; Ago-2 – Argonaute 2; TRIM32 – 
Tripartate motif-containing protein 32  
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Although this field is still in its infancy, it appears that miRNA interference provides 
a critical means for moderating cellular responses. In particular, p53-mediated 
effectors are tightly regulated by microRNA-mediated self-regulatory feedback 
loops which are activated during genotoxic stress (149, 151, 152). Additionally, 
expression of miRNA regulatory factors is functionally linked to p53-mediated 
signaling (150). miRNAs regulate the expression of DNA repair proteins and 
effectors of the DNA damage response (153, 154) and consequently impaired 
miRNA-mediated regulation of cellular growth and survival signaling is a common 
feature of disease pathology (155). 
1.2.2 Epigenetics and Carcinogenesis 
It is increasingly evident that maintaining epigenetic control is vital to genomic 
integrity during an organism’s lifespan. A strong association exists between altered 
epigenetic imprinting and the pathophysiology of chronic disease states (156-158). 
Despite this, a causal link between disrupted epigenetic control and cancer 
initiation is a matter of debate. Numerous epigenetic events have been identified as 
cancer hallmarks. On a global scale, these include disruptions to the nuclear 
architecture, the CpG island methylator phenotype, and inactivation of DNA repair 
mechanisms (9, 17, 20, 159). Regional chromatin reorganization in cancer cells 
occurs in response to altered expression or activity of epigenetic modifiers and 
chromatin remodelers (160, 161). Thus manipulation of epigenetic factors such as 
DNA methylation, histone modifications and miRNAs provides the potential for 
intervening in pathological processes or monitoring disease progression (162, 163). 
1.2.2.1 Cancer and DNA Methylation 
During the past twenty years, a strong link between epigenetic reprogramming and 
carcinogenesis has been revealed – partly through genomic analysis of imprinting 
disorders, but also due to the association between cancer development and 
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germline mutations of DNA methylation control enzymes (164). Since then, a 
consistent pattern of global demethylation, juxtaposed against hypermethylation of 
CpG islands in gene promoter sequences has been uncovered in many cancer types 
(157, 165). As our understanding of carcinogenesis has evolved, Knudson’s ‘two hit 
hypothesis’ has been revised to reflect both the loss of heterozygosity and the loss 
of imprinting observed in cancer (166, 167). To this end, disrupted DNA methylation 
patterns and microsatellite instability have both been proposed as stage-specific 
biomarkers for individual cancer subtypes (158, 168, 169). More than 40 tumour 
suppressor genes are known to be silenced by hypermethylation in both solid 
cancers (prostate, breast, GIT) and haematological malignancies (leukemia, 
lymphoma, myelodysplastic syndromes) (168). Importantly, any defects which 
affect expression of DNA repair genes or DNMT activity facilitate the acquisition of 
phenotypic characteristics which drive cancer (170-173). 
Imprinted methylation patterns are altered during carcinogenic transformation, 
causing genomewide hypomethylation and promoter hypermethylation (167, 174). 
Cancer-associated hypomethylation generally occurs within intergenic and intronic 
regions of the DNA at microsatellite repeat sequences and transposable elements, 
and is believed to promote chromosomal instability (158). This is particularly 
evident for impairments which influence the DNA damage response, as chromatin 
dynamics facilitate the process of DNA repair and regulate epigenetic patterning 
following genotoxic damage (108).  
1.2.2.2 Cancer and Histone Modifications 
Altered patterns of histone modifications are increasingly recognized as important 
epigenetic features of cancer, with histone lysine acetylation and methylation being 
the best characterized. The role of HAT and HDAC activity in modifying acetylation 
status is vital for regulating gene expression and epigenetic memory, and thus over- 
or under-expression of these enzymes leads to the aberrant histone acetylation 
patterns associated with carcinogenesis (175-177). Early in carcinogenic 
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transformation, levels of monoacetylated H4-K16 and trimethylated H4-K20 
decrease, and this characteristic increases with tumour progression (178, 179). 
These alterations in turn influence recruitment of chromatin remodeling proteins 
(such as Polycomb group complexes), and promote the cancer phenotype by 
altering tumour suppressor gene transcription (180-182).  
1.2.2.3 Cancer and MicroRNAs 
The role of non-coding RNAs in the coordination of cellular responses remains to be 
fully characterised, however many miRNAs have targets whose regulatory control is 
disrupted during carcinogenesis (183-185) [Table 1:2].  
Table 1:3 Neoplastic microRNA Targets  
MicroRNAs Targets Role 
miR-221, miR-222, miR106a, miR-290 
cluster 
p27(Kip1), p21(Cip1), 
Cdk6, Cdc25A, 
Cyclin D2, Cyclin E2, 
Cdk4, pRb, 
p130/RBL2 
Cell cycle regulators 
miR-29b, miR-34 family, miR-15a, miR-16 Mcl-1, Bcl-2, p53 Antiapoptotic gene 
repression  
miR-10b, miR-21, miR-127, miR-199a, 
miR-210, miR-373, miR-520c 
HOXD10 
PTEN 
Metastatic inducers 
Let-7 family, miR-100, miR-126, miR-218, 
miR-335 
Ras family 
HMGA2 
Metastatic suppressors 
miR-17-92 cluster (miR-17, miR-18a, miR-
19a, miR-20a, miR-19b-1, miR-92a-1), 
miR-378, miR-27a, miR-126 
Tsp-1, CTGF Angiogenesis 
miR-200 family, miR-429, miR-30 family Cell Migration, Invasion, 
E-M transition 
miR-34 family, miR-181, miR-21, Let7 
family 
Cancer stem cells 
miR-9, miR-181, miR-34a, miR-340 Invasion 
miR-205, miR-326, miR-21, miR-335, miR-
92a, miR-141 
Serological diagnosis 
PTEN: phosphatase and tensin homologue 
CLL: chronic lymphocytic leukemia 
Bcl2: B cell lymphoma 
HCC: hepatocellular carcinoma 
pRb: Retinoblastoma protein 
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The significance of these observations is twofold – first, miRNAs have a key role in 
regulating oncogene expression; and second, promoter regions in miRNA genes are 
frequently affected by mutation and/or changes in epigenetic patterns of 
expression (155, 186, 187). These alterations have potential clinical applications as 
diagnostic and prognostic biomarkers in cancer (188, 189). 
Defective microRNA biogenesis is linked to the pathogenesis of chronic disease, and 
is an emerging finding in cancer subtypes. Dicer1 haploinsufficiency promotes 
tumour progression in mouse models (190, 191), and Dicer/Drosha expression 
correlates with tumour severity and therapeutic outcomes (192-195). As a 
consequence, global patterns of miRNA expression are frequently altered in cancer 
(138, 196, 197). 
1.2.3 Epigenetic Antineoplastics 
Epigenetic repatterning is associated with the pathology of many diseases – 
particularly cancer – and these changes have implications for improved diagnosis 
and the efficacy of treatment regimes. Uncovering the regulatory mechanism which 
governs epigenetic repatterning is important to our understanding of disease 
processes, and in particular, those disorders which are associated with ageing or 
exposure to environmental toxins (128). Equally important is to understand how 
epigenetic regulation processes can be manipulated to enhance pharmaceutical 
efficacy and prevent resistance. Use of histone modifiers and DNMT inhibitors in 
chemotherapy is in its infancy, however results are promising.  
A combinatorial strategy which targets epigenetic modifiers is emerging as a way to 
improve remission rates during cancer chemotherapy. Epigenetic antineoplastic 
drugs currently under review predominantly target DNMTs and Class I and II HDACs, 
albeit via a variety of different biochemical mechanisms. The use of epigenetic 
modulators to target epimutations in cancerous tissue has rapidly gained support 
amongst the medical community. DNA methyltransferase inhibitors such as 
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Suberoylanilide hydroxamic acid (SAHA, Vorinostat) are currently used in clinical 
settings as chemotherapeutic agents (198). These studies have also demonstrated 
HDACi-induced downregulation of DNA repair and cell survival proteins, which is 
thought to render tumorigenic cells more susceptible to other modalities of cancer 
therapy than ‘normal cells’. The intention of this treatment strategy is to 1) restore 
sensitivity to intracellular oxidative and metabolic stress associated with 
carcinogenesis, and 2) synergistically enhance the cytotoxicity of commonly used 
antineoplastics (175, 199).  
SIRT1 is an NAD+ dependent lysine deacetylase which has nuclear and cytoplasmic 
substrates, of which p53 is the most extensively characterised (200). SIRT1 
suppresses p53-regulated transcriptional activity by stabilising p53 in its non-
acetylated form (201). SIRT1-mediated deacetylation inhibits p53 transactivation 
(202), blocks nuclear translocation (203) and down-regulates expression of p53 
transcriptional gene targets. Modulation of SIRT1 activity has been proposed as a 
strategy for reducing the pathological features of diseases associated with ageing 
(204, 205), and for overcoming resistance in diseases with p53 inactivation as part 
of their etiology (90, 206). However, as yet, few in vitro studies have been 
performed to test the efficacy of SIRT1 activity modulators as adjuvants in 
chemotherapy regimens (207). The effect of SIRT1 on cellular physiology and the 
use of SIRT1-targeting pharmaceuticals will be explored in more detail later in this 
chapter. 
 1.3 HISTONE DEACETYLASES  
Histone deacetylases (HDACs) belong to a family of enzymes which modulate 
chromatin structure by altering the acetylation status of nucleosomal histones. 
Their general cellular role is to regulate transcriptional activity by opposing the 
action of histone acetyltransferases. These enzymes also influence the activity of 
non-histone proteins, including transcription factors and glucocorticoid receptors; 
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and perform functional roles in maintaining genomic integrity by recruiting and 
stabilizing DNA methylation and repair complexes. Thus HDACs are considered to 
be integral to the coordination of the epigenetic machinery.  
Mammalian HDACs are categorised into four classes based on their homology to 
histone deacetylases in yeast. Members of Classes I, II (subdivided into IIa and IIb) 
and IV have metal ion-dependent catalytic activity, whereas Class III HDACs are 
NAD+-dependent. Although all classes are specific for acetylated lysine residues, 
individual family members have unique subcellular localisation, tissue specificity 
and cellular function (208) [Table 1:3]. 
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Table 1:4 Classification of Histone Deacetylases 
Class Enzyme Subcellular Localization Site/Expression Function Refs 
Class I (yRpd3-like) HDAC1 Nucleus Sin3, NuRD, CoREST, PRC2 Transcriptional Repression (113) 
(209) HDAC2 Nucleus 
HDAC3 Nucleus/cytoplasm N-CoR-SMRT 
HDAC8 Nucleus 
Class IIa (yHda1-like) HDAC4 Nucleus/cytoplasm Brain, skeleton Transcriptional repression 
Coordinate extracellular signals with gene 
expression during development and disease 
(113) 
(209) HDAC5 Nucleus/cytoplasm Muscle, heart, brain 
HDAC7 Nucleus/cytoplasm Endothelium, thymocytes 
HDAC9 Nucleus/cytoplasm Muscle, heart, brain 
Class IIb (yHda1-like) HDAC6 Cytoplasm α-Tubulin, cortactin, interferon 
receptor IFNαR, 
chaperones 
Cytoskeletal remodeling, membrane translocation (209) 
HDAC10 Nucleus/cytoplasm 
Class III (ySir2-like) Sirtuins Nucleus/cytoplasm/Mitochondria SEE TABLE 1.4 FOR DETAILS 
Class IV HDAC 11 Unknown Brain, heart, muscle, kidney, 
testis 
Unknown (209) 
yRpd3 - yeast Reduced potassium dependency 3; yHda1 - yeast Histone deacetylase-A1; ySir2 - yeast Silent information regulator 2 
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1.3.1 Class III Histone Deacetylases 
Sirtuins belong to a conserved family of NAD+-dependent deacetylases which share 
homology with silent information regulator 2 (Sir2) enzymes from yeast. Sirtuins 
couple the enzymatic cleavage of NAD+ to the deacetylation of key acetyl-lysine 
residues to generate nicotinamide and 2′-O-acetyl-ADP-ribose (189-191) [Figure 
1:7]. Although the majority of sirtuins have NAD+-dependent deacetylases activity, 
two Sir2 family enzymes (SIRT4 and SIRT6) predominantly catalyse ADP-ribosylation 
reactions, which proceed via cleavage of NAD+ with the subsequent production of 
nicotinamide (210, 211). 
Figure 1:7 Class III Histone Deacetylase Catalytic Mechanism  
Sir2 family NAD+-dependent deacetylases couple the hydrolysis of NAD+ to the deacetylation of 
acetyl-lysine residues of protein substrates to yield nicotinamide (Nam) and the metabolite O-acetyl-
ADP-ribose (OAADPr). (212, 213). 
Sirtuins are functionally important for numerous cellular processes, including cell 
cycle regulation, nutrient metabolism, and cellular ageing (214). The cellular 
outcome of sirtuin-mediated regulatory control is activation of cellular adaptive 
responses to environmental change [Table 1:4]. Sirtuin activity realigns cellular 
imprinting patterns, causing long-term adaptive change which reactivates 
oncogenes and/or down-regulates tumour suppressor gene expression (209, 215). 
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Table 1:5 Functions of Class III Deacetylases in Humans 
Localisation Targets Function 
SIRT1 Nuclear/Cytoplasmic P53, NF-κB, FOXO1, FOXO3, Bax, HIF1α, MyoD, Ku70, β-Catenin, c-Myc, FXR, TORC2, 
SREBP, PER2, LXR, PPARγ, p300, Tat, PCAF, ERα, AR, SMAD7, p73, Sox9, HSF1, PGC1α, 
HEY2, NCoR/SMRT, E2F1, CLOCK, RelA/p65 
Energy metabolism 
Fatty acid and cholesterol mobilisation 
Circadian rhythm regulation 
DNA damage response 
SIRT2 Nuclear/Cytoplasmic αTubulin, FOXO3a, H4 Cell cycle control 
SIRT3 Mitochondrial AceCS2, GDH Complex 1, LCAD, HMG-CoA Synthase 2, IDH2, MnSOD, SOD2 ATP production 
Regulation of mitochondrial proteins 
Thermogenesis 
SIRT4 Mitochondrial GDH, IDE, ANT Insulin secretion 
Fatty acid oxidation 
SIRT5 Mitochondrial CPS1 Urea cycle 
SIRT6 Nuclear NF-κB, HIF1α, Helicase, DNA Polymerase β, CtIP, H3K9, H3K56 Telomeric stability 
DNA repair 
Inflammation 
SIRT7 Nucleolus RNA Polymerase Type I, E1A, SMAD6 RNA polymerase I transcription 
Key - P53: tumour suppressor protein p53; FOXO: Forkhead box O; Bax: Bcl2-associated protein 2; HIF: Hypoxia-inducible factor; HSF1: Heat shock factor 1; PGC-1α: 
Peroxisome proliferator-activated receptor gamma coactivator 1α; NF-κB: Nuclear factor kappa B; TORC2: Transcriptional coactivator for CREB; LXR: liver X receptor; FXR: 
farnesoid X receptor; SREBP: Sterol regulatory element binding protein; PER2: period circadian homologue 2; NCoR/SMRT: nuclear corepressor/silencing mediator for 
retinoid and thyroid receptors; H4: histone 4; AceCS2: Acetyl-CoA synthase 2; LCAD: long chain Acyl-CoA dehydrogenase; HMG-CoA synthase 2: 3-hydroxy-3-methylglutaryl 
CoA synthase 2; IDH2: isocitrate dehydrogenase 2; MnSOD: Mn-superoxide dismutase; SOD2: superoxide dismutase 2; GDH: Glutamate dehydrogenase; CPS1: carbamoyl 
phosphate synthase 1; CtIP: C-terminal binding protein interacting protein; H3K9: histone 3 lysine 9; H3K56: histone 3 lysine 56. (Based on reviews by 200, 210, 216, 217) 
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 1.3.2 SIRT1 
Human SIRT1 shares the closest homology with its yeast counterpart, and its 
cellular and physiological roles have been the most extensively characterized. The 
rest of this chapter will focus on biochemical features of SIRT1, with particular 
emphasis on the role SIRT1 plays in regulating cellular responses to genotoxic 
damage, and the potential use of SIRT1 modulators in therapeutic disease 
intervention.  
SIRT1 is predominantly localised in the nucleus, and has both histone and non-
histone substrates (218). Identified in the 1990s, SIRT1 rapidly gained a reputation 
as an anti-ageing enzyme for its role in prolonging lifespan in yeast, worm and fly 
models. Since then, numerous physiological effects of SIRT1 in various cell types 
have been identified. To date, the most extensively studied effects of SIRT1 activity 
are those which influence adaptive responses to metabolic, oxidative and 
oncogenic stress. Non-histone substrates of SIRT1 regulate transcriptional 
activation, cell cycle progression, survival and senescence, DNA damage and DNA 
repair responses, metabolic activity, gene expression and signal transduction. These 
induce physiological changes which affect fat storage and mobilisation, insulin 
sensitivity, glucose tolerance, neuroprotection, cardioprotection, inflammation and 
stress resistance in a tissue-specific manner [Table 1:5]. 
SIRT1 influences gene transcription and genomic stability by modifying the activity 
of chromatin remodelling complexes, DNA methyltransferases, and histone 
regulatory enzymes. Furthermore, in its role as a histone deacetylase, SIRT1 is 
recruited to sites of genotoxic DNA damage and regulates the acetylation status of 
histones in proximity to the lesion. Thus SIRT1 maintains genomic integrity by 
activating and recruiting the DNA repair machinery and by remodelling regional 
areas of chromatin when cells are exposed to mutagens (219).
33 |  
 
Table 1:6 Physiological Roles of SIRT1 
Tissue Target Physiological Effects Organismal Outcome 
Liver ↑PGC1α, ↑FOXO1, ↓TORC2, ↓STAT3 ↑ Late Gluconeogenesis, ↓Glycolysis Metabolic homeostasis 
↑PGC1α, ↑PPARα ↑Fatty Acid Oxidation ↑Insulin sensitivity 
↑LXRα, ↑FXR, ↓SREBP ↑Cholesterol Efflux ↑Glucose tolerance 
↓NF-κB ↓Inflammation ↓Fatty Liver 
Adipose Tissue ↓PPARγ ↑Lipolysis ↓Fat storage 
↓PPARγ ↑Mobilisation of FFAs ↑Insulin sensitivity 
↓PPARγ ↓Lipogenesis ↓Macrophage infiltration 
Pancreas (β Cells) ↓Ucp2 ↑Insulin Secretion ↑Glucose tolerance 
Brain/CNS  ↑AgRP ↓Leptin Signaling ↓Neurodegeneration 
↓POMC ↓Energy Expenditure 
↑CLOCK:BMAL1, ↑PER2 ↑Stabilization of Circadian Rhythm ↑NAD Biosynthesis 
Heart ↓PPARγ ↑Insulin sensitivity ↑Cardioprotection 
Skeletal Muscle ↑PGC1α ↑Mitochondrial fatty acid oxidation Improved insulin sensitivity 
↓PTP1B ↓Inflammation 
Key - PGC1α: peroxisome proliferator-activated receptor-γ coactivator 1α; PPARα: peroxisome proliferator-activated receptor α; LXRα: liver X receptor α; FXR: farnesoid X 
receptor; SREBP: steroid receptor binding protein; Ucp2: uncoupling protein 2; FOXO1: forkhead box O1; TORC2: transcriptional coactivator for CREB; STAT3: signal 
transducer and activator of transcription 3; POMC: propiomelanocortin; BMAL1: brain and muscle aryl hydrocarbon receptor nuclear translocator (ARNT)-like; CLOCK: 
Circadian Locomotor Output Cycles Kaput; PER2: Period circadian protein homologue 2. (Based on reviews by  220, 221-224)  
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1.3.2.1 Modulation of SIRT1 Activity 
SIRT1 binds a consensus peptide sequence [K(V/S)(V/T)GGKKXXK], however 
specificity for the target lysine residue within this region varies between substrates, 
with the greatest affinity shown for histone H4 acetylated at lysine 16 [H4 Ac(K16)], 
and p53 acetylated at lysine 382 [p53 Ac(K382)] [Table 1:6]. Based on relative SIRT1 
substrate affinities acetylation of p53 at residue 382 was used as a marker for p53 
activity in this study. 
Table 1:7 Binding affinity for SIRT1 substrate sequences  
Substrate Sequence Km (µM) 
Consensus K(V/S)(V/T)GGKKXXK 
p53 Ac(K382) HLKSKKGQSTSRHKKLMFKTEG 4.3 ± 0.5 
H3 Ac(K9) ARTKQTARKSTGGKAPRKQL ~239 
H3 Ac(K14) KSTGGKAPRKQ 420 ± 40 
H3 Ac(K115) HAKRVTIQKKD 9.2 ± 1.6 
H4 Ac(K5) SGRGKGGKGLGKGGAKRHRK 140 ± 32 
H4 Ac(K8) SGRGKGGKGLGKGGAKRHRK 54 ± 17 
H4 Ac(K12) SGRGKGGKGLGKGGAKRHRK 105 ± 15 
H4 Ac(K16) SGRGKGGKGLGKGGAKRHRKILRD 1.1 ± 0.3 
H4 Ac(K77) HAKRKTVTSLD 13.1 ± 1.8 
H4 Ac(K79) HAKRKTVTSLD 10.5 ± 1.4 
H2B Ac(K82) YNKKSTISARE ND 
(from 225, 226), Target lysine residue is marked in bold; ND: Not Determined 
Structurally, SIRT1 is more open in its unbound apo- state, and adopts a closed 
conformation during entry of target substrates into the binding site [Figure 1:8]. 
Affinity for NAD+ entry into the catalytic core increases when SIRT1 is in its closed 
conformation, and thus conformational changes are induced upon substrate 
binding which enhances catalytic turnover (227).  
Since the discovery of SIRT1’s anti-ageing potential, there has been a drive to 
develop novel SIRT1 activity modulators as therapeutic agents. Nutritional 
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compounds were amongst the original SIRT1 modulators identified, however their 
pharmacokinetic properties proved a hindrance to therapeutic efficiency. Synthetic 
SIRT1 modulators which increase the Vmax or lower the Km for substrates are 
considered to have the most attractive clinical potential, with EX-527 reaching the 
clinical trial stage in recent months [Table 1:7]. 
Figure 1:8  SIRT1 undergoes conformational changes during inhibition and substrate binding 
Figure was created using 3D protein structures uploaded to the Molecular Modelling Database by 
Zhao et al. and Davenport et al (228, 229). Data files were manipulated with Cn3D 4.3.1 software 
produced by the National Center for Biotechnology Information (230). The SIRT1 enzyme reaction 
proceeds via an alkylamidate intermediate, formation of which facilitates transfer of the acetyl 
moiety from the substrate lysine residue. 2′-O-acetyl-adenosine diphosphoribose (OAADPr) is 
released from the catalytic site along with the deacetylated substrate and nicotinamide (212, 231-
233). NAD+: Nicotinamide adenine dinucleotide; EX-527: 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-
1-carboxamide; OAADPr: 2′-O-acetyl-adenosine diphosphoribose 
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EX-527 is an indole analogue which was developed to target human SIRT1 in a 
concentration-dependent manner, with an IC50 of 38 nM measured using an in vitro 
Fluor de Lys assay (234). EX-527 has some inhibitory effect on other members of 
the sirtuin family, with much lower potency (SIRT2, IC50 = 19.6 µM; and SIRT3, IC50 = 
48.7 µM)(235). On entry to the hydrophobic binding pocket, EX-527 interacts with 
the NAD+ ribose moiety and stabilises SIRT1 in its closed structure, forcing NAD+ to 
extend into an inactive conformation (229) and blocking substrate release (236) 
[Figure 1:9]. 
Table 1:8  SIRT1 Activity Modulators (Based on reviews by 214, 237, 238-241) 
Type Modulator Kinetics/Function 
Nutraceuticals Sulforaphane 
Resveratrol 
Quercetin 
Butein 
Inhibitor 
Activator 
Activator 
Activator 
Inhibitors Nicotinamide 
2-Anilino-benzamide 
Suramin 
Cu2+/Zn2+ 
EX-527 
Sirtinol 
Meta-sirtinol 
Para-sirtinol 
Salermide 
Tenovin-1 
Cambinol 
Splitomicin 
IC50: 50-100 μM 
IC50: 17 μM 
IC50: 2.42 μM 
IC50: 1 μM 
IC50: 0.098-1 μM 
IC50: 37.6-131 μM 
IC50: 63 μM 
IC50: 13 μM 
IC50: 76 μM 
IC50: 21 μM 
IC50: 56 μM 
IC50: 5 μM 
Activators NAD+ 
SRT1720 
SRT2183 
Pyrroloquinoxaline 
Oxazolopyridine 
Km: 90 μM 
Km: 0.16 μM 
EC1.5: 10 μM 
EC1.5: 0.09 μM 
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Figure 1:9  EX-527 and NAD+ interact within the SIRT1 catalytic cleft 
EX-527 occupies the C-binding pocket in the catalytic cleft of SIRT1, and interacts with the NAD+ 
ribose moiety to block catalysis (229, 236).  
 
1.3.2.2 Biological Regulators 
SIRT1 activity is coupled to substrate usage by its relationship with NAD+ availability 
and the NAMPT/NMNAT1 salvage pathway for NAD+ regeneration (242-244), and 
has three main classes of endogenous protein regulators – protein kinases, catalytic 
domain binders and sumoylation regulators. Phosphorylation of SIRT1 at Thr522 by 
Dual specificity regulated kinases (DYRK1A or DYRK3) increases SIRT1 activity, 
promoting cell survival during genotoxic stress (245). 
Casein kinase 2 (CK2) increases SIRT1-mediated p53 deacetylation by 
phosphorylating Ser 154, 649, 651 and 683 residues (246), and phosphorylation of 
Ser27 by c-Jun N-terminal kinase 2 (JNK2) increases SIRT1 activity by promoting 
stabilisation (247). N-terminal domain binding of active regulator of SIRT1 (AROS) 
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also promotes SIRT1 activity by lowering its Km (248), whereas deleted in breast 
cancer (DBC-1) acts as a SIRT1 catalytic domain inhibitor (249). Interestingly, the 
catalytic activity of SIRT1 is enhanced by sumoylation of lysine 734 during DNA 
damage, and yet is suppressed by SENP1 (sentrin-specific protease)-mediated 
desumoylation during chronic stress conditions (239), indicating that SIRT1 may 
modulate different cell survival responses depending on the intracellular 
environment. SIRT1 expression varies according to tissue type and its metabolic 
requirements, with transcription regulated by p53, hypermethylated in cancer 
(HIC1) and E2F1 response elements in its promoter region. HIC1 is a transcriptional 
repressor which is activated by p53, and whose inhibition of SIRT1 transcription is 
thought to act as a regulatory feedback loop (250). E2F1-mediated pro-apoptotic 
signaling during the DNA damage response is also mediated by SIRT1. Activation of 
E2F1 by ATM stimulates SIRT1 transcription, and SIRT1-mediated deacetylation of 
E2F feeds back to suppress its transcriptional activity (251). Additionally, SIRT1 
expression is regulated at the level of protein translation via HuR-mediated 
stabilization of SIRT1 mRNA (252), and non-coding RNA-induced interference by 
microRNAs miR34a, miR199 and miR200a (253).  
1.3.2.3 Targets 
SIRT1 is predominantly known for its effect on cellular growth and survival via 
inactivation of p53-mediated apoptosis and cell cycle arrest (201, 202, 254). 
However SIRT1 also induces p53-independent effects on survival signaling. SIRT1 
deacetylation of Smad7 at Lys64 and 70 inhibits TGFβ-induced apoptosis in 
mesangial cells, and also plays a role in regulating Smad7 expression through Smad 
ubiquitination regulatory factor (SMURF)-mediated proteolysis (255). SIRT1 also 
acts as a negative regulator of the histone acetyltransferase p300 by deacetylation 
and subsequent sumoylation of lysines 1020 and 1024. Both SIRT1 and p300 co-
regulate a subset of common substrates which are important for cellular growth 
and proliferation via this mechanism (256).  Additionally, mTOR-mediated 
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phosphorylation of SIRT1 at serine 47 inhibits SIRT1 activity and promotes cellular 
senescence rather than growth during genotoxic damage (257). SIRT1 also blocks 
inflammatory signaling by deacetylating the RelA/p65 subunit of NF-κB at lysine 
310, promoting TNFα-induced apoptosis (258) and STAT3 transcriptional activity 
(259). 
SIRT1 influences epigenetic control of gene transcription through histone-mediated 
chromatin remodeling (219). This is achieved, in part, by modulation of histone 
methyltransferase SUV39H1 targeting, which promotes accumulation of 
trimethylated histone H3 at lysines 9, 79 and 20 (260); deacetylation of histone H4 
at lysine 16 and histone H3 at lysine 9 (261); and recruitment of histone H1b to 
facultative heterochromatin (262). This may be associated with maintenance of CpG 
island imprinting patterns and gene silencing through co-recruitment of DNA 
methyltransferase 3b (DNMT3b) (263). SIRT1 is also thought to influence the 
structural maintenance of chromatin within the nucleus. In this model, 
heterochromatin islands within the nuclear architecture are destabilized by 
environmental insult, and depend on SIRT1 activity for restoration (264).  
The role of SIRT1 as a histone deacetylase has implications for embryonic growth 
and development, with the SIRT1 null genotype proving to be lethal in the perinatal 
period (265-267). Future work to uncover the role of SIRT1 in Notch signaling may 
provide clues as to why this is the case. In Drosophila, SIRT1 forms a co-repressor 
complex with Lysine-specific demethylase 1 (LSD1) to remove H4K16 acetylation 
marks in genes regulated by the Notch signaling pathway by associating with CSL in 
Notch target genes (268). Interestingly, although the SIRT1+/− genotype in mice is 
compatible with life, SIRT1 haploinsufficiency is associated with tumorigenesis, 
particularly in conjunction with impaired p53 or PARP1 expression. Primary 
tumours in these mice demonstrate numerous chromosomal abnormalities, 
including extensive aneuploidy, translocations, dicentricity, strand breaks and 
deletions (266). Also, SIRT1 expression is reduced in certain human carcinomas, 
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suggesting that loss of functional SIRT1 interferes with the DNA damage response 
and contributes to genomewide instability. 
1.3.2.4 SIRT1 and the DNA Damage Response 
SIRT1 plays numerous roles in the maintenance of genomic stability and plays an 
integral role in the coordinated repair of stress-induced DNA damage.  (269, 270). In 
the DNA damage sensing complex, SIRT1 deacetylates Nijmegen breakage 
syndrome 1 (NBS1), activating ATM and ATR cell cycle checkpoint kinases (271, 
272), and promoting γH2AX foci formation (273). SIRT1 also promotes and 
integrates the activity of different types of DNA repair. Increased UV-induced strand 
break repair is associated with SIRT1-mediated Ku70 activation (274), and 
deacetylation of XPA (Xeroderma Pigmentosum Group A) by SIRT1 at lysines 63 and 
67, indicating a role in nucleotide excision repair (NER) (275).  
Additionally, SIRT1 deacetylates Apurinic endonuclease/redox-factor 1 (APE/Ref1) 
at lysines 6 & 7, facilitating its binding to X-ray Repair Cross Complementing 1 
(XRCC1) during base excision repair (BER) (269), and is recruited to double strand 
breaks, where it promotes homologous recombination by deacetylating Werner 
helicase (WRN) (276, 277). SIRT1-mediated regulation of signaling targets produces 
a differential effect on cell cycle control and apoptotic signalling. SIRT1 potentiates 
p53-, p73 and FOXO-mediated growth arrest and up-regulates DNA repair genes 
whilst attenuating stress-induced apoptosis (202, 278-280); and triggers cell cycle 
arrest and senescence by deacetylating Rb and c-Myc (281, 282) [Figure 1:10]. 
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Figure 1:10 SIRT1 and the DNA Damage Response 
SIRT1 influences cellular adaptation to genotoxic stress by deacetylating mediators of the DNA 
damage response. By promoting cellular growth and DNA repair, SIRT1 primes cells to overcome 
DNA damage. SIRT1 also blocks p53-mediated cell cycle arrest and apoptosis, preventing DNA 
damage-induced senescence and allowing progression through cell cycle checkpoints  
Key – DNMT3B: DNA methyltransferase 3B; NBS1: Nijmengen Breakage Syndrome protein 1; H2AX: 
histone 2AX; ATM: ataxia-telangiecatesia-mutated protein; ATR: ATM and Rad3-related protein; 
NHEJ: non-homologous end joining; NER: nucleotide excision repair; BER: base excision repair; XPA: 
Xeroderma Pigmentosum Group A; PARP1: poly(ADP-ribosyl) polymerase; APE: ; FOXO1 & 3: 
forkhead box O 1 & 3; HIF1α: hypoxia-inducible factor 1α; NF-κB: nuclear factor kappaβ 
1.3.2.5 The role of SIRT1 in cancer 
According to current mechanistic evidence, SIRT1 activity can be tumour-promoting 
or tumour-suppressing, and thus classification of SIRT1 as either a tumour 
suppressor or oncogene is ambiguous. SIRT1 prevents tumorigenesis in normally 
functioning cells by maintaining DNA fidelity (264, 265). Once initiation has 
occurred, however, SIRT1 promotes cancer progression by enabling neoplastic cells 
to adapt to the tumour microenvironment (266), and can facilitate cancer evolution 
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through the accumulation of genetic alterations (267), evasion of growth 
suppression and resistance to cell death signalling (245, 268, 269).  
Additionally, SIRT1 promotes multidrug resistance by inducing enzymes which 
regulate drug metabolism and by activating cellular detoxification mechanisms 
(183, 270, 271). Neoplastic cells frequently overexpress SIRT1 (272, 273), and 
consequently inhibition of SIRT1 is a potential pharmaceutical strategy for 
sensitising resistant cancer cells to cytotoxic drug therapy (274). 
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1.4 ARSENIC-MEDIATED CARCINOGENICITY 
Arsenic is classified as a Class 1 human carcinogen by the International Agency for 
Research on Cancer (IARC) monographs (283, 284). Based on criteria outlined in the 
IARC Preamble (285), the general consensus is that that there is sufficient 
epidemiological evidence for the carcinogenicity of inorganic arsenic compounds, 
including arsenic trioxide, arsenite, and arsenate, and these agents cause cancer of 
the lung, urinary bladder, and skin (283, 286, 287). Yet regardless of a clear 
association between arsenic exposure and cancer risk determined in 
epidemiological studies, the nature of arsenic-induced cancer remains a complex 
and incompletely understood process. Consequently, investigators are keen to 
uncover mechanistic data which provides evidence for arsenic carcinogenesis which 
may reduce the uncertainty introduced in meta-analyses.  
So far, the consensus opinion is that arsenic does not directly interact with cellular 
DNA, although it appears to introduce conditions which promote mutagenesis. 
These include induction of oxidative DNA damage (288, 289), aneuploidy (290), 
destabilisation of the genome (microsatellites), and suppression of DNA repair. 
Additionally, although arsenic does not cause point mutations, it acts as a co-
mutagen with UV or ionising radiation (291), and in the presence of DNA alkylating 
agents such as methyl methanesulfonate (292). These investigations support 
epidemiological findings of an increased cancer risk with sun exposure and for 
individuals who ingest tobacco smoke or who chew betel nut (293-295). For 
exposed populations, risk of arsenic-induced skin lesions is significantly related to 
prolonged sun exposure (296), polymorphisms of glutathione-S-transferase (GST), 
methylene tetrahydrofolate reductase (MTFR), and DNA repair genes (297, 298), 
folate deficiency/vitamin B intake (299, 300), and clearance capacity of urinary 
metabolites (301-303). Thus, epidemiological and experimental studies indicate 
that several different mechanisms may be involved. 
44 | 
Chapter 1 
Oral administration of arsenate will cause cancer in mice, rats or hamsters; 
however there are questions as to the relevance of animal models of carcinogenesis 
when applied to human cancer risk. The main issue with these studies is how 
arsenic-induced carcinogenesis in animals should be interpreted in the context of 
human exposure (304, 305), as biotransformation and detoxification capacity 
differs between humans and animals (306). Ultimately, these analyses reveal 
problems inherent in confirmation of causality in toxicological studies performed 
with animal models.  
Cell transformation assays are an alternative to animal studies for investigations 
into arsenic carcinogenicity. Using anchorage-independent growth, colony 
formation and tumour formation in SCID mice as endpoints, these studies 
demonstrate that arsenic induces transformation in culture. Investigations into 
human cell transformation use genetically altered cell lines, rather than primary 
cultures, in which the cells have acquired an immortalised phenotype through 
mutations to the p53 gene, introduction of TERT genes, or by SV40 viral infection. 
During carcinogenesis, cell populations undergo a sequential process in which cells 
with procarcinogenic mutational changes are retained, whilst non-immortalised 
(finite lifespan) cell strains senesce before they have acquired all the genetic 
changes necessary for transformation (307). To date, in vitro arsenic exposure 
models have shown that at least 20 weeks of treatment is required in order for 
arsenic-exposed cells to acquire a malignant phenotype. However in none of these 
studies was a primary cell strain used. The most likely reason for using an adapted 
cell line is that a limited number of divisions achievable from primary cells is 
prohibitive for use in extended treatment regimes. Therefore it could be argued 
that these are not actual models of carcinogenesis but instead describe changes to 
cells with pre-existing mutations which have adapted them for culture.  
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1.4.1 Carcinogenic Properties of Arsenic 
Arsenic does not interact directly with the DNA in a manner such as direct 
carcinogens, although it can introduce intranuclear conditions by which 
mutagenesis is more likely. These include induction of oxidative DNA damage (288, 
289), aneuploidy (290), interference with DNA repair and genomic instability 
(microsatellite formation). Additionally, arsenic produces phenotypic changes which 
appear to promote cellular transformation. Patterns of gene expression are altered 
in arsenic exposed tissues as a consequence of epigenetic changes to gene 
promoters (308, 309), dysregulated signal transduction pathway activation (310-
313), and shifts in steroid receptor binding (314). Moreover, arsenic influences 
mitochondrial function such that cells adopt an anaerobic profile consistent with 
oncogenic reprogramming of nutrient use and energy production (315).  
Long-term low level exposure to arsenic induces other pro-carcinogenic cellular 
changes, many of which are adaptive responses to arsenic toxicity (316, 317). These 
include dysregulated energy metabolism, altered genomic fidelity and pathological 
gene expression (286). In combination with extracellular conditions which facilitate 
clonal selection, arsenic toxicity produces gradual genotypic, phenotypic and 
morphological changes which progress to tumour formation.  
Dose-response data further complicates our understanding of arsenic-induced 
carcinogenesis. Whilst sublethal concentrations of arsenic (generally 0-5 µM, 
depending on cell type) generate protective responses consist with stress 
adaptation (antioxidant gene expression, DNA repair, pre-inflammatory cytokines, 
proliferative signalling) (310, 318-320), higher concentrations (5-100 µM) induce 
genes which trigger cell cycle arrest and apoptosis (321-324). From these data, it 
appears that lower arsenic doses induce phenotypic changes which promote 
carcinogenesis, and evidence for this this is supported by in vitro transformation 
studies.  
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1.4.1.1 Gene Expression 
Arsenic exposure interferes with oncogene and tumor suppressor gene expression, 
producing an outcome which depends on cell type, concentration and duration of 
exposure. Microarray analyses of gene expression in arsenic treated cells have 
identified hundreds of affected genes, most of which fall within these specific 
categories: cellular stress response, cell cycle control, redox regulation, and DNA 
repair (325-328).  
Arsenic exposure influences cell cycle control by disrupting the p53-Mdm2 axis 
(329), inhibiting the activity of checkpoint proteins, and by altering cyclin D1 
expression (330). However the outcome of arsenic-induced cell cycle dysregulation 
is dose- and duration- specific. Prolonged arsenite exposure at higher 
concentrations causes p53 to accumulate, increasing expression of the cyclin-
dependent protein kinase inhibitors (CDKIs) p21 WAF1 and p27, and stalling the cell 
cycle at G1/S (331). Non-lethal (submicromolar) arsenite concentrations, however, 
have the opposite effect, causing an up-regulation of cyclin D1 transcription which 
disrupts cell cycle control (332). Intermediate doses of arsenic (5-25 uM) also 
induce proliferation by activating Elk1 and ATF2 (333); and by increasing cyclin D1 
levels (334).  
In tissue systems, arsenic promotes cellular invasiveness and tumour migration by 
stimulating extracellular matrix remodeling, anchorage-independence and 
neovascularization. Arsenic stimulates matrix metalloproteinase production (335, 
336), although this observation appears to be limited to lower treatment doses 
(337). In vitro vascularization studies demonstrate low-dose stimulation and high-
dose inhibition of vascular endothelial growth factor (VEGF) secretion and 
endothelial cell proliferation with arsenic exposure (338, 339). In vivo studies 
correlate with these findings, demonstrating increased vessel growth and density in 
chicken chorionic membrane and murine studies conducted at arsenic 
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concentrations between 0.033 and 1 μM (340, 341); however tumour vasculature 
breaks down at higher (> 1 μM) doses (342).  
Arsenic exposure generates a dose- and duration-dependent effect on cell survival. 
Acute high doses activate intrinsic apoptotic pathways through p53 and JNK-
induced production of proapoptotic proteins. Long-term exposure to 
submicromolar concentrations of arsenic, however, induces transformational 
changes in cells which promote apoptotic resistance (343). Apoptotic resistance is 
linked to shifts in signal pathway flux, with preferential activation of PI3K-Akt/PKB 
signaling in arsenic treated cells and dampening of proapoptotic NF-κB and JNK 
signaling (310, 313). The transcription factors AP-1 and NF-κB are regulated by 
arsenic, presumably as a result of signal transduction pathway activation by 
reactive oxygen species (ROS) (344, 345). Acute low-dose arsenite up-regulates AP-
1 and NF-κB expression in human fibroblasts, while chronic exposures down-
regulates AP-1 and NF-κB (346). Also, in aortic endothelial cells and rat lung tissue, 
acute low dose arsenic treatment promotes nuclear accumulation of NF-κB (347, 
348). Cell survival-modulating changes to telomerase activity and telomere length 
have also been documented in cells treated with arsenic. Submicromolar doses of 
arsenite maintain telomere length by increasing telomerase activity; whereas 
higher concentrations promote telomere attrition and apoptotic cell death by 
inhibiting telomerase (349, 350).  
Arsenic disrupts redox state and re-routes metabolic activity within the cell (315). 
Metabolic reprogramming is now considered to be a hallmark/driver of cancer (12) 
which enhances cellular use of glycolytic metabolic pathways for energy production 
in aerobic conditions (351, 352). This process disrupts the provision of one-carbon 
intermediates to downstream metabolites through folate and methionine cycling 
pathways. One-carbon metabolism integrates cellular nutrient status by cycling 
carbon units from amino acid inputs to generate diverse outputs, including 
nucleotide metabolism, cellular biosynthesis and maintenance of redox 
homeostasis by restoring NADPH status and glutathione content (353).  
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Shifts in metabolic pathway flux have an indirect effect on gene expression 
programs through their impact on the activity of epigenetic modifiers, which rely on 
one carbon metabolism to maintain cofactor availability. Consequently, the 
epigenetic status of cells transformed by arsenic seems to be directly linked to one-
carbon metabolism through its influence on histone acetylation and nucleic acid 
methylation. 
1.4.2 Arsenic as an Epimutagen 
Arsenic-induced carcinogenesis is associated with epigenetic changes which 
influence the entire genome. Long-term, low-dose arsenic exposure is known to 
induce genome-wide changes to the epigenetic landscape in cultured cells, and 
these changes appear to mirror those observed in epidemiological studies. A causal 
relationship between arsenic-induced epigenetic damage and/or cancer risk in 
exposed populations, however, has yet to be established. Although the rate of 
epigenetic change varies somewhat between cell lines, histone posttranslational 
modifications occur within 24 hours (354, 355) and DNA methylation changes 
within 2-3 days of low-dose arsenic treatment (309, 356, 357). Long-term in vitro 
arsenic treatment generates epigenetic changes which are consistent with 
carcinogenic progression. These studies also indicate that exposure for 8-20 weeks 
is required for these changes to be associated with pre-carcinogenic transformation 
(358-360), however a mechanism for arsenic-induced epimutagenesis is yet to be 
uncovered. 
1.4.2.1 Methylation Damage 
Widespread modifications to genomic DNA methylation patterns are associated 
with arsenic exposure. Dose-dependent hypermethylation of gene promoters was 
first noticed in regions of the p53 gene following exposure of cultured cells to either 
As(III) or As(V) (309). Similarly, the p53 promoter region was shown to be 
hypermethylated in basal cell carcinomas (BCCs) from arsenic exposed individuals 
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relative to BCCs from non-exposed patients (361). In contrast, chronic treatment of 
rat liver cells with arsenic causes global hypomethylation of promoters and 
malignant transformation (360, 362). Changes to methylation patterns induced by 
arsenic are persistent, destabilizing (290), and have the potential to promote 
aberrant expression of genes involved in cell development and regulation, creating 
a procarcinogenic state (363).  
Activity and expression of p53 is dysregulated in arsenic-induced BCC and up-
regulated in sporadic (UV-induced) BCC, and this is thought to result from 
differences in the mutagenic mechanism of the agents involved (361, 364). Arsenic 
impairs the pattern of p53 expression by increasing DNA methylation at its 
promoter region (308), whereas characteristic UV-induced mutational lesions 
inactivate the DNA binding domain and extend its half-life by altering protein 
stability (365-368). This mutational fingerprint is characteristic of UV-induced 
NMSC, and so it appears that these cases may have resulted from combined arsenic 
and UV exposure.  
At this point in time, arsenic-induced DNA methylation changes are thought to 
result from impaired nucleotide methylation during replication. DNA 
methyltransferase-1 (DNMT1) is primarily involved with the maintenance of 
genomic imprinting patterns by transferring methyl groups from S-adenosyl 
methionine (SAM) to cysteine nucleotides (369). Extended arsenic exposure directly 
inhibits DNMT activity and expression in vivo and in vitro, and many studies also 
demonstrate decreased SAM availability and reduced global DNA methylation (370-
372). The most widely cited mechanism for CpG hypomethylation in arsenic-
transformed cells is competition for available methyl groups by DNMT1 and 
arsenite methyltransferase during arsenic biomethylation (360, 362). An alternative 
mechanism proposes that glutathione synthesis during oxidative stress redirects 
cellular stores of homocysteine from pathways which recycle DNMT cofactors, such 
as SAM (373, 374). However, although there is plenty of evidence to support a 
causative link between SAM insufficiency and DNA hypomethylation (375), some 
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inconsistencies and confounders exist – mostly due to the concomitant impact of B-
group vitamin availability on SAM synthesis. Human population studies are 
particularly contradictory, in part due to a wide range of exposure duration and 
dose in recorded populations, but also due to the significant impact of dietary 
folate on methylation capacity in exposed groups (376, 377). 
Adding to the epimutagenic nature of arsenic exposure, there is some evidence that 
DNMT1 plays a role in strand discrimination during DNA mismatch repair (378). 
Reversal of DNA methylation damage is most likely to proceed via the BER pathway, 
with GADD45α implicated in its coordination (379-381). Given the critical nature of 
the BER pathway for the repair of methylation changes and DNA damage created by 
oxidative stress, arsenic-induced disruption of BER has the potential to seriously 
impact cellular maintenance of epigenetic and genomic integrity, contributing to 
the procarcinogenic properties of arsenic.  
1.4.2.2 Chromatin Modifications 
Arsenic is known to influence histone posttranslational modifications, although 
investigations in this area are scant. Microarray experiments demonstrate global 
changes to histone methylation and promoter-specific shifts in histone H3 
acetylation with long-term exposure to arsenite (356, 382). Analysis of the 
relationship between arsenic-induced gene upregulation and histone H3 
modifications at a single promoter region during malignant transformation shows a 
significant reduction in trimethylated lysine 27 and dimethylated lysine 9, and 
significantly increased H3 acetylation and dimethylated lysine 4 (357, 383). 
Additionally, arsenite-induced histone H3 phosphoacetylation is associated with 
ERK-mediated c-fos and c-jun upregulation and caspase-10 induction (354, 355). 
Our hypothesis is that disruptions to metabolic and redox homeostasis in arsenic-
exposed cells are responsible for epigenetic reprogramming by modulating the 
activity of chromatin remodeling enzymes. Cellular metabolic activity influences the 
supply of cofactors for posttranslational histone modifications such as acetylation 
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and methylation (384, 385). Additionally, histone modifying enzymes are commonly 
redox sensitive (213, 386, 387), and maintenance of deacetylase activity in cancer is 
dysregulated by altered NAD availability (388). Thus environmental toxins which 
induce oxidative stress (such as arsenic) therefore promote cancer indirectly as a 
consequence of epigenomic remodeling during metabolic reprogramming. To test 
our hypothesis, this investigation aims to interrogate the relationship between the 
epigenetic effects of arsenic toxicity and histone deacetylase activity. 
1.4.2.3 MicroRNA Expression 
Investigations into the impact of arsenic on microRNA expression are in their 
infancy, however a handful of studies indicate that arsenic exposure significantly 
alters the cellular miRNA profile. Arsenic treatment (4 µM, 24 hours) upregulated 
miR-24, miR-29a, miR-30a and miR-210 in HepG-2 cells (389); and was associated 
with down-regulation of miR-19a and up-regulation of miR-222* in T24 cells (390). 
The microRNA expression profile changes in cells transformed with As(III), and 
interestingly, these changes appear to be cell line-specific [Table 1:9]. 
As yet, a mechanism of action for arsenic-mediated changes in miRNA regulation 
has not been uncovered. Also, whether arsenic-induced carcinogenesis in exposed 
human populations is characterized by specific changes in microRNA expression is 
yet to be determined. However, considering the relationship between arsenic 
exposure and DNA methylation, there may be a causal link between arsenic-
induced promoter hypermethylation and miRNA precursor expression. We intend 
to investigate this hypothesis during the course of this study. 
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Table 1:9  microRNA expression profiles in arsenic-exposed cell lines 
As(III) (µM) Duration Cell line miRNA Change miRNA Change Ref 
4.0 µM 24 hr HepG2 miR-30a 3.84 miR-744 0.64 (389) 
miR-210 3.09 miR-296-5p 0.63 
miR-29a 2.99 miR-663 0.59 
miR-24 2.9 miR-675 0.58 
miR-886-3p 1.8 
2.5 µM 16 wks HBEC miR-200b 0.0049 miR-141 0.013 (391) 
miR-200a 0.11 miR-429 0.015 
miR-200c 0.018 
4.0 µM 24 hr T24 miR-19a 0.420 miR-222* 2.32 (390) 
1.0 µM 15 wks HELF miR-21 6.8 (392) 
2.0 µM 48 hr HL-60 let-7d 0.45 (393) 
NB4 miR-766 0.6 
5.0 µM 29 wks RWPE-1 miR-134 ↓14.6 miR-125a-5p ↓2.6 (394) 
miR-127-5p ↓13.2 let 7b ↓2.6 
miR-373 ↓10.6 miR-181b ↓2.6 
miR-9 ↑7.4 miR-98 ↓2.4 
miR-34c-5p ↓5.9 let-7i ↓2.1 
miR-146b-5p ↓5.7 miR-34a ↓2 
miR-135b ↓5.4 miR-196a ↓2 
miR-222 ↓5 miR-181a ↓2 
miR-155 ↓4.4 miR-183 ↑2 
miR-138 ↓4.2 let-7e ↓1.9 
miR-205 ↓4.1 miR-181c ↓1.9 
miR-218 ↓2.9 let-7c ↓1.8 
miR-10b ↓2.9 miR-125c ↓1.8 
miR-181d ↓2.8 miR-126 ↓1.6 
miR-96 ↑2.7 
5.0 µM 18 wks WPE miR-9 ↓2.6 miR-143 ↓4.8 
miR-34c-5p ↓2.4 let-29b ↑1.9 
miR-135b ↓5 miR-193b ↑1.8 
miR-138 ↓1.8 miR-355 ↓1.8 
miR-205 ↓2.4 miR-7 ↑1.7 
miR-218 ↓4.4 miR-148a ↓1.7 
miR-34a ↑2.3 
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Table 1:10  Arsenic-Induced Epimutagenesis 
Cell Line/Species Concentration Duration Epigenetic Change Reference 
Mouse lung 50 ppm As(V) 12 weeks ↓ methylation in promoter regions, no change in coding domain (395) 
Mouse liver 45 ppm 48 weeks Global hypomethylation; ↓ methylation of the ER-α promoter (362) 
HepG2 & Huh-7  2 & 10 uM As(III) 24, 48, 72 hours Reversal of hypermethylation - p16INK4a, RASSF1A, E-Cadherin, GSTP1  (371) 
A/J mouse lung 1, 10, 100 ppm As(V) 18 months ↑ in promoter methylation of p16INK4a and RASSF1A  (370) 
Molt4, MUTZ-1, 
U937, U266, 
CA46 
0.5, 1 and 2 uM As(III) Demethylation of CDKN2B and CDKN2A promoter sequences (372) 
UROtsa 1 uM As(III); 50 nM MMAs(III) 24, 52 weeks ↓ H3 acetylation DBC1, FAM83A, ZSCAN12, C1QTNF6, ↑ H3 acetylation NEFL (356) 
↑ AcH3K9, AcH3K14 and me2H3K4;  ↓ me3H3K27 and me2H3K9 (357) 
Promoter hypermethylation (single copy elements), hypomethylation 
(microsatellites)  
(383) 
NB4 0.2, 0.4, 0.8, 1.6 uM As(III) 24-72 hrs ↑ H3 phosphorylation (S10) and H3 acetylation (K14) of caspase-10 associated 
chromatin 
(354) 
WI38 50, 100, 200, 400 uM As(III) 10, 30, 60 min ↑ H3 phosphorylation (S10) and H3 acetylation (K14) of c-fos and c-jun  (355) 
A549 0.08-2 uM As(III); 30-300 uM 
As(V); 2-2000 uM 
DMAs(III) 
1-2 weeks ↑ CCGG methylation status; ↑ in 5-MeC content [p53 promoter] (309) 
HaCaT  0.2 uM; 25 uM As(III) 1 - 72 hrs Global hypomethylation (reduced 5-methyl-dCMP) [0.2 uM, 10 passages] (396) 
V79-C13  10 uM As(III) 24 hrs Genome-wide DNA hypomethylation (290) 
TRL1215  0.125, 0.25, 0.5 uM As(III)  8, 18 weeks Dose-dependent genomic hypomethylation (360) 
A549, BEAS-2B 0.1, 1, 2.5, 5, 10 uM As(III)  24 hours ↑ me3H3K4;  ↑ me2H3K9, ↓ me3H3K27 (382) 
SK-MEL5, SK-MEL28, 
SK-MEL31, 
RPMI7951  
1, 2.5, 5 uM As(III) 24 hours Dose-dependent increase in H2AX phosphorylation (S139) (397) 
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Exposure to sub-lethal doses of arsenite promotes the genotoxicity of mutagens. 
One of the more critical stages in carcinogenic transformation is the ability to 
successfully adopt genetic changes acquired during initiation. Arsenic exposure 
facilitates the transition from initiation to promotion stages in carcinogenesis by 
generating a combination of oxidative DNA damage, altered regulation of cellular 
stress responses, and inhibition of DNA repair. For these changes to progress it has 
been generally accepted that a secondary contributing mutagen (such as UV 
exposure) is necessary for arsenic to produce malignant clonal lines. However, 
more recent insights into the role of epimutagenesis in cancer indicate that arsenic-
induced epigenetic damage may provide the requisite changes necessary for 
autonomous progression. 
Long-term in vitro arsenic treatment generates epigenetic changes consistent with 
this model of carcinogenesis, progressively increasing chromosomal instability and 
epigenetic changes with exposure [Table 1:10]. Maintaining control over gene 
transcription is particularly important to cellular function. Equally important is the 
cell’s ability to maintain and perpetuate its genetic code. Alterations to both of 
these processes are common to most, if not all cancers. How these changes develop 
in the presence of carcinogenic stimuli and how cellular stress responses influence 
epigenetic patterns are major questions addressed by our investigation. 
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Overview 
TP53 is the most frequently mutated gene in cancer, indeed p53-mediated 
regulation of cell cycle control and cell death signalling is a barrier which must be 
overcome for cancer to progress. However, p53 mutations which contribute to 
cancer are complex and produce a heterogeneous suite of cellular responses. The 
conformation and expression of mutated p53 proteins is highly variable and 
consequently, the efficacy of p53-based cancer therapy is dependent on p53 
mutational status.  
Mediators of the DNA damage response pathway in tumour cells are attractive 
targets for chemotherapeutic development. In particular, treatments which 
generate DNA damage-dependent responses have the potential to overcome 
apoptotic resistance and/or trigger functional senescence in cells with functional 
mutations to p53. This is a valuable property in targeted cancer therapy, 
considering the ubiquitous nature of TP53 loss of function mutations in human 
tumours.  
Altered epigenetic expression patterns are common features of tumourigenesis and 
contribute to the development of the cancer phenotype. The maintenance of 
normal epigenetic imprinting across cell generations is intrinsically linked to the 
DNA damage response, and thus disrupted regulation of effector activity impacts on 
the epigenetic code. As such, changes in promoter methylation, chromatin 
condensation patterns and microRNA expression are useful biomarkers for cancer 
development and prognosis. Our understanding of SIRT1 and miR-34a as key 
regulators of adaptive responses to cellular stress has increased dramatically during 
the past 10 years. Consequently, impairments to miR-34a-mediated feedback 
regulation of SIRT1 are intrinsically associated with the pathology of chronic 
disease.  
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Arsenic exposure disrupts established patterns of DNA methylation and 
posttranslational histone modifications; however the relationship between arsenic-
induced epigenetic dysregulation and carcinogenesis has not been conclusively 
established. Our hypothesis is that arsenic interferes with the regulatory activity of 
epigenetic modifying enzymes such as SIRT1. This thesis explores the mechanism by 
which an effective cellular response to chronic stress is affected by the lysine 
deacetylase SIRT1 in keratinocytes with p53 mutations. Specifically, this 
investigation will address the role of SIRT1 in arsenic-mediated keratinocyte 
transformation and skin cancer development. 
Overall aims of this project: 
1. To determine the influence of p53 mutational status on p53/SIRT1/miR-34a
axis activity by comparing cellular stress responses in normal and p53-
mutated keratinocytes
2. To observe the influence of arsenic on keratinocyte growth and replication
in culture
3. To investigate the effect of arsenic exposure on feedback regulation of the
p53/SIRT1/miR-34a axis in human keratinocytes
4. To document the effect of arsenic exposure on epigenetic regulation of the
p53/SIRT1/miR-34a axis by measuring histone modifications and CpG island
methylation changes at SIRT1 and miR-34a gene promoters
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Structure of the Thesis 
A review of the relevant literature is presented in Chapter 1, followed by a general 
description of experimental materials and methods used during the investigation 
(Chapter 2). Chapter 3 covers initial work performed in order to characterise cell 
lines and optimise culture conditions prior to investigating the research aims. 
Chapters 4 and 5 describe the relationship between SIRT1 activity, p53 acetylation 
status and genotoxic stress responses in human keratinocytes (Research Aim 1). 
These investigations used RNAi and pharmaceutical techniques to alter target gene 
expression and activity, and assayed apoptotic signalling in wild-type and p53-
mutated keratinocytes. 
Chapter 6 evaluates the effect of arsenic on histone acetylation status and 
chromatin condensation at target gene promoters using a 24 hour exposure period 
(Research Aims 3 and 4). 
Long term studies in Chapter 7 were designed to explore a correlation between 
procarcinogenic effects of arsenic exposure on epigenetic regulation of SIRT1 and 
miR-34a gene expression in cultured human keratinocytes by documenting CpG 
dinucleotide methylation at gene promoters (Research Aims 2, 3, 4). 
Research Chapters 3-7 are followed by a General Discussion and Summary of the 
thesis. The last sections describe buffer solutions and procedures performed to 
optimise experimental methods (Supplementary Material), and abstracts from 
manuscripts and presentations produced during the course of the investigation. 
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General Materials and Methods 
Chapter 2 
2.1 GENERAL PROCEDURES 2.1.1 Biological Containment and Sterilisation 
Buffer solutions for use in cell culture, and consumables contaminated with 
biological material were sterilised by autoclaving at 121°C (115 kPa) for 20 minutes. 
Heal labile solutions such as growth media and bovine serum albumin (BSA) were 
sterilised by passing the solution through a sterile disposable 0.2 µm filter unit. 
Frequently used sterile solutions for use in cell culture were stored in aliquots. 2.1.2 Maintaining Sample Integrity 
Procedures involving nucleotide extraction, reverse transcription and PCR setup 
were all carried out using filtered pipette tips to prevent between-sample cross-
contamination. When purified nucleotide extracts were used, all procedures were 
performed in a controlled airflow cabinet to minimise aerosol production. Prior to 
RNA extraction, workbenches were treated with RNaseZap® to reduce RNase 
contamination. 2.1.3 Stock Solutions 
Commonly used solutions and buffers were prepared as stock concentrates and 
stored at room temperature or −20°C as indicated. Recipes are provided in the 
Supplementary Materials. 
The vendors, catalogue numbers, lot numbers and dilutions of antibody solutions 
used in this study are as follows: 
2.2 SPECIFIC MATERIALS 
Vendors, catalogue numbers, lot numbers and dilutions of antibody solutions used 
in this study are as follows: 
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Target Antibody Vendor Location Catalogue # Lot # Dilution
SirT1(C14H4) Rabbit mAb Cell Signaling Technology Beverly, MA 2496 Lot 1 1:1000
Acetyl-p53 (Lys382) Antibody Cell Signaling Technology Beverly, MA 2525 Lot 10 1:500
X-Actin Antibody Millipore Billerica, MA MAB 1501R
LV1519577/LV
1368255
1:5000
p53 Antibody  Cell Signaling Technology Beverly, MA 9282S Lot 4
1:1000 (WB); 
1:100 (ChIP)
Anti-Involucrin Antibody Abcam Cambridge, UK ab97764 1:1000
Anti-Cytokeratin 10 Antibody Abcam Cambridge, UK ab53112 1:500
Anti-Filaggrin Antibody Abcam Cambridge, UK ab81468 1:1000
Nanog (D73G4) Cell Signaling Technology Beverly, MA 4903 1:1000 (WB)
p53 Antibody (Pab 1801) [N-
terminal aas 32-79]
Santa-Cruz Biotechnology Santa-Cruz, CA sc-98 D2009
1:1,000 (WB); 
1:100 (IP)
SirT1 (D739) Antibody Cell Signaling Technology Beverly, MA 2493S 0002 1:1000 (WB)
p53 (7F5) Antibody Cell Signaling Technology Beverly, MA 2527S 0006 1:1000 (WB)
Anti-acetyl Histone H4 (Lys16) Millipore Temecula, CA 07-329 2178420 1.0 mg/ml
Anti-Histone H4 antibody - 
ChIP Grade
Abcam Cambridge, UK ab10158 GR103452
2 ug/25 ug 
chromatin
Anti Histone H4 (acetyl K16) 
antibody - ChIP Grade
Abcam Cambridge, UK ab61240 0.1 ug/ml
HRP-Conjugated anti-Rabbit 
IgG
Cell Signaling Technology Beverly, MA 7074P2 20 1:10000
HRP-Conjugated anti-Mouse 
IgG
Cell Signaling Technology Beverly, MA 7076S 22 1:10000
Mouse Anti-Rabbit IgG (Light 
Chain Specific) (L57A3) mAb
Cell Signaling Technology Beverly, MA 2525S 1:1000
p53 Antibody  Cell Signaling Technology Beverly, MA 9282S Lot 4
1:1000 (WB); 
1:100 (ChIP)
PARP Antibody Cell Signaling Technology Beverly, MA 9542 1:1000
61 | 
Chapter 2 
2.3 CELL CULTURE 2.3.1 Cultured Cells 
2.3.1.1 Primary Keratinocytes (NHEKs) 
Primary human epidermal (NHEK) keratinocytes isolated from neonatal foreskin 
and cryopreserved at the end of primary culture were obtained from Cascade 
Biologics (Life Technologies Corporation, Carlsbad, CA) [Figure 2:1]; and maintained 
in EpiLife® Medium supplemented with Human Keratinocyte Growth Supplement 
(HKGS) and 100 ng/ml kanamycin sulfate in a humidified incubator at 37°C and 5% 
CO2. Cells were seeded at a density of ≥ 2.5 × 103 cells/cm2 and the culture medium 
replaced every 2-3 days. 
NHEK cells were passaged when confluence reached ≤70% in the following manner: 
growth medium was aspirated from the culture flask, and the cells washed in 20 ml 
of pre-warmed Hank’s balanced salt solution (HBSS, Ca2+ and Mg2+ free). Adherent 
cells were detached from the culture flask by incubation for 3-5 min in 0.025% 
trypsin-EDTA, and the reaction quenched by adding an equivalent volume of 0.5 
mg/ml soybean trypsin inhibitor in PBS to the suspension.  Culture flasks were re-
seeded with 1:10 of the harvested cells in complete media, and the remainder used 
to seed plates for subsequent experimental treatments. 
2.3.1.2 HaCaT Keratinocytes 
The HaCaT cell line is a spontaneously transformed adult keratinocyte cell line 
which is non-tumorigenic and considered immortal due to its ability to proliferate 
beyond passage 140 in culture (398) [Figure 2:1]. HaCaTs are compound 
heterozygotes with mutations to the conserved domains of the P53 gene. These 
were identified as a C → T transition in codon 179 of exon 5 in one P53 allele, and 
consecutive CC → TT transitions in codons 281 and 282 of exon 8 in the other P53 
allele (Lehman 1993). The codon 179 mutation causes a histidine residue to be 
replaced with tyrosine in the DNA binding domain of the p53 protein, whereas the 
codon 282 mutation results in replacement of arginine with tryptophan. Codon 282 
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of P53 is a frequently mutated CpG site which is considered to be particularly 
vulnerable to sunlight-induced UV damage. This mutation is associated with 
accumulation of p53 protein, possibly as a result of structural changes to the Mdm2 
binding site. 
Mutations to the p53 gene in our HaCaT cell line were confirmed by sequencing PCR 
product amplified from cDNA following reverse transcription from RNA (sequencing 
experiments are described in detail in Chapter 3). Additionally, no mutations were 
found in the p53 sequence of NHEK cells. These results allow us to be confident that 
the assumptions we made with regards to p53 status in both HaCaT and NHEKs 
which informed our experimental model are sound. 
Figure 2:1 Neonatal human (NHEK) and p53-mutated (HaCaT) keratinocytes – Morphology in Culture 
Human keratinocyte cells were seeded in 6 well culture plates at a density of 4  105 cells/cm2 and 
allowed to recover overnight. The culture medium was removed and the cells fixed in ice-cold 3.7% 
formaldehyde/PBS solution prior to staining with 0.05% crystal violet solution for 30 minutes. 
Stained cells were magnified with an Olympus IX71 inverted microscope (Olympus, Center Valley, 
USA) and photographed using an Optronics digital camera (model 60800, Goleta, USA). Images were 
generated using Optronics Magnafire software (version 2.1, Goleta, USA). 
HaCaT cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with 
Ham’s Nutrient Mixture F-12 (D-MEM/F-12) supplemented with 7.35 mg/L 
GlutaMAX™, 100 ng/ml kanamycin sulfate and 5 % foetal bovine serum (FBS) or 
EpiLife® Medium supplemented with Human Keratinocyte Growth Supplement 
(HKGS) and 100 ng/ml kanamycin sulfate in a humidified incubator at 37°C and 5% 
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CO2.  The HaCaT cell line was passaged at ≤80% confluence in the following manner: 
growth medium was aspirated from the culture flask, and the cells washed in 20 ml 
of pre-warmed phosphate buffered saline (PBS, Ca2+ and Mg2+ free). Adherent cells 
were detached from the culture flask by incubation for 3-5 min in 0.025% trypsin-
EDTA, and the reaction quenched by adding an equivalent volume of complete 
media to the suspension. Culture flasks were re-seeded with 1:20 of the harvested 
cells in complete media, and the remainder used to seed plates for subsequent 
experimental treatments.  
2.3.2 Performing Cell Counts 
Detached cells were pelleted by centrifugation at 150g for 5 min at room 
temperature, the supernatant aspirated and the cells resuspended in a known 
volume of liquid. Ten microliters of a 1:10 dilution of cell suspension stained with 
0.1% Trypan Blue solution was loaded into a haemocytometer chamber and viable 
cells counted using an inverted microscope. Harvested cells were equal to the outer 
square count multiplied by 10 (dilution factor) × 104 cells/ml. Active dye exclusion 
enabled viable cells to be differentiated from blue stained dead cells, and the viable 
cell count estimated from the percentage of live cells within the total population.  2.3.3 Cryopreservation and Reconstitution of Cell Lines 
Early passage (P1/P2) cells were harvested, pelleted, and the viable cell count 
determined using techniques outlined above. The cell pellet was resuspended at a 
density of 1 × 106 cells per ml in cold freezing medium [10% FBS & 7.5% dimethyl 
sulfoxide (DMSO) in D-MEM/F12 (HaCaT) or 5% DMSO in EpiLife® with HKGS (NHEK, 
HaCaT)] and divided into 1 ml aliquots in Greiner BioOne cryovials. The cryovials 
were placed in a NALGENE® Cryo 1°C Freezing Container containing isopropanol 
and frozen overnight in a −80°C freezer before transferring to liquid nitrogen. 
Cells were revived by thawing the cryovials rapidly in a 37°C waterbath the cell 
suspension diluted in 10 ml of prewarmed complete medium (dropwise with gentle 
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agitation for the initial 2 ml, gradually thereafter) and the suspension was triturated 
slowly for 5 minutes to promote DMSO expulsion. Revived cells were pelleted by 
centrifugation at 150g for 5 minutes, the cryopreservation medium aspirated and 
the pellet reconstituted in growth medium for incubation at 37°C and 5% CO2. 
2.4 MICROPLATE ASSAYS 2.4.1 Viability Assays 
2.4.1.1 AlamarBlue 
Prior to each experiment, a within-well assay was used to titrate treatment doses 
for each culture. The alamarBlue® assay measures innate metabolic activity of 
viable cells with an oxidation-reduction indicator (resozurin) that both fluoresces 
and changes colour in response to chemical reduction (399, 400). Cells were 
exposed to test compounds and alamarBlue® reagent added to each well at 10% of 
the treatment medium volume at the end of the treatment period (typically 24 hrs). 
Culture plates were incubated with alamarBlue® reagent for 3 hours, after which 
fluorescence emission was measured at 595 nm using excitation at 540 nm using an 
Infinite M200-Pro plate reader [Tecan, GmbH, Grödig, Austria]. Positive and 
negative (medium only) control wells were included on each plate to calibrate the 
fluorescence reading and to allow for between-plate standardisation.  
2.4.1.2 CyQUANT 
Since alamarBlue was unable to discriminate between apoptotic and necrotic cell 
death, more specific multiwell cytotoxicity assays which use target-bound 
fluorophores or target-triggered chemiluminescence were required to quantitate 
apoptosis. As the signal generated in these assays is sensitive to cell number as well 
as apoptotic activity, two cell proliferation assays were used in order to standardise 
the signal for variations in seeding density. Toxicity assays were normalised for 
metabolically active cell number using a fluorescent assay for cellular DNA content 
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(CyQUANT® NF assay [Molecular Probes, Inc. Eugene, OR]), and a chemiluminescent 
assay for cellular ATP content (ATPLite assay [Perkin Elmer, Boston, MA. USA]).   
The CyQUANT assay uses fluorescent dye binding to cellular DNA as a quantitative 
measure of cell number [Figure 2:2 (a)]. To perform the analysis, microplates were 
removed from incubation and equilibrated to room temperature. Treatment media 
was aspirated and replaced with working CyQUANT NF dye reagent (1:500 dilution 
of DNA dye binding solution in Hank’s Balanced Salt Solution (HBSS). Fluorescence 
was read using an Infinite M200-Pro plate reader [Tecan, GmbH, Grödig, Austria] 
with an excitation wavelength of 485 nm and an emission wavelength of 530 nm 
after 60 min incubation at 37°C. The signal was analysed relative to a no 
cell/medium only background reading.  
Figure 2:2  Cell Proliferation assays – Linearity 
Primary keratinocyte (NHEK) and p53-mutated (HaCaT) cells were seeded into microplate wells using 
a suspension series from 0-10,000 cells/well and incubated overnight at 37°C and 5% CO2. Cell 
number was analysed by relative fluorescence and chemiluminescence using CyQUANT and ATPLite 
viability assays according to the manufacturer’s instructions. Both CyQUANT and ATPLite assays 
generated a linear analytical response from 0-10,000 per well in a 96 well microplate. 
2.4.1.3 ATPLite 
The ATPLite assay provides a quantitative determination of cell viability through 
detection of ATP content using luciferase and D-luciferin according to the following 
reaction scheme: 
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To perform the assay, microplates were removed from incubation, equilibrated to 
room temperature and cells lysed with mammalian lysis solution for 5 min prior to 
addition of luciferin substrate. Luminescence was read a using an Infinite M200-Pro 
plate reader [Tecan, GmbH, Grödig, Austria] after 5 min incubation on an orbital 
shaker. The signal was analysed relative to a no cell/medium only background 
reading [Figure 2:2 (b)]. 
2.4.2 Cytotoxicity Assays 
The Topoisomerase I inhibitor, camptothecin (CPT), is a well-established S-phase-
specific component of chemotherapeutic management strategies which activates 
the cell death program in cancer cells by generating DNA strand breaks (401, 402). 
CPT-mediated apoptosis is predominantly p53-dependent (37), and has been widely 
characterised in cultured cell systems. For this study, 24 hr exposure duration was 
used to be more efficient time-wise. 
Colorimetric, fluorimetric and chemiluminescent assays were used to measure 
metabolic activity, caspase 3/7 activity, LDH release and PARP cleavage as apoptotic 
endpoints. Care was taken to minimise variability by using identical growth medium 
constituents for both cell cultures (see Chapter 3 for details), and by 
standardisation of inter-assay treatment and sampling parameters. 
2.4.2.1 Apo-ONE Caspase 3/7 Assays 
Apoptotic cells can be recognised by a characteristic pattern of morphological, 
biochemical and molecular changes. Broadly speaking, the apoptotic fraction of a 
population is determined by i) measuring membrane changes, ii) assaying changes 
in mitochondrial and/or cytoplasmic enzyme activity, and iii) analysing DNA 
fragmentation. For this study, the Apo-ONE Homogeneous Caspase-3/7 Activity 
Assay [Promega, Madison, MI, USA], the CytoTox-ONE™ Assay [Promega, Madison, 
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MI, USA] and relative PARP cleavage were employed to assay cytotoxicity and to 
discriminate between apoptotic and necrotic effects on treated cells. 
The Apo-ONE assay uses the caspase 3/7 substrate rhodamine 110, bis-(N-CBZ-L-
aspartyl-L-glutamyl-L-valyl-L-aspartic acid amide); [Z-DEVD-R110], which exists as a 
profluorescent substrate prior to the assay. Upon sequential cleavage and removal 
of the DEVD peptides by cellular caspase-3/7 activity and excitation at 499 nm, the 
rhodamine 110 leaving group fluoresces with an emission wavelength of 530 nm. 
The amount of fluorescent product generated is proportional to the amount of 
caspase-3/7 cleavage activity present in the sample. To perform the assay, Apo-ONE 
reagent was added to pre-equilibrated microplates and incubated at room 
temperature for 30 min while protected from light. Fluorescence intensity was 
measured using an Infinite M200-Pro plate reader [Tecan, GmbH, Grödig, Austria]. 
2.4.2.2 CytoTox-ONE LDH Release Assay 
The CytoTox-ONE assay measures lactate dehydrogenase (LDH) release from cells 
with a damaged membrane. Release of LDH from damaged cells is measured by 
supplying lactate, NAD+, and resazurin as substrates in the presence of diaphorase. 
Generation of the fluorescent resorufin product is proportional to the amount of 
LDH in the culture medium. 
To perform the assay, CytoTox-ONE reagent was added to pre-equilibrated 
microplates and incubated at room temperature for 10 min while protected from 
light. The reaction was quenched with Stop solution to stabilise the signal and 
fluorescence read at an emission wavelength of 590 nm after excitation at 560 nm 
using an Infinite M200-Pro plate reader [Tecan, GmbH, Grödig, Austria]. LDH 
release was analysed by subtraction of background fluorescence from all values.  
2.4.2.3 PARP Cleavage 
Relative PARP cleavage was determined by immunoblotting cell lysates from 
treated NHEKs and HaCaTs cultured in 6-well plates. PARP1 binds to breaks in the 
sugar-phosphate backbone of DNA, modifying surrounding histones to induce 
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chromatin relaxation. Additionally, contact with DNA strand breaks triggers 
autoribosylation and recruits DNA repair enzymes to the site of DNA damage. 
During apoptosis, PARP undergoes caspase 3-mediated proteolytic cleavage from a 
full-length 116 kDa protein to 89 kDa (carboxy-terminal catalytic domain) and 24 
kDa (amino-terminal DNA binding domain) fragments. Thus PARP1 acts as a DNA 
damage sensor within the cell, and can be used as a molecular biomarker for 
apoptotic activity. 
Homogenisation of cells releases proteolytic enzymes into the lysate and shears 
DNA. PARP1 undergoes autoribosylation in these conditions, even in the presence 
of protease inhibitors. Posttranslational modification by polyribosylation alters the 
molecular weight of full length and cleaved PARP during immunoblotting, making 
quantitation difficult. This can be abrogated by including urea in the sample 
extraction buffer, which dissociates PARP from any DNA in the lysate, preventing 
activation of the ribosylation reaction [Figure 2:3]. 
Figure 2:3 Immunoblotting of apoptotic samples extracted in RIPA or PARP lysis buffer solutions 
Primary keratinocyte (NHEK) and p53-mutated (HaCaT) cells were grown in 6-well culture plates 
and treated with 5 µM CPT for 24 hr. Protein was isolated using Radioimmunoprecipitation assay 
(RIPA) and PARP lysis buffer solutions and separated on 8% polyacrylamide by SDS-PAGE. Full-
length and cleaved PARP subunits were detected using anti-PARP1 antibodies by immunoblotting. 
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In order to include all apoptotic cells for analysis of PARP cleavage, the detached 
fraction of cells in treatment medium was aspirated separately from each well, 
pelleted by centrifugation at 500 rcf for 5 min and washed in ice-cold PBS, 
repelleted and lysed using 50 µL of PARP sample buffer [62.5 mM Tris/HCl, pH 6.8; 
6M urea; 10% glycerol; 2% SDS; 0.00125% bromophenol blue; 5% β-
mercaptoethanol, protease and phosphatase inhibitors]. The adherent fraction of 
cells was washed in PBS and lysed in situ on ice using a further 100 µL of PARP 
sample buffer. The two fractions of lysed cells were combined, and the DNA 
sheared by passing the sample 6-7 times through a 25 gauge needle. These samples 
were boiled for 10 min and loaded onto 8% polyacrylamide for separation by SDS-
PAGE. Expression of full-length and cleaved PARP was detected using polyclonal 
antibodies directed towards the PARP1 cleavage site (Asp214-Gly216) [Cell 
Signaling Technology #9542; Beverly, MA] by western protein analysis according to 
the protocol outlined below. 
2.5 WESTERN PROTEIN ANALYSIS 2.5.1 Sample Preparation 
2.5.1.1 Cell Lysates 
Treatment media was aspirated from the culture vessel and cells washed once in 
ice-cold PBS. Chilled lysis buffer was added (150 µl per well) and plates incubated 
for 20 minutes on ice. Wells were scraped with a cell scraper and detached cell 
samples aspirated into 1.5 ml microcentrifuge tubes. Homogenisation was 
completed by passing the lysate through a 25 gauge needle 5-6 times. Lysates were 
clarified by centrifugation at 15,000g for 10 minutes in a chilled centrifuge, and the 
supernatant transferred to a fresh tube. Total protein was assayed and the lysates 
stored at −20°C until use.   
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2.5.1.2 Determination of Total Protein 
Working BCA assay reagent was prepared according to the manufacturer’s 
specifications [4% copper (II) sulphate pentahydrate solution diluted 1:50 in 
bicinchoninic acid solution]. Two hundred microliters of working solution was mixed 
with 25 µl cell lysate diluted 1:5 in lysis buffer in a 96 well microtiter plate and 
incubated at 37°C for 30 minutes. Absorbance was measured at 595 nm using a 
microplate reader, and protein readings were determined against a standard curve 
prepared by diluting bovine serum albumin (BSA) in lysis buffer. 
2.5.2 SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis) 
Polyacrylamide gels were prepared in a BioRad casting module using the following 
formulations. During polymerisation, the separating gel was overlaid with water-
saturated butanol, after which the butanol was aspirated and replaced with a 4.5% 
stacking gel into which the comb was placed. After complete polymerisation 
(approx. 1 hour), gels were assembled in a BioRad Mini-PROTEAN® Tetra Cell 
electrophoresis module and equilibrated in SDS-PAGE running buffer for 5 minutes. 
Separating Gel; 37.5:1 Stack Resolving 
Component 4.5% 10% 15% 8% X% 
40% Acrylamide 240 ul 2.43 ml 3.51 1.944 ml 2.34*[Vol (ml)]*(X%) 
2% Bisacrylamide 130 ul 1.34 ml 2.01 1.072 ml 1.34*[Vol (ml)]*(X%) 
0.5 M Tris-HCl (6.8) 630 ul 
1.5 M Tris-HCl (8.8) 2.5 ml 2.5 ml 2.5 ml Total/4 
20% SDS 25 ul 100 ul 100 ul 100 ul Total/100 
H2O 1.46 ml 3.58 ml 1.825 ml 4.329 ml 
10% APS 12.5 ul 50 ul 50 ul 50 ul Total/200 
TEMED 2.5 ul 5 ul 5 ul 5 ul Total/2000 
Total 2.5 ml 10 ml 10 ml 10 ml 
Samples were prepared by boiling for 5 min at 99°C in 4× Laemmli reducing buffer, 
and the equivalent of 10 μg total protein was loaded onto the gel. A dye-conjugated 
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molecular weight marker was loaded onto each gel for reference. Proteins were 
separated by electrophoresis at 120V for 2 hours. 
2.5.3 Immunoblot Preparation and Analysis 
SDS-PAGE gels were removed from the electrophoresis tank and equilibrated in 
cold transfer buffer for 15 minutes prior to transfer sandwich assembly. PVDF 
membranes were pre-wetted in 100% methanol for 30 seconds and the gels placed 
next to PVDF membrane between cellulose blotting paper. Proteins were 
transferred to the membrane at 1.5 Amps and 25 V in a BioRad Trans-Blot Turbo® 
electrophoretic transfer system. Following transfer, the membranes were 
incubated in blocking buffer (5% non-fat milk powder in Tris-buffered Tween-20 
[TBST]) for 30 minutes at room temperature, rinsed briefly in TBST and placed in 50 
ml Falcon tubes with primary antibody solution for overnight incubation at 4°C on a 
roller. Membranes were then washed three times for 5 minutes each in TBST, and 
incubated for 2 hours in horseradish peroxidase-conjugated (HRP) secondary 
antibody solution at room temperature. Residual secondary antibody was removed 
from the membrane by washing four times for 5 minutes each in TBST, and the 
membranes were developed in chemiluminescent HRP substrate (Millipore, 
Billerica, MA) for 5 minutes. The chemiluminescent signal was detected using a Las-
3000 Luminescent Image Analyser (Fujifilm, JPN), and MultiGauge software 
(Fujifilm, JPN) used for densitometric analysis of the signal.   
2.6 GENE EXPRESSION 2.6.1 RNA Extraction 
Cellular RNA was extracted from treated samples using a MO-BIO Ultraclean® 
Tissue & Cells RNA Isolation kit according to the manufacturers’ instructions with 
minor changes. Briefly, approximately 5 × 105 cells were disrupted in 250 µl Solution 
TR1 with 1% β-mercaptoethanol, scraped into a 1.5 ml microcentrifuge tube and 
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homogenised by passing the solution through a 25 gauge needle 5-6 times. An 
equal volume of Solution TR2 was added to the lysate, mixed thoroughly by 
pipetting and the sample transferred to a spin column. The spin column was 
centrifuged at ≥ 10,000 rpm for 1 min in a microcentrifuge and the flow-through 
discarded. The spin filter was washed by adding 500 µl Solution TR3 and 
centrifuging at ≥ 10,000 rpm for 1 min and transferred to a fresh collection tube. 
The spin column was washed twice using 500 µl of Solution TR4 with centrifugation 
at ≥ 10,000 rpm for 1 min after each step. The spin filter was thoroughly dried by 
centrifugation at 13,000 rpm for 2 min and transferred to a new collection tube. 
Sample RNA was eluted from the membrane by adding 30 µl of Solution TR5 
directly to the membrane; incubating at room temperature for 1 minute and 
centrifugation ≥ 10,000 rpm for 2 min. Eluted RNA was stored at −20°C (1 month) or 
−80°C (6 months).  
2.6.1.1 Total RNA 
Working RNA assay solution was prepared by diluting Qubit™ RNA BR Reagent 
1:200 in Qubit™ RNA BR Buffer. A 1:10 dilution of each sample was added to 
working RNA assay reagent to a final volume of 200 µl, vortexed thoroughly and 
incubated at room temperature for 2 minutes prior to reading fluorescence with a 
Qubit™ fluorometer. RNA concentration was determined relative to a standard 
curve prepared using a 100 ng/µl standard solution.  
2.6.1.2 RNA Integrity 
The integrity of extracted RNA was analysed using the Experion™ automated 
electrophoresis system according to the manufacturer’s instructions (BioRad). 
Briefly, StdSens RNA analysis reagents were allowed to come to room temperature 
and the analysis chip was primed by adding 9 µl of Gel Stain solution into the 
priming well, and running the priming program. The chip was prepared with Gel and 
Gel Stain solution, and buffer added to each sample well. RNA ladder and sample 
were denatured by heating for 2 minutes at 70°C and cooling on ice for 5 minutes, 
and loaded onto the chip. Each electrophoretogram was analysed for RNA 
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concentration and integrity on an Experion analyser using the Experion software 
[Figure 2:4]. 
Figure 2:4 Quantification and determination of RNA integrity 
Electrophoretogram (a) and Virtual Gel (b) of RNA extracts analysed using the Experion Automated 
Electrophoresis System 
2.6.2 Reverse Transcription 
First strand cDNA was synthesised using a Tetro cDNA Synthesis Kit (Bioline). One 
microgram of total RNA from each sample was incubated with 1 μl Oligo (dT)18 and 
1 μl of 10 mM dNTP mix in 10 μl total volume at 70°C for 5 min and chilled on ice 
for 1 min. To this primer premix, 10 μl of RT master mix (4 μl of 5X RT Buffer, 1 μl of 
10U/μl RNase inhibitor, 1 μl of 200U/μl H-MLV Reverse Transcriptase, 4 μl of 
RNase-free water) was added and incubated at 45°C for 60 min. Reactions were 
terminated by inactivating the enzyme at 85°C for 5 min, samples were diluted 1:10 
in RNase-free water and stored at −20°C. 
2.6.3 Quantitative Real-Time PCR 
Sample cDNA was amplified on a BioRad iCycler MYiQ™ using iQ™ SYBR® Green 
Supermix. Primer concentration and annealing temperature was optimized by 
performing melt curve analysis for each primer set. Reactions without sample 
template were included with each Reverse Transcription (RT Negative) and PCR run 
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(PCR Negative) to screen for reagent contamination. PCR efficiency was determined 
by including a 3-fold dilution series in each PCR run. All standards and samples were 
amplified in triplicate. Results were analysed using the ΔΔCt method (403, 404): 
Relative expression = 2^[Control Ct(normalised) – Treatment Ct(normalised)] where 
Ct of each sample is normalised to the input cDNA using 5S rRNA as an internal 
control gene: 
Ct(normalised) = [Ct(target gene) – Ct(5S rRNA)]. 
2.6.4 Agarose Gel Electrophoresis 
Agarose gels were used to resolve PCR product following amplification. Gels were 
prepared by dissolving high resolution agarose in TBE buffer with SYBR® Safe DNA 
Gel Stain. For PCR product, 3% gels were run at 100V for 2 hours; and for chromatin 
digests, 1% gels were run at 80V for 1 hour in a BioRad Mini-Sub Cell® GT at room 
temperature. Bioline EasyLadder I DNA standards were run with each gel and 
resolved DNA was visualised using a Las-3000 imaging system. 
2.6.4.1 Primers 
Primers for RT-PCR were designed from NCBI Reference sequences derived from 
the GRCh38 GenBank record with Primer3 software [365] using primer design 
parameters outlined by Dieffenbach et al [366]: 
Gene HGNC ID RefSeq Sequence Amplicon  
5S rRNA 34362 NR_023363 GTAACCCGTTGAACCCCATTACAC 
CCATCCAATCGGTAGTAGCG 
151 bp 
SIRT1 14929 NM_001142498 GCAGATTAGTAGGCGGCTTGAAGA 
TCTGGCATGTCCCACTATCA 
152 bp 
miR-34a 31635 NR_029610 CCAGCTGTGAGTGTTTCTTTGGCAG 
CCCACAACGTGCAGCACTTCTAG 
104 bp 
P53 11998 NM_000546 CCATGTGCTCAAGACTGGCGCT 
AGTCTGGCTGCCAATCCAGGGAA 
161 bp 
U6 snoRNA 32688 NR_003098 CGCTTCGGCAGCACATATACTAA 
TATGGAACGCTTCACGAATTTGC 
97 bp 
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2.7 ANALYSIS OF MATURE MICRORNA EXPRESSION 2.7.1 RNA Extraction 
Mature microRNAs were isolated as part of the total RNA isolate extracted using a 
miRCURY RNA Isolation Kit [Exiqon, Vedbaek, Denmark]. Hsa-miR-34a expression 
was detected with a miRCURY Universal RT-PCR kit using LNA PCR primer sets for 
miR-34a with U6 snoRNA and 5S rRNA as internal controls. This kit discriminates 
between primary and mature sequences in 20 ng of the total RNA isolate by 
polyadenylation and first strand cDNA synthesis of mature microRNAs. LNA primers 
used in the PCR step are stabilised to be specific for the mature microRNA and not 
for its step-loop precursor and so can be detected using SYBR green dye during the 
PCR amplification process. 
The cDNA template was diluted 1:80 in Nuclease-free water and amplified with 
ExiLENT SYBR green master mix [Exiqon, Vedbaek, Denmark] on an ABI 7500 
StepOne Plus PCR Cycler according to the manufacturer’s protocol. A synthetic 
control template (UniSp6 CP, RNA spike-in) was added to the polyadenylation and 
first strand synthesis reaction to control for differences in the efficiency of cDNA 
synthesis between samples. Primers for UniSp6 CP were used to amplify the RNA 
spike-in during PCR amplification. 
2.7.2 Taqman PCR Assays 
Primers and probes for TaqMan Gene Expression, TaqMan Pri-miRNA and TaqMan 
microRNA assays were obtained from Applied Biosystems (Life Technologies, 
Carlsbad CA). Assays were performed according to the provided protocols using 
cDNA template prepared as described previously. 
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2.7.2.1 Primers for Taqman PCR 
Gene Expression Targets 
Target RefSeq Accession # Location 
18SrRNA NR_003286.2 Chr.Un_NT_167214: 109078 - 110946 
BIRC5/Survivin NM_001012270.1 Chr.17: 76210277 - 76221716 
BCL2 NM_000633 Chr.18: 60790579 - 60986613 
DICER1 NM_001195573.1 Chr.14: 95552565 - 95623759 
Pri-miRNA Targets 
Target RefSeq Accession # Location 
hsa-miR-145 MI0000461 Chr. 5 - 148810209 - 148810296 [+] 
hsa-miR-200c MI0000650 Chr.12: 7073260 - 7073354 [+] 
hsa-miR-107 MI0000114 Chr.10: 91352504 - 91352584 [-] 
hsa-miR-16-1 MI0000069 Chr.13: 50623255 - 50623337 [-] 
Taqman microRNA Assays [Applied Biosystems, Carlsbad, CA, USA] were used for 
detection of hsa-miR-145, hsa-miR-141, hsa-miR-107 and hsa-miR-15a expression. 
For these assays, differentiation of mature microRNAs from their precursors in total 
RNA isolates was achieved by using target-specific stem-loop primers at the first 
strand cDNA synthesis step. 
In order to amplify multiple microRNA targets from each sample, the reverse 
transcription step was multiplexed by pooling the target primers (10 µl of each 5 
stem-loop primer solution in 1 ml TE buffer). First strand synthesis was carried out 
using a TaqMan MicroRNA RT Kit [Applied Biosystems, Carlsbad, CA, USA] in the 
following manner: 
Component Vol/Rx (µl) 
RT Primer Pool 6 
dNTPs (100 mM) 0.3 
Multiscribe Reverse Transcriptase (50 U/µl) 3 
10 RT Reaction Buffer 1.5 
RNase Inhibitor (20 U/µl) 0.19 
Template RNA 350 ng 
Nuclease-free water To 15 µl 
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Reactions were prepared in PCR tubes, mixed by inversion and incubated on ice for 
5 min and amplified using thermal cycling conditions outlined by the supplier. 
MicroRNA Targets 
Target RefSeq Accession # Sequence 
hsa-miR-34a MIMAT0000255 UGGCAGUGUCUUAGCUGGUUGU 
hsa-miR-200a MIMAT0001620 UAACACUGUCUGGUAACGAUGU 
hsa-miR-145 MIMAT0000437 GUCCAGUUUUCCCAGGAAUCCCU 
hsa-miR-141 MIMAT0000432 UAACACUGUCUGGUAAAGAUGG 
hsa-miR-107 MIMAT0000104 AGCAGCAUUGUACAGGGCUAUCA 
hsa-miR-15a MIMAT0000068 UAGCAGCACAUAAUGGUUUGUG 
2.8 TRANSIENT GENE SILENCING BY RNAi 
OnTarget siRNA targeting pools (Dharmacon, Thermo-Fisher) were used for 
transient p53 and SIRT1 knockdown. To achieve efficient ablation of target genes 
whilst minimising off-target effects, transfection protocol was optimised to find 
conditions which produce >80% depletion of target mRNA content while 
maintaining >80% cell viability (see Supplementary Material for details). 2.8.1 Sample Preparation 
Following detachment, cells were pelleted by centrifugation at 500g for 5 minutes 
and resuspended in growth media with supplements and without antibiotics. For 24 
hour treatments, cells were seeded into tissue culture plates at a density of 2×104 
cells per well (96-well), 1×105 cells per well (12-well), or 2×105 cells per well (6-
well) and allowed to recover in an incubator overnight at 37°C and 5% CO2.  
2.8.2 Transfection Protocol 
Cells were seeded in 6-well plates in antibiotic-free medium at a density of 1.5×105 
cells per well and allowed to recover overnight.  
78 | 
Chapter 2 
Figure 2:5  Knockdown of SIRT1 and p53 in primary keratinocytes 
Transient transfection of primary human (NHEK) and p53-mutated (HaCaT) keratinocyts for 72 hr 
with 10 nM SIRT1 and p53 siRNA targeting pools was achieved using RNAiMAX as a transfection 
agent. RNA expression in transfected keratinocytes was measured by RT-PCR, and total p53 and 
SIRT1 protein by Western Blotting. 5S rRNA was used to normalise RNA expression and Actin was 
used as a loading control in immunoblotting. Results were analysed relative to expression in 
keratinocytes transfected with an equivalent concentration of a non-targeting siRNA pool. 
On the day of transfection, the seeding medium was removed, the cells washed 
once with buffered saline solution and 1.5 ml of antibiotic-free medium added to 
each well. Transfection solution was prepared by combining diluted RNAiMAX 
solution (5 µl RNAiMAX + 250 µl reduced serum media) and siRNA solution (5 µl of 5 
mM On-Target Smartpool siRNAs in 1X siRNA buffer) and incubating the mix at 
room temperature for 20 minutes. The solution was then overlaid onto the culture 
medium in each well and the transfection reaction incubated for 4-5 hours at 37°C 
and 5% CO2. After this time, the transfection medium was replaced with relevant 
cell treatments in antibiotic-free media and returned to the incubator. RNA was 
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extracted at 24 hours and protein extracted at 48 hours following treatment for 
functional assays. Using the optimised protocol, ≤ 25% ablation of SIRT1 [Figure 
2:5(a, b)] and p53 [Figure 2:5(c, d)] was achieved in NHEK and HaCaT cells after 48 
hours transfection with 10 nM siRNA targeting pool. 
2.9 IMMUNOPRECIPITATION 
Cell lysates were prepared in a non-ionic extraction buffer [50 mM Tris-HCl (7.4), 1 
mM EDTA, 1% Triton X-100, 5 mM sodium pyrophosphate, 10 mM β-
glycerophosphate, 0.1% β-mercaptoethanol, 50 mM NaF, 0.5 mM sodium 
orthovanadate, 0.1 mM PMSF, 1X protease inhibiter cocktail mix)], and antibody- 
bound magnetic beads were used to capture SIRT1:p53 protein complexes. 
SIRT1:p53 protein complexes were pulled down from the beads, and co-associated 
proteins detected by western blotting.  
Figure 2:6  Detection of p53 from immunoblot prepared with anti-p53 mouse mAb using anti-rabbit 
IgG secondary antibodies by isotype switching 
Lane 1: Eluate from a p53 immunoprecipitation experiment was separated by SDS-PAGE and 
visualised by immunoblotting using the same p53-targeting primary antibody and HRP-conjugated 
anti-rabbit IgG secondary antibodies for detection. The heavy chain IgG subunit (anti-p53 rabbit 
mAb) generates a band at ~50 kDa, in the same region as the target protein (p53).  
Lane 2: The isotype for secondary antibody detection was switched by incubating the membrane in 
mouse anti-rabbit IgG (light chain specific) monoclonal antibody solution, and then using HRP-
conjugated anti-mouse IgG secondary antibodies for immunodetection. Heavy chain IgG subunit is 
no longer present. 
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Antibodies obtained for use in this experiment were optimised for 
immunoprecipitation by the manufacturer and used at the recommended 
concentration. As the denatured rabbit IgG heavy chain of the SIRT1 primary 
antibody used for immunoprecipitation runs at approximately 50 kDa and p53 
protein is 53 kDa, bands from the eluate on the subsequent western blot appear at 
approximately the same region. To differentiate between bands generated by the 
target (p53) and the antibody (IgG), and so accurately quantitate p53 protein, 
immunoblots were incubated with light chain-specific anti-isotype antibodies 
[Figure 2:6]. 
Figure 2:7  SIRT1:p53 co-immunoprecipitation in EX-527 treated keratinocytes 
Primary human keratinocytes (NHEK) were grown to 75% confluence in 100 cm2 culture plates and 
treated with 1 µM EX-527 for 24 h. Total protein was extracted in non-ionic lysis buffer and 
p53:SIRT1 immunocomplexes captured overnight at 4°C. WB – Western Blot; I – Input; E – Eluate. 
Immunoprecipitation using this technique generated a wide degree of within-
treatment variability occurred in replicate samples [Figure 2:7]. To compensate for 
this during analysis, results were normalised using densitometric data from the 
81 | 
Chapter 2 
input signal and the pull-down to accurately compare replicates and treatments. 
Firstly, the signal obtained from the eluate was standardised with 2% v/v of the 
sample lysate used for immunoprecipitation; and secondly, the eluate signal 
detected in the SIRT1 immunoblot was standardised to the quantity of pulled down 
immunocomplexes (detected by immunoblotting with anti-p53 antibodies). 
This compensated for the between-sample variability inherent in lysate preparation 
and differences in efficacy of immunocomplex capture (including differences in 
antibody affinity, magnetic bead loading, bead washing, and elution). 
2.10 CHROMATIN ACCESSIBILITY RT-PCR (CHART-PCR) 
ChART-PCR detects structural differences in the chromatin of target regions using 
micrococcal nuclease (MNase) to create conditions for differential PCR 
amplification across nucleosomal boundaries. Unlike formaldehyde-mediated 
crosslinking used in ChIP, nucleosome-bound DNA is protected from MNase, 
enabling conformational variability in higher order chromatin structure to be 
detected (405). Chromatin remodelling is determined semi-quantitatively by the 
dropoff in PCR amplification (406). 
2.10.1 Stabilisation of Chromatin and Nuclear Extraction 
Treated cells were detached using TrypLE [incubated at 37°C for 5 min (Life 
Technologies Corporation, Carlsbad, CA)] and washed once in warmed PBS. Washed 
cells were pelleted by centrifugation at 500 g for 5 min. Nuclei were extracted by 
incubation in NP-40 lysis buffer [10 mM Tris.HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2, 
0.5% NP-40, 0.15 mM Spermine hydrochloride, 0.5 mM Spermidine, 1X Protease 
Inhibitor Cocktail] for 5 min on ice. Nuclei were pelleted at 1000 rpm for 5 min at 
4°C, and washed once in calcium free MNase reaction buffer [10 mM Tris.HCl (pH 
7.4), 15 mM NaCl, 60 mM KCl, 0.5% NP-40, 0.15 mM Spermine hydrochloride, 0.5 
mM Spermidine]. Sensitivity was maximised in this assay by maintaining the 
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structural integrity of extracted chromatin prior to MNase digestion. Nuclear 
membrane damage was reduced by pelleting nuclei at ≤1000 rpm and minimal 
pipetting was used during resuspension steps. This was crucial to prevent nuclei 
from adhering to the wall of pipettes or from forming a solid pellet, as the nuclei 
were permeabilised during extraction to allow MNase digestion. To minimise 
endonuclease activity, samples were processed and prepared rapidly (within a 1 
hour time frame) and kept on ice at all times. Spermine and spermidine were 
included in nuclear isolation and wash buffers to provide counter-ions for 
chromatin stabilisation (407). 
2.10.2 Digestion of DNA with Micrococcal Nuclease 
Each sample was resuspended in 200 µl reaction buffer and divided equally 
between two 1.5 ml microcentrifuge tubes. CaCl2 was adjusted to 5 mM and one 
aliquot was digested with micrococcal nuclease (20 kU/ml) at room temperature 
whilst the other was placed on ice (as a digestion control). Reactions were 
quenched after 5 min by adding 20 µl Stop Buffer (100 mM EDTA + 10 mM EGTA).  
Figure 2:8  Micrococcal nuclease digest of nuclear extracts 
Nuclei were isolated from NHEK and HaCaT cells and incubated with micrococcal nuclease at 37°C 
for 20 min. DNA fragments were separated on 1% agarose gel and visualised with SYBR Safe DNA 
stain. 
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DNA was released from the nuclei by adding 80 µl reaction buffer containing 4% 
SDS and incubating each sample at 65°C for 2 hrs with 3 µl Proteinase K, and 
purified using Bioline Isolate II DNA extraction columns. Twenty kU/ml of MNase 
enzyme was sufficient to cut chromatin into a nucleosomal ladder [Figure 2:8]. 
2.10.3 Measurement of Chromatin Accessibility by PCR Amplification 
2.10.3.1 Determination of Relative Chromatin Condensation 
DNA eluates were quantitated and diluted to a concentration of 5 ng/µl in nuclease-
free water.  
Primers were designed to amplify a nucleosome-spanning region of the promoter 
sequence for each gene (> 2  147 bp). 
Gene ID Coordinates Sequence Amplicon  
Rhodopsin 3q21 chr3:129242616 
chr3:12924
3256 
GCTAAGCCCCTAATCCACCG 
ACACAGTCATTACCATCAGCGA 
641 bp 
SIRT1 10q21.3 chr10:69643221 
chr10:6964
3951 
GGCCAGAACCCATACTAGGC 
AAGAGAGGCAAAAGGAGGCG 
731 bp 
miR-34a 1p36.22 chr1: 9241106 
chr1: 9242223 
AAGATATCTCAGAACTGGGCAGAG 
TGGGCTTGCCTGGGCTTGTT 
1118 bp 
A total of 10 ng DNA was amplified using BioRad iQ SYBR Green Supermix (BioRad, 
Gladesville, NSW) with the following reaction conditions: 
Denaturation 95°C 10 min 
Anneal and Extend [40 cycles] 
95°C 15 sec 
60/65°C 30 sec 
72°C 1 min 
84 | 
Chapter 2 
MNase-mediated internucleosomal cutting was assayed using a standardised 
concentration of DNA template for each PCR reaction.  
2.10.3.2 Calculations 
The ChART-PCR assay was standardised by equalising the concentration of DNA 
template used in each reaction and by normalising samples for endogenous DNase 
activity using undigested Input template. Chromatin accessibility was calculated 
using the following method: 
Change in accessibility = 2^[Treatment Ct(adjusted) – Control Ct(adjusted)] 
where Ct of sample DNA is adjusted by normalisation to the input template using 
the formula: Ct(adjusted) = [Ct(digest)– Ct(input)]. 
Figure 2:9  Amplification of MNase digested chromatin after EX-527 treatment 
Nuclei were isolated from NHEK cells which had been treated for 24 hrs with 1 µM EX-527 or DMSO 
(vehicle) and incubated with micrococcal nuclease at 37°C or 22°C for 5 min. DNA was extracted 
according to the ChART protocol outlined in Chapter 2, and equal concentrations were amplified for 
40 PCR cycles using pri-miR-34a ChART primers.  
Undigested DNA from Vehicle and SIRT1-inhibited samples was amplified as a reference (Input). PCR 
product was run on 2% agarose gel and visualised with SYBR Safe DNA stain. 
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When SIRT1 was inhibited in NHEKs for 24 hrs, amplification of the pri-miR-34a 
gene promoter decreased when digested with MNase for 5 minutes [Figure 2:9]. 
This effect was more evident using a lower reaction temperature [Figure 2:9], and 
therefore MNase digestion was performed at 22°C to enhance assay sensitivity 
when used to measure chromatin accessibility. 
The effect of SIRT1 inhibition on MNase accessibility in chromatin at the Rhodopsin 
gene promoter was quantified from Ct values generated during qPCR analysis 
[Figure 2:10(a)]. Quantification of these data using the previously outlined method 
demonstrates that inhibition of SIRT1 increases MNase accessibility in NHEKs 
[Figure 2:10(b)].  
Figure 2:10  Analysis of MNase accessibility by PCR amplification 
Primary (NHEK) keratinocytes were treated for 24 hrs with 1 µM EX-527 or DMSO (vehicle) and 
MNase-digested chromatin was prepared according to the ChART protocol outlined in Chapter 2. 
MNase-digested and undigested input DNA was analysed by qPCR with Rhodopsin primers using iQ 
SYBR Green Supermix (BioRad, Gladesville, NSW).  
Panel a: qPCR amplification curves from Input and MNase digested chromatin 
Panel b: Analysis of MNase sensitivity of the Rhodopsin gene in SIRT1 inhibited keratinocytes 
EX-527-treated samples were analysed by paired t-test relative to vehicle control, with *** 
(p<0.001); n=3. 
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2.11 CHROMATIN IMMUNOPRECIPITATION (ChIP) 
ChIP is a technique which enables analysis of DNA-protein interactions. Associations 
are measured by selective immunoprecipitation of DNA fragments crosslinked with 
the protein(s) of interest, after which the DNA fragments are purified. Here, RT-PCR 
was used to quantitate the association between gene locus and the protein of 
interest. 2.11.1 Preparation of Crosslinked Chromatin 
Cells were grown to 80% confluence in 150 cm2 culture plates and treated in 20 ml 
of media. DNA was crosslinked to the chromatin by incubation in 1% formaldehyde 
for 15 minutes on a rotator (40 rpm) at room temperature, after which the reaction 
was stopped by addition of 1M glycine solution to a final concentration of 0.125M. 
Culture medium was removed and the cells washed twice in ice-cold PBS prior to 
addition of cell lysis buffer [5 ml/plate; 20 mM Tris.HCl (pH 8.0), 85 mM KCl, 0.5% 
NP40 + 1 Protease Inhibitor Cocktail]. The cell suspension was scraped into 15 ml 
Falcon tubes and incubated on ice for 10 min with regular inversion. Samples were 
pelleted by centrifugation at 1500 rpm for 5 min at 4°C, and the supernatant 
aspirated. Nuclei were washed in 10 ml of ice-cold PBS, and repelleted by 
centrifugation at 1500 rpm for 5 min. Cells were resuspended in 1 ml of PBS and 10 
µl removed for counting.  
2.11.1.1 Chromatin Fragmentation 
Nuclei were pelleted at 3,000 rpm for 5 min at 4°C, resuspended in Nuclear Lysis 
Buffer [50 mM Tris.HCl (pH 8.0), 10 mM EDTA, 1% SDS, 1 Protease Inhibitor 
Cocktail] at a concentration of approximately 3-4107 nuclei/ml and incubated on 
ice for 10 min. Chromatin was sheared using a Sonics Ultrasonicator to generate 
DNA fragments of 300 – 1000 bp.  
2.11.1.2 Fragment Size Analysis 
Fifty microliters of nuclear lysate was incubated at 37 °C with 2 µl RNase A solution 
with 6 µl 5 M NaCl in 100 µl water for 20 min, after which 2 µl of 20 mg/ml 
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Proteinase K solution was added and crosslinks reversed at 65°C for 2 hours. DNA 
was purified using a BioLine DNA extraction kit into a final volume of 20 µl eluate. 
Total DNA extracts were resolved by submarine electrophoresis on 1% high 
resolution agarose gels at 80V for 1 hour. Resolved DNA was visualised using a Las-
3000 imaging system. 
2.11.1.3 Empirical Determination of Sonication Conditions 
Sonication was optimised by determining the conditions required for nuclear lysis 
and extending the sonication time incrementally to shear chromatin. Nuclear 
extracts in 250 µl aliquots were exposed to 5 min sonication sets (10 cycles of 30 
seconds on/30 seconds off at the 100% amplitude setting) on ice to maintain 
protein:DNA interactions. After each set, 10 µl of the sample was viewed under a 
microscope to determine the degree of nuclear lysis.  
Figure 2:11  Optimisation of chromatin fragmentation conditions. 
Nuclei from primary neonatal (NHEK) keratinocytes were isolated and sonicated on ice using 10 
cycles of 30 seconds on/30 seconds off at the 100% amplitude setting. DNA fragments were purified 
from crosslinked chromatin and separated on 1% agarose by electrophoresis. Total sonication time is 
indicated. 
Panel a: 10 minutes 
Panel b: 15 minutes 
Panel c: 30 minutes 
Note: Non-lysed nuclei are circled (red) 
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For NHEK and HaCaT keratinocyte nuclei prepared using the above manner, whole 
nuclei remained in solution in solutions exposed to sonication energy for < 30 min, 
and  3 sets of 5 min sonication cycles (15 min total) was required to release 
crosslinked chromatin into solution [Figure 2:11]. Ten minutes of sonication time 
sheared DNA to a fragment size range between 250 and 2500 bp; at fifteen 
minutes, fragment size range was between 100 and 1000 bp; and after 30 minutes, 
DNA fragments were between 100 and 250 bp [Figure 2:11]. From these results, 15 
minutes was decided on as the optimal sonication conditions. 
2.12 IMMUNOPRECIPITATION 2.12.1 Antibody loading (magnetic beads) 
Target antibodies were preloaded and crosslinked to Protein G-coupled Dynabeads 
(Dynal AS, Life Technologies, Oslo, Norway) with bis(sulfosuccinimidyl) suberate 
(BS3) (ThermoFisher Scienctific, Rockford IL). Five µg antibody stock was diluted in 
200 µl PBS + 0.02% Tween20 (PBST) and added to 1.5 mg Dynabeads in a 1.5 ml 
screwtop microcentrifuge. Antibody loading was carried out on a roller at room 
temperature for 60 minutes. The beads were washed twice in 200 µl Conjugation 
Buffer [20 mM phosphate buffer (pH 7.5), 150 mM NaCl] and resuspended in 250 µl 
of 5mM BS3 solution [20 mM phosphate buffer (pH 7.5), 150 mM NaCl, 5 mM BS3]. 
Antibody bound beads were crosslinked on a roller at room temperature for 30 
minutes, and the reaction quenched by adding Tris.HCl (pH 7.5) to a final 
concentration of 20 mM. Following a 15 min incubation period, antibody-
crosslinked beads were washed 3 in 200 µl PBST by gentle pipetting and stored in 
PBST at 2-8°C.  
The crosslinked chromatin solution was diluted 1:10 in ChIP buffer [16.7 mM 
Tris.HCl (8.0), 167 mM NaCl, 1.2 mM EDTA, 1% Triton X-100, 1  protease inhibitor 
cocktail]. A 100 μl aliquot was removed from the diluted preparation and stored at 
–20 °C to use as a 2% input sample. Immunocomplexes were captured by adding 25
µg of antibody-loaded magnetic beads (2.5 µg antibody solution per reaction) to 1 
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ml aliquots of diluted chromatin solution with overnight incubation at 4°C on a 
roller mixer. One sample from each preparation was incubated with magnetic 
beads loaded with 2.5 µg normal Rabbit IgG as a negative control. 
Beads with captured immunocomplexes were washed once in 1 ml low salt wash 
[20 mM Tris.HCl (pH 8.0), 0.1 % SDS, 150 mM NaCl, 2 mM EDTA, 1% Triton-X100], 1 
ml high salt wash [20 mM Tris.HCl (pH 8.0), 0.1% SDS, 500 mM NaCl, 2 mM EDTA, 
1% Triton X-100], and twice each in 1 ml LiCl wash [10 mM Tris.HCl (pH 8.0), 250 
mM LiCl, 1% Igepal/NP-40, 1% Sodium deoxycholate, 1 mm EDTA], and TE buffer 
[10 mM Tris.HCl (pH 8.0), 1 mM EDTA] for 5 minutes at 4 °C with rotation for each 
wash. Immunocomplexes were eluted by adding 150 μl ChIP elution buffer [100 
mM NaHCO3, 1% SDS] and incubating the beads for 30 minutes at 65 °C on a 
thermomixer at 1200 rpm. The supernatant was aspirated and transferred to a new 
tube.  2.12.2 Elution and Extraction of Crosslinked DNA 
The salt concentration of each sample was raised to 200 mM by adding 6 μl of 5 
M NaCl and the crosslinks reversed by incubating for 2 hr with 3 μl of 20 mg/ml 
Proteinase K at 65 °C on a thermomixer at 700 rpm. DNA was purified by spin 
column extraction, eluted into 50 μl buffer and stored at – 20 °C until PCR 
quantification. 
2.12.3 PCR Analysis of Associated Genes 
2.12.3.1 Primer Design 
Nucleotide sequences were were retrieved using the NCBI/RefSeq database and 
screened for regulatory features with the Ensembl database. For each gene, the 
sequence was expanded to include regulatory regions upstream of the coding 
domain.  
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Primers were designed according to the following parameters: 
Primer Length 24 nucleotides 
Optimum Tm 60°C (58-60°C) 
Optimum CG content 50% (30-80%) 
Amplicon size 80-160 bp 
Gene ID Site Coordinates Sequence Amplicon  
RPL30 8q22 99057030 
99057144 
AAGGGCCAAACACCACAATCGCTA 
AATCGAAGAGACTGAACGGGCTTCG 
139 bp 
miR-34a 1p36 Upstream 9241106 
9241207 
AAGATATCTCAGAACTGGGCAGAG 
GCATGTGAAACTCTAGCAGATACC 
102 bp 
1 9241825 
9241977 
TAATGAAAACCCTGTTCAATTGTG 
CTGGAGATAGAGGAGGGAAGAAAG 
153 bp 
2 9242156 
9242223 
TCCAAATGCCCCCGATCTGCGT 
TGGGCTTGCCTGGGCTTGTT 
68 bp 
SIRT1 10q21 1 69643806 
69643959 
TGTATACCACCCTACAAGTGATGG 
TAAGTAGGAAGAGAGGCAAAAGGA 
154 bp 
2 69643284 
69643426 
GATAGAAACGCTGTGCTCCAGGCA 
AAAGCCCTTCCACTTTCCTCTCTCCC 
143 bp 
3` 69674963 
69675157 
CTTTGGAGAGAACTTGAGATAGGC 
TTGGGGTTTAAGTGAAAGAGTAGG 
195 bp 
[seehttp://www.genenames.org/data/hgnc_data.php?hgnc_id=14929(SIRT1) 
andhttp://www.genenames.org/data/hgnc_data.php?hgnc_id=31635(miR-34a)] 
Template DNA was amplified with target primer sets using 2 BioRad SYBR green 
reaction mix on an iCycler MYiQ™ [Bio-Rad Laboratories, CA, USA] using the 
following cycling conditions: 
Temp (°C) Time 
Activation 95 10 min 
Denaturation 95 
10 sec 40 cycles 
Anneal and Extend 60 60 sec 
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ChIP data were calculated by quantifying the RT-PCR results from the ChIP reaction 
relative to the Input reaction. Input Ct values were adjusted to the dilution factor 
(DF) [Ct-Log2(DF)]. 
The amount of genomic DNA co-precipitated with the antibody was calculated as an 
IP:Input ratio using the following formula:  
% total = 2 ΔCT     Where ΔCT = CT(adjusted Input) – CT(ChIP) 
2.13 DNA METHYLATION ANALYSIS 
Normal human keratinocytes (NHEK) were cultured for 10 weeks in EpiLife 
Keratinocyte growth medium into which had been added arsenite [As(III)] to a final 
concentration of 0.5 µM. Cells were grown in 75 cm2 flasks using a seeding density 
of 5  105 cells and allowing an overnight settle prior to addition of the treatment 
medium. When the flasks had reached 75-85% confluence (approximately once per 
week), the cells were detached using TrypLE dissociation reagent (Invitrogen, 
Carlsbad, CA, USA), rinsed in Epilife and counted using a Haemocytometer. Half a 
million cells were passaged into a new flask and the remaining harvested cells 
washed in PBS. The harvested NHEKs were pelleted in aliquots of 1  106 cells and 
stored at −80°C until use. Untreated NHEK cells grown in EpiLife were harvested 
concurrently as passage matched controls. 
2.13.1 Bisulfite Conversion 
Methylated cytosine bases are differentiated from non-methylated bases by 
treatment with sodium bisulfite. Methylation of cytosine confers resistance to 
sodium bisulfite treatment, whereas unmethylated bases are converted to uracil 
and are amplified as thymine during PCR (408) [Figure 2:12].  
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Figure 2:12 Detection of cytosine methylation by bisulfite conversion 
Cytosine bases (C) are converted to uracil (U) by bisulfite treatment. These bases are subsequently 
converted to thymine (T) during the 1st round of PCR amplification. Methylated cytosine bases (Cm) 
are unaffected by bisulfite treatment, and remain cytosines during PCR amplification. 
During conversion, bisulfite is added to the 5,6 double bond, generating cytosine 
sulfonate in equilibrium with cytosine. In acidic conditions, cytosine sulfonate is 
deaminated to uracil sulfonate. Removal of bisulfite in alkaline conditions removes 
the sulfonate group and covers the 5,6 uracil double bond. Methylation of cytosine 
at its 5′ position inhibits sulfonation [Figure 2:13].  
Figure 2:13 Bisulfite Conversion of Cytosine to Uracil 
Bisulfite is added to the 5,6 double bond, generating cytosine sulfonate in equilibrium with cytosine. 
In acidic conditions, cytosine sulfonate is deaminated to uracil sulfonate. Removal of bisulfite in 
alkaline conditions removes the sulfonate group and covers the 5,6 uracil double bond. Methylation 
of cytosine at its 5′ position inhibits sulfonation (408).  
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DNA from treated cells was bisulfite converted using a Cells-to-CpG Bisulfite 
Conversion Kit (Applied Biosystems, Foster City, CA, USA). The recommended 
protocol is optimized for conversion of 5000 to 105 cultured cells, therefore a cell 
count was performed during harvest to optimise the concentration of input DNA. 
Cells were lysed and denatured at 50°C for 10 min prior to addition of the 
conversion reagent. The bisulfite reaction mix was added and the sample incubated 
according to cycling protocols in Table 2:1. Samples were desalted and 
desulfonated immediately following conversion, and the converted DNA stored at − 
80°C prior to use in PCR amplification reactions. 
Table 2:1  Bisulfite conversion protocol 
Input DNA 100 ng - 2 µg Input DNA 50 pg - 100 ng Input DNA ≥ 2 µg 
Temp (°C) Time (min) Temp (°C) Time (min) Temp (°C) Time (min) 
65 30 65 30 95 3 
95 1.5 95 0.5 65 60 
65 30 65 30 95 3 
95 1.5 95 0.5 65 30 
65 30 65 30 4 Up to 4 hrs 
4 Up to 4 hrs 4 Up to 4 hrs 
2.13.2 Bisulfite PCR 
2.13.2.1 Primer Design 
Conversion-specific primers were designed to span CpG rich regulatory domains of 
target genes using Methyl Primer Express Software v1.0 (Applied Biosystems) (409) 
[Table 2:2].  
The output from this program was screened for potential target candidates using 
primer design parameters described by Li and Dahiya (410) and Wojdacz et al. 
(411): 
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• Primer pairs were designed to amplify a CpG-rich region, and target loci
contain a minimum number of non-CpG cytosines in their sequence.
• The target amplicon has a length of no greater than 450 bp and no less than
100 bp.
• The melting temperature of the primers are matched to within 1°C
• To ensure bisulfite-specific amplification, the 3′ end of the primer contains
one or more T corresponding to non-CpG cytosines.
Primers containing CpG dinucleotides were placed as close as possible to the 5′ end 
of the primer and degenerate bases represent the methylated and unmethylated 
cytosines. Y was used to represent C and T in a forward primer, and R was used to 
represent G and A in a reverse primer. 
Table 2:2  Primers for Bisulfite Sequencing 
Gene Region ID Sequence bp % CG 
SIRT1 10q21.3 SIRT1BisF 
SIRT1BisR 
GTGATTYGTAGTGTTGTGGTTT 
CCATCTTCCAACTACCTCTCTAAC 
190 61.58 
miR-34a 1p36.22 miR-34aBisF 
miR-34aBisR 
AAGGGGATGAGGATTAGGAT 
AAACAAACCCAAACAAAACC 
346 45.09 
hMLH1 3p21 hMLH1BisF 
hMLH1BisR 
GGAGTGAAGGAGGTTACGGGTAAGT 
AAAAACGATAAAACCCTATACCTAATCTATC 
182 68 
A CpG-rich region of the hMLH1 gene was used as a methylation-sensitive control 
sequence during analysis. Candidate primer sets were checked and tested for 
bisulfite sequence sensitivity and specificity using gDNA controls [Cells-to-CpG 
Methylated and Unmethylated gDNA Control Kit (Applied Biosystems, Foster City, 
CA, USA)]. Quantitative PCR was performed on a StepOne PCR cycler (Applied 
Biosystems, Foster City, CA, USA) using BioRad iQ SYBR Green Supermix (BioRad, 
Gladesville, NSW). 
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Primer specificity was assayed by amplifying converted and non-converted (raw) 
DNA using conversion-specific PCR primers. Bisulfite converted DNA templates 
amplified with bisulfite-specific primers for both gene targets, whereas 
unconverted DNA was not amplified [Figure 2:14]. 
Although the primer sets are specific for bisulfite-converted DNA, Ct values were 
>30 for the methylated template amplified with miR-34a bisulfite primers. In order 
to achieve sufficient template amplification for analysis by gel electrophoresis, high 
resolution melt curve analysis or for sequencing, 60-80 cycles of amplification were 
required for future applications. 
Figure 2:14  Bisulfite Conversion Specificity 
Bisulfite converted DNA and unconverted (raw) sample templates were amplified using bisulfite-
specific primer sets for SIRT1 and miR-34a targets, where Control 1 is unmethylated gDNA template 
and Control 2 is fully methylated gDNA template. Relative quantitation was determined using ΔCt 
values for each sample compared to Control 1 unconverted DNA (Raw). Quantitative PCR was 
performed on a StepOne PCR cycler (Applied Biosystems, Foster City, CA, USA) using BioRad iQ SYBR 
Green Supermix (BioRad, Gladesville, NSW). Note- both bisulfite PCR primer sets amplify templates 
in a conversion-specific manner. 
2.13.2.2 Amplification Efficiency 
As bisulfite PCR uses CG rich regions of the gene as templates, target sequences are 
prone to secondary structure formation and mispriming which can inhibit 
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amplification. DMSO disrupts intra-strand reannealing, allowing the higher Tm 
associated with cytosine-guanine bonding to be overcome (412).  
By including DMSO at a final concentration of 2% in each PCR reaction, 
amplification of target sequences improved significantly [Figure 2:15].  
Figure 2:15  Bisulfite PCR adjuvants – miR-34a Primers 
Bisulfite converted DNA template was amplified using a temperature gradient with miR-34a bisulfite 
primers for 80 cycles. PCR product was separated on 2% agarose gel by electrophoresis and 
visualised using SYBR safe DNA stain. PCR product was amplified with (Right panel), and without 
(Left panel) DMSO included in the PCR reaction mix at a final concentration of 2%. Note- off-target 
amplification increases with temperatures < 60°C.  
2.13.3 High Resolution Melt Curve Analysis 
Bisulfite converted sequences differ in their thermal stability in a methylation-
dependent manner. Conversion of non-methylated cytosines to thymine following 
bisulfite treatment causes its PCR product to melt at a lower temperature than its 
methylated counterpart (385) [Figure 2:16]. Different melting properties of 
converted sequences were analysed using the relative fluorescence of a double-
stranded DNA binding dye such as SYBR green (386). 
As the effect of arsenic on SIRT1 or miR-34a methylation in keratinocytes was 
unknown prior to this investigation, high resolution melt curve analysis was 
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performed to screen for changes in the target regions prior to sequencing. To gauge 
the effect of arsenic on CpG methylation of the target genes, methylation-specific 
standards were prepared from fully methylated and unmethylated gDNA [Table 2:3 
& Table 2:4] and treated by bisulfite for conversion prior to use in melt curve 
analysis studies.  
Figure 2:16  Melting Properties of Methylated and Unmethylated DNA 
Pri-miR-34a sequences were amplified from unmethylated (0%, blue) and fully methylated (100%, 
red) control DNA following bisulfite conversion.  
Table 2:3  High % methylation standards 
Control gDNA Input volume (µl) 
Fully methylated DNA (20 ng/µl) 10 7.5 5 2.5 1 0 
Non-methylated DNA (20 ng/µl) 0 2.5 5 7.5 9 10 
Standard (% methylation) 100 75% 50% 25% 10% 0% 
Table 2:4  Low % methylation standards 
Fully methylated DNA (20 ng/µl) 10 0.75 0.5 0.25 0.1 0.01 0 
Non-methylated DNA (20 ng/µl) 0 9.25 9.50 9.75 9.90 9.99 10 
Standard (% methylation) 100 7.5% 5% 2.5% 1% 0.1% 0% 
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DNA was prepared for HRM analysis with a Cells-to-CpG Bisulfite Conversion Kit 
(Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s 
instructions. Genomic DNA from treated cells was amplified with MeltDoctor HRM 
reagents (Applied Biosystems, Foster City, CA, USA) using cycling conditions 
optimized for each individual primer set used, and then subjected to melt curve 
analysis. hMLH primer sets were designed to amplify bisulfite-converted 
methylation standards, and used to test the sensitivity of melt curve analysis to 
discriminate between high [Figure 2:17(a & c)] and low [Figure 2:17(b & d)] % 
methylation of PCR product. 
Figure 2:17 Melt Curve Plots – Methylation Standards 
Methylation standards were prepared by mixing 100% methylated and unmethylated control DNA. 
Standards were amplified using hMLH primers and high resolution melting performed with 
MeltDoctor HRM Reagents. Melt curves (Panels a & b) were analysed and difference plots (Panels c 
& d) were generated from the data using High Resolution Melt Software v3.0 (Applied Biosystems, 
Foster City, CA, USA). 
Once amplification conditions had been optimized for SIRT1 and miR-34a gene 
targets, methylation standards were used to generate high resolution melt curves 
for use as reference plots during analysis of arsenic-treated samples [Figure 2:18]. 
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HRM analysis confirmed that 0.5 µM arsenic induced progressive changes in the 
methylation profile of the target genes when compared with untreated controls, 
and that a 10 week treatment schedule provides sufficient exposure time to create 
detectable results for bisulfite sequencing experiments (see Supplementary 
Material for Details). 
Figure 2:18  Melt Curve Analysis – Sensitivity of HRM 
Methylation standards were amplified using SIRT1 and pri-miR-34a bisulfite primers. High resolution 
melting performed with MeltDoctor HRM Reagents and and difference plots generated from melt 
curve analysis data using High Resolution Melt Software v3.0 (Applied Biosystems, Foster City, CA, 
USA). 
Panels a & b – Difference plots, SIRT1 methylation standards 
Panels c & d – Difference plots, Pri-miR-34a methylation standards 
2.13.4 Bisulfite Sequencing 
When determining the effect of a treatment on methylation status at a locus, the 
gold standard technique is to insert a fragment of the target region into a plasmid 
vector and to analyse an aggregate of the cloned population. In this study, direct 
sequencing of the endogenous PCR product was used as an alternative. Although 
the sequences generated in this manner were from a heterogeneous population, 
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differences in chromatogram signal intensity were sensitive enough to provide a 
general comparison of CpG methylation between samples. Residual nucleotides, 
primers and salts were removed from PCR products using a MinElute PCR cleanup 
kit by following the manufacturer’s instructions. The resultant purified PCR 
products were analysed for extracted DNA on a Qubit fluorometer using a dsDNA 
HS assay kit (Molecular Probes, Life Technologies). Total extracted PCR product was 
between 20 and 450 ng DNA for all samples. 
2.13.4.1 BigDye Reaction Setup and Cycle Sequencing 
Sequencing reactions were set up in PCR tubes as follows: 
Component Quantity/Rx (ul) 
5X Sequencing Buffer 1.75 
BigDye Terminator 0.25 
Template to 100 ng* 
Primer 3.3 pmol 
H2O  to 10 ul 
Reactions were spun down in a microcentrifuge and BigDye Terminator bound to 
the DNA template by placing the sample sequencing reactions on a thermocycler 
using the following conditions: 
Denaturation 96°C 1 min 
25 cycles 
96°C 10 sec 
50°C 5 sec 
60°C 4 min 
Hold 4°C 
2.13.4.2 Cleanup and Analysis 
To remove unincorporated dye-labelled terminators, DNA was precipitated onto 
CleanSeq magnetic beads (10 µl/Rx) by adding 42 µl of 85% ethanol to each sample 
and mixing thoroughly by pipetting. The contaminated supernatant was aspirated 
by placing the PCR strips onto a magnetic plate and allowing the beads to settle for 
3-5 minutes. Captured DNA was washed by adding 100 µl of 85% ethanol to the 
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beads, incubating for 30 seconds and aspirating the supernatant as before. Excess 
ethanol was removed from the DNA by air drying for 10 minutes, and captured DNA 
was eluted by incubating the beads in 40 µl of water at room temperature for 5 
minutes. Thirty microliters of cleared DNA solution was aspirated for analysis on the 
ABI Prism 310 Genetic Analyser. 
Unmethylated and fully methylated bisulfite converted sequences were aligned to 
the original (unconverted) sequence using the CLC Main Workbench application 
(Version 6.7.1) [Figure 2:19]. 
Figure 2:19  Chromatogram of bisulfite-converted gDNA 
SIRT1 amplified PCR product. Bases with heterogeneous cytosine methylation in the sample are 
circled in red. 
Note: Complementary DNA sequence is represented here [G→A replaces C→T] 
2.13.4.3 Conversion Efficiency 
Sequencing of sample DNA was performed according to the protocol outlined in 
Chapter 2. Unmethylated and fully methylated bisulfite converted sequences and 
unknown samples were aligned to the original (unconverted) sequence using the 
CLC Main Workbench application (Version 6.7.1). When sequencing traces were 
analysed, whole cell samples processed in initial bisulfite conversion experiments 
proved to have a conversion efficiency of <100% [see Figure 2:20(a-b)]. To improve 
data accuracy, sequencing was repeated using samples generated with a separate 
DNA extraction step. Although the sequences generated in this manner were from a 
heterogeneous population, differences in chromatogram signal intensity were 
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sensitive enough to provide a general comparison of CpG methylation between 
samples.  
Figure 2:20  Incomplete bisulfite conversion 
Panel a: Chromatogram of PCR product generated from normal keratinocytes bisulfite converted 
from cell extracts without a separate DNA isolation step. 
Panel b: Sequence alignment. Mixed base signals are circled. 
Key: Red – thymine (T); Green – adenosine (A); Blue – cytosine (C); Black – guanine (G) 
2.13.4.4 Representation of Data from Methylation Analysis 
No consensus exists for the representation of bisulfite sequencing data. From the 
original sequence alignment [Figure 2:21(a)], methylated cytosines can be identified 
[Figure 2:21 (b)], and the relationship between cytosine methylation and CpG 
dinucleotides determined using the BiQ Analyser software program (413). CpG 
methylation is conventionally represented in a ‘ball and stick/lollipop’ format for 
shorter regions, or as frequency histograms for genomewide data [Figure 2:21 (c)]. 
For the short PCR amplified sequences analysed in this study, the ball and stick 
format provided the clearest representation of CpG methylation status across the 
region tested [Figure 2:21(d)].  
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Figure 2:21 Representation of Bisulfite Sequencing Data 
Genomic DNA from primary neonatal (NHEK) and HaCaT keratinocytes was bisulfite converted and 
the SIRT1:p53 response element amplified and sequenced on an ABI Prism 310 Genetic Analyser.  
Panel a: Clustal W (1.83) multiple sequence alignment  
Key: Red – thymine (T); Green – adenosine (A); Blue – cytosine (C); Black – guanine (G); Black - mixed 
bases A/G (R). 
Panel b: Cytosine methylation – Lollipop Style Diagram 
Key: Red – methylated cytosines; White/Grey/Black – unmethylated cytosines  
Panel c: CpG Methylation Analysis - Aggregated Representation  
Key: Black – methylated CpG; White – unmethylated CpG 
Panel d: CpG Methylation Analysis – Bead Style Representation  
Key: Black – methylated CpG; White – unmethylated CpG 
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Cell Line Characterisation 
Chapter 3 
3.1 ABSTRACT 
The aim of this chapter was to define the parameters of the experimental model by 
differentiating cultured keratinocytes with characteristic UV-induced p53 mutations 
from wild-type keratinocytes by their genotypic and phenotypic properties. In order 
to achieve this aim, firstly the p53 mutational status of the HaCaT cell line was 
confirmed; secondly culture conditions were optimised for discrimination of p53-
dependent phenotypic responses; and thirdly, expression and acetylation of p53 
and p53-regulated genes was analysed in the HaCaT cell line by comparison with 
cultured keratinocytes expressing wild-type p53. 
For this study, primary neonatal keratinocytes, NHEK, and the spontaneously 
immortalised human keratinocyte cell line, HaCaT, were used to demonstrate the 
relationship between SIRT1-mediated gene regulation and cellular stress responses. 
The HaCaT cell line was derived from the normal margin of an excised melanoma, 
and although non tumorigenic, contains mutations to each p53 allele which affect 
its expression and activity. The HaCaT cell line therefore acts as a model for the pro-
carcinogenic effect of UV-induced p53 gene mutations in keratinocytes. 
For detailed descriptions of the Materials and Methods, refer to Chapter 2: General Materials and 
Methods 
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3.2 INTRODUCTION 
Tumour Protein 53 (TP53) Mutations in Keratinocytes 
Carcinogenic TP53 mutations impede the pattern of p53 protein expression, block 
posttranslational modifications which promote nuclear translocation and 
oligomerisation, and/or interfere with DNA binding affinity (81, 414). The most 
frequently mutated bases (R175, R248, R249 and R273) make up 25% of all TP53 
mutations, of which R248W and R273H impair DNA contact and R175H and R249S 
alter protein conformation (69, 70). A phenotype driven by p53 mutations 
differentiates normal cells from malignantly transformed cells in many cancer 
types, including 36% of all skin cancers (415). Features of the mutated p53 
phenotype include: suppression of DNA repair, dysregulated cell cycle control and 
impaired survival/cell death signalling (83), and therefore p53 is an attractive target 
for anti-cancer treatments. Current p53-targeting therapies seek to rescue p53 
function or block p53 overexpression in order to enhance the efficacy of 
chemotherapeutics.  
Ultra violet radiation (UVR) is the primary mutagen responsible for skin cancer. UVB 
interacts directly with DNA in epidermal keratinocytes, forming 6-4 photoproducts 
and cyclopyrimidine dimers, whereas UVA acts indirectly by generating oxidative 
radicals (416). Repair of the resultant photolesions can create strand breaks and 
induce modifications to damaged pyrimidine bases such that the DNA sequence is 
permanently altered (417). These T→C or TT→CC transition mutations form the 
characteristic mutational signature of UVR damage in skin cancer (367, 418). The 
p53 gene in keratinocytes is susceptible to UV damage at 7 identified ‘hotspots’ – 
>30% of which are found at methylated CpG dinucleotides (165). UVB preferentially 
forms cyclobutane dimers at methylated CpG sites (419), and methylation of the 
cytosine residue at these CpG dinucleotides encourages hydrolytic deamination 
during repair of UV-induced DNA damage (72).  
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Figure 3:1 Mutational Events in Skin Cancer 
Keratinocytes commonly undergo discrete steps as they progress to a carcinogenic phenotype. These events are precipitated by exposure to UV radiation, generating 
sunburn cells. UV-exposed keratinocytes with signature C→T transversions at TP53 mutational hotspots escape cell cycle regulatory control and p53-mediated apoptotic 
death. Clonal expansion of p53-mutated keratinocytes increases sensitivity to subsequent UV-induced DNA damage and drives malignant transformation from 
precarcinogenic actinic keratosis to squamous cell carcinoma (366, 420-422). 
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The number of keratinocyte colonies bearing missense and nonsense mutations in 
human skin increase with age and the level of sun exposure (423). On a 
physiological level, p53-mediated stress signalling is activated in keratinocytes 
exposed to UVR, which arrests cell cycle progression, induces the DNA damage 
response and activates cell death programs (producing sunburn cells) (366). If DNA 
repair is successful, replication is restarted, however if photolesions persist in the 
genome, cell death signalling culminates in apoptosis (418). Consequently, 
keratinocytes with impaired p53 expression and activity are unable to mount a 
normal response to UVR exposure, and can survive with additional UVR-mediated 
mutational damage [Figure 3:1].  
In Vitro Culture of Keratinocytes 
Primary keratinocytes require a complex environment for growth in vitro. 
Keratinocyte culture systems have progressed with our understanding of epidermal 
growth and differentiation, from the use of feeder layers and supplementation with 
bovine serum solutions in the early 1980s to the defined media used today. A 
defined, serum-free medium supplemented with epidermal growth factor, insulin, 
hydrocortisone, ethanolamine and phosphoethanolamine was developed by Boyce 
and Ham for optimal propagation of keratinocytes in culture (424). These 
conditions enable primary keratinocytes to be maintained in culture for 
approximately 10-12 population doublings in a relatively undifferentiated state. 
Keratinocyte Differentiation 
In human skin, keratinocytes undergo a process of terminal differentiation as they 
migrate from basal to suprabasal layers of the epidermis. As keratinocytes 
differentiate, their proliferative capacity and morphology alters, giving the outer 
layer of skin its structural and functional properties. The process of keratinocyte 
differentiation is associated with well-characterised changes in cytokeratin, 
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transglutaminase, involucrin and filaggrin expression. These shifts in gene 
expression are linked to the intracellular accumulation of keratohyalin granules, 
formation of a cornified envelope, and interconnecting desmosomal junctions. 
The stratified layers of the skin develop within a calcium gradient which contributes 
to the progressive conversion of proliferative, undifferentiated keratinocytes in the 
basal layer to the non-proliferative phenotype characteristic of the suprabasal 
layers (425, 426). Increases in calcium concentration trigger formation of a cornified 
envelope in cultured keratinocytes by up-regulating involucrin expression and 
facilitating crosslinking by activation of transglutaminase (427-429).  
The HaCaT Cell Line 
The HaCaT cell line has T→C and TT→CC mutations to codons 179, 281 & 282 of its 
TP53 alleles (430), which impairs DNA binding properties and increases cellular 
expression of mutant p53 proteins (431). Primary keratinocytes in culture rapidly 
enter replicative senescence and undergo terminal differentiation; however HaCaT 
cells retain their proliferative potential (even) in high calcium media. The loss of 
senescence that triggered the immortality of HaCaTs is attributed to a series of 
spontaneous events that occurred during in vitro culture of the cell line which 
resulted in the loss of chromosomes 3p, 4p and 9p, the gain of an isochromosome 
containing 9q, and the formation of a stable hypotetraploid population at passage 
10 (398). Although the overall chromosomal content of the HaCaT cell line has 
remained stable, numerous additional rearrangements have occurred since (432). 
Importantly, the occurrence of phenotypic changes in the HaCaT cell line which 
contributed to its independent growth occurred after genotypic stabilisation when 
the chromosomes were no longer undergoing rearrangements (passage 70). This 
observation has been attributed to epigenetic modifications which enabled the cell 
line to adapt to culture conditions (432), and are therefore reversible. Despite 
concerns regarding the impact of these mutations on their phenotype, HaCaT cells 
110 | 
Chapter 3 
retain their morphological features and the capacity to differentiate into a polarised 
and stratified epithelium (433). This allows HaCaTs to be used as a representative 
model for keratinocyte responses in culture and is consistent with changes that are 
known to occur during the process of oncogenesis (formation of skin cancers). 
For our investigations, two keratinocyte cell lines were used – primary neonatal 
human keratinocytes (NHEK; Cascade Biologics, cat# C-001-5C) purchased from 
Gibco-Invitrogen, (Life Technologies), and an immortalised HaCaT cell line which 
had been cultured in DMEM/F12 with added foetal bovine serum. NHEKs are 
fastidious to culture, requiring a complex defined medium for survival in vitro; 
however the HaCaT cell line displays unlimited population doublings in a less 
defined medium such as DMEM/F12. Prior to commencing experimentation, the 
HaCaT cell line was adapted to the same defined growth medium (low calcium, 
serum free) in order to minimise medium-specific variability in gene expression 
between the two keratinocyte cell lines. Phenotypic changes acquired by the HaCaT 
cell line during this process were monitored using keratinocyte differentiation 
markers. 
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3.3 RESULTS 
Confirmation of the HaCaT Phenotype 
Our HaCaT cells were obtained as a live culture from a colleague who is well 
respected in the field of photobiology. Regardless of the source, we felt it was 
important to confirm the p53 mutational status of this cell line, as this assumption 
informed our hypotheses and conclusions based on the results obtained from 
experimentation. Contamination and misidentification of cultured cell lines has 
been an increasing issue in the field of research (434, 435). A recent Nature 
Methods retraction (436) has demonstrated the importance of cell line 
identification in the field of research. Although short tandem repeat (STR) profiling 
is recommended for cell line authentication (437), we considered the source of our 
cell lines was reliable enough to not warrant further investigation. 
The HaCaT cell line was developed by Boukamp et al. from a skin sample which 
became spontaneously immortalised in culture following a replicative crisis 
between passages 6-10 (398). Acquisition of altered replication capacity in this cell 
line is attributed to an increase in telomerase expression resulting from 
hypotetraploidy triggered during this process (432, 438, 439). HaCaT keratinocytes 
are a useful in vitro cell line for modelling molecular mechanisms in the skin, partly 
due to their unlimited replicative potential, but also as they have retained their 
capacity for differentiation and are non-tumorigenic. A well-documented feature of 
HaCaT keratinocytes is its compound heterozygous mutations to each TP53 allele. 
Although the HaCaT cell line was derived from morphologically normal skin, it had 
been exposed to UVR at a genotoxic level which was sufficient to produce the 
adjacent melanoma. The TP53 mutations found in this cell line are characteristic of 
UVR damage and affect codon 179 of exon 5 in one allele and codons 281 and 282 
of exon 8 in the other (430, 440). Since TP53 mutations are a common feature of 
non-melanoma skin cancer, our assumption is that these mutations generate a pre-
carcinogenic phenotype which is related to UV-induced TP53 damage in the skin.  
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TP53 gene mutations in the cell line used for study experiments were identified by 
comparing its p53 cDNA sequence with the sequence obtained from wild-type 
human keratinocytes (NHEK, see Chapter 2 for details). The use of cDNA for 
sequencing p53 was challenging, due to the number of potential splice variants 
yielded by its 11 exons. Over 9 isoforms of this gene transcript have been identified, 
with the p53TA isoform representing the full-length transcript (441-443). The IARC 
TP53 Database [http://p53.iarc.fr/ProtocolsAndTools.aspx] (444, 445) recommends 
detection of p53 mutations by direct sequencing and outlines a protocol for 
targeting small (<500 bp) fragments. Although most p53 mutations are found within 
exons 5-8 (including those recorded for HaCaTs – see IARC TP53 Database 
(http://p53.iarc.fr/CellLines.aspx), we decided to screen the entire ORF sequence 
(exons 2-11) of isoform 1. 
Figure 3:2  Amplification Temperature Gradient 
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Primers were designed to flank the p53 ORF in order to amplify the entire region of 
interest. Unfortunately, we were unable to amplify the entire region using this 
method – either because of the number of isoforms involved, or due to a high 
degree of secondary structure which impaired primer annealing [Figure 3:2].   
To overcome this issue, the region was amplified in two overlapping sections of 
~1000 bp each, and primers designed using transcript variant 1 for Homo Sapiens 
tumour protein p53 (TP53) mRNA (NCBI Reference Sequence: NM_000546.5) 
[Figure 3:3].  
Figure 3:3  Schematic for p53 primer walking 
Amplification scheme proposed for sequencing analysis of the p53 gene product in human 
keratinocytes. Diagrammatic representation of the TP53 gene and its transcribed mRNA product are 
shown for comparison.  
Despite concerns about splice variants, a single band was obtained with these 
primer sets when amplified cDNA from NHEK and HaCaT cells was analysed via 
agarose gel electrophoresis [Figure 3:4]. Following purification of the amplified PCR 
product, ~500 bp regions of Amplicon 1 or 2 were sequenced by the Australian 
Cancer Research Foundation (AGRF) facility at the University of Queensland 
according to the primer schematic in Figure 3 [Table 3:1]. 
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Figure 3:4  p53 PCR Template for Sequencing 
P53 cDNA prepared from primary neonatal (NHEK) and p53-mutated (HaCaT) keratinocytes was 
amplified in two overlapping sections (PCR Amplicons 1 and 2). PCR product was purified for 
sequencing using a QIAquick PCR Purification Kit, and separated by agarose gel electrophoresis. 
Single bands obtained by PCR amplification were stained with SYBR Safe DNA stain (Molecular 
Probes, Eugene, OR) and visualised with a LAS-3000 Luminescent Image Analyser (Fujifilm, JPN).   
Table 3:1  Primers for p53 Sequencing 
ID Strand Amplicon Sequence Site 
P53SeqF1 Forward 1 GGTGACACGCTTCCCTGGAT 152..171 
P53SeqR2 Reverse 1 AAGGCCTCATTCAGCTCTCG 1226..1245 
P53SeqF4 Forward 2 GCCCCTCCTCAGCATCTTAT 781..802 
P53SeqR4 Reverse 2 CGGGAGGTAGACTGACCCTT 1338..1319 
P53SeqR5 Reverse 1 TCAAAGCTGTTCCGTCCCAG 1014..995 
P53SeqR6 Reverse 1 TTGTTGAGGGCAGGGGAGT 601..582 
P53SeqR7 Reverse 2 GAAGTGGGCCCCTACCTAGA 1708..1689 
The ABI traces obtained from this facility were analysed using CLC Main Workbench 
software (CLC Bio Version 6.7.1). Inspection of the trace data demonstrated 
difficulties associated with direct sequencing of heterozygous mutations are not 
rapidly revealed by standard sequencing techniques, and must be discovered 
manually (446). Alternative sequencing methods (such as pyrosequencing) are 
recommended for high-throughput screening of multiple samples (447). 
Additionally, if the mutation is known, specific wild-type and mutant–targeting 
primers can be used to yield traces for each allele, however whilst this technique 
has been successfully used to differentiate p53 mutations in the HaCaT cell line 
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(440) [Figure 3:5], it has poor practical applications due to the highly variable nature 
of p53 mutations in a clinical setting. 
Figure 3:5 Identification of mixed alleles from sequencing traces derived from p53 cDNA 
PCR product obtained from amplicons 1 & 2 were purified using a QIAquick PCR Purification Kit, and 
60 ng of this template + 10 pmol primer oligonucleotides in 12 µl total volume were assayed by 
Sanger sequencing using a 3730xl DNA Analyser (Applied Biosystems). Regions of the HaCaT 
sequence displaying mixed bases on each allele are circled. Note – base data shown represents the 
cDNA complementary sequence. NHEK and HaCaT sequencing data was aligned with the NCBI TP53 
gene sequence using CLC Main Workbench software (CLC Bio Version 6.7.1). 
Analysis showed a single C > T and double CC > TT mutations at bases 600 and 1000 
relative to the reference p53 sequence [NM_000546.5; Figure 3:5]. These findings 
correlate with the aforementioned mutations at exon 5 (H179Y) and exon 8 
(R282W) (430), and confirmed the mutational status of p53 in our cell line has 
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remained consistent. Additionally, the NHEK cell strain did not display any 
mutations to its p53 sequence when analysed in comparison to NCBI-registered 
human p53 sequences, confirming that its p53 gene has ‘wild-type’ status. These 
results allowed us to be confident that the assumptions we made with regards to 
p53 status in both HaCaT and NHEKs which informed our experimental model were 
sound. 
Next, growth conditions for in vitro culture were standardised to ensure any 
phenotypic features and physiological responses measured during investigations 
were unique to the cultured cells used in the study and not environmentally 
imposed by the composition of the culture medium. 
Growth and morphology of HaCaT keratinocytes is dependent on growth medium 
Numerous investigations have shown that the primary trigger for differentiation of 
cultured keratinocytes is proximity during growth (448). To retain the replicative 
potential of primary keratinocytes, cells need to be maintained at a subconfluent 
density. In order to promote de-differentiation of HaCaTs in RPMI-1640 with 5% 
FBS, cells were seeded in 75T flasks at a density of 2.5  104 cells per cm2 and flasks 
were passaged before 75% confluence was reached. Following adaptation, these 
cells were weaned to the defined keratinocyte medium (EpiLife supplemented with 
Human Keratinocyte Growth Supplement) containing 60 μM calcium for 
experiments. Epilife is a proprietary solution from Cascade Biologics. Although the 
exact concentration of its components is unavailable to consumers, it has been 
developed from MCDB 153 by modifying Ham’s nutrient mixture F12 for growth of 
keratinocytes in culture (424, 449). Therefore the composition of MCDB 153 basal 
medium has been included for comparison with DMEM F12 and RPMI 1640 (Gibco 
Invitrogen) [Table 3:2]. 
117 | 
Table 3:2  Composition of Keratinocyte Culture Medium 
DMEM-F12 RPMI 1640 MCDB 153 
   Inorganic Salts CaCl2 1.05 
 
0.06 
Ca(NO3)2 • 4H2O 
 
0.424 
CuSO4 • 5H2O 0.0000052 0.0000108 
Fe(NO3)3 • 9H2O 0.000124 
FeSO4 • 7H2O 0.0015 0.005 
MgCl2 0.301 
 
0.6014 
MgSO4 0.407 0.407 0.00000125 
Ammonium Metavanadate 0.00000496 
Molybdic Acid • 4H2O (ammonium) 0.000001003 
Nickel Chloride • 6H2O 
  
0.000000505 
KCl 4.16 5.33 1.49 
NaHCO3 29.02 23.81 
NaCl 120.68 103.45 131.02 
Na2HPO4 0.5 5.63 2.00062 
NaH2PO4 0.453 
Sodium Metasilicate • 9H2O 0.0004996 
Sodium Acetate (anhydrous) 3.6772 
Sodium Selenite 0.000022 
Stannous Chloride • 2H2O 
 
5.008E-07 
ZnSO4 • 7H2O 0.0015 0.0005 
Amino Acids L-Alanine 0.05 
 
0.1 
L-Arginine • HCl 0.699 1.15 0.9986 
L-Asparagine • H2O 0.05 0.379 0.1 
L-Aspartic Acid 0.05 0.15 0.03 
L-Cystine • 2HCl 0.1 0.208 
L-Cysteine • HCl • H2O 0.0998 
 
0.2389 
L-Glutamic Acid 0.05 0.136 0.1 
L-Alanyl-L-Glutamine (GlutaMax) 2.5 2.06 4.042 
Glycine 0.25 0.133 0.1 
L-Histidine • HCl • H2O 0.15 0.0968 0.07986 
L-Isoleucine 0.416 0.382 0.015 
L-Leucine 0.451 0.382 0.5 
L-Lysine • HCl 0.499 0.219 0.0998 
L-Methionine 0.116 0.101 0.03 
L-Phenylalanine 0.215 0.0909 0.03 
L-Proline 0.15 0.174 0.3 
L-Hydroxyproline 
 
0.153 
L-Serine 0.25 0.286 0.6 
L-Threonine 0.449 0.168 0.1 
L-Tryptophan 0.0442 0.0245 0.015 
L-Tyrosine • 2Na • 2H2O 0.214 0.11 0.013 
L-Valine 0.452 0.171 0.3 
Vitamins D-Biotin 0.0000143 0.00082 0.00005984 
Choline Chloride 0.0641 0.0214 0.0997 
Folic Acid 0.00601 0.00227 0.00179 
myo-Inositol 0.07 0.194 0.1 
Niacinamide 0.0166 0.0082 0.0003 
D-Pantothenic Acid • ½Ca 0.0047 0.000524 0.000499 
Pyridoxal • HCl 
 
0.0073 
Pyridoxine • HCl 0.00986 0.00485 0.0002995 
Riboflavin 0.000582 0.000532 0.0001 
Thiamine • HCl 0.00644 0.00297 0.001 
Vitamin B12 0.000502 0.0000037 0.0003 
Adenine • HCl 0.18 
Other D-Glucose 17.51 11.11 6 
Lipoic Acid 0.00051 0.001 
Hypoxanthine 0.015 
Linolenic Acid 0.00015 
 Phenol Red • Na 0.0215 0.0133 0.0033 
Putrescine • HCl 0.000503 0.001 
Pyruvic Acid • Na 0.5 0.5 
Thymidine 0.00151 
 
0.003 
Glutathione 0.00326 
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Exposure to a high calcium environment (>1 mM) promotes differentiation in 
primary keratinocytes (424, 450), however calcium is thought to have a permissive, 
rather than an initiating role in the differentiation process (451). Nonetheless, 
calcium concentration is a well-documented modulator of keratinocyte 
morphology. To adapt HaCaT keratinocytes previously cultured in DMEM, cells were 
grown in RPMI-1640 (0.424 mM calcium) for 4-5 weeks. During this time frame, FBS 
was maintained at 5% to ensure that any changes measured were specific to the 
altered calcium concentration. 
After 10 days (2 passages) in RPMI-1640 + 5% FBS, decreased replication and 
increased detachment of senescent cells was observed. Calcium concentration is 
not considered limiting for keratinocyte growth (450), however when compared to 
normal keratinocytes, HaCaTs demonstrate an increase in proliferation and fraction 
of S and G2/M cells with higher calcium concentrations (452). Thus culture in RPMI-
1640 + 5% FBS provides a selective pressure for survival of HaCaT clonal lines with a 
less differentiated phenotype as a consequence of the change in micronutrient 
concentration due to sloughing of differentiated squames into the growth medium.  
HaCaT Keratinocytes are de-differentiated by culture in low calcium media 
HaCaTs cultured in DMEM/F12 display intracellular features of the granular and 
cornified epidermal layers, and these features are no longer evident after 
adaptation to EpiLife. When the HaCaT cell line is grown in DMEM-F12 + 5% FBS, 
cells display morphological features consistent with differentiated keratinocytes 
[cell-cell adhesion, stratification, flattening and spreading] [Figure 3:6]. 
Intermediate filaments and desmosomal junctions are features of suprabasal 
keratinocytes in the spinous layer. Keratohyaline granules predominantly form in 
the granular layer and contain profilaggrin, keratins 1, 2 & 10 and transglutaminase 
3. The cornified envelope develops in the outer stratum corneum from loricrin,
involucrin, trichohyalin, S100 proteins and small proline-rich proteins (453). 
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Interestingly, primary keratinocytes cultured from human foreskins also form a 
cornified envelope, and produce filaggrin-containing keratinohyaline granules when 
cultured in DMEM (454, 455). Involucrin is synthesised as a soluble precursor of the 
cornified envelope in the suprabasal epidermis. The cornified envelope is formed by 
transglutaminase-catalysed ε-γ-glutamyl-lysine bonding between involucrin and 
plasma membrane-bound proteins (456). Transglutaminase activity is calcium-
dependent (457, 458); hence construction of a cornified envelope by keratinocytes 
grown in low calcium medium is limited. 
Figure 3:6 Ultrastructure of HaCaT keratinocytes changes following adaptation 
HaCaT keratinocytes cultured in DMEM-F12 and 5% FBS or EpiLife with HKGS were seeded at a 
density of 5  105 cells per well in 6 well tissue culture plates and allowed to recover overnight. 
Microphotographs were prepared after staining with 0.05 % crystal violet in PBS.  
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Whilst HaCaT cells grown in DMEM-F12 produce colony-like clusters in culture 
[Figure 3:7(a & d], when this cell line is cultured in EpiLife [Figure 3:7 (b & e)], the 
growth pattern correlates more closely with NHEKs [Figure 3:7(c & f)].  
Figure 3:7  Gross morphology of keratinocytes cultured in DMEM-F12 or EpiLife culture media 
Primary neonatal (NHEK) and HaCaT keratinocytes were seeded at a density of 5  105 cells per well 
in 6 well tissue culture plates and allowed to recover overnight. Microphotographs of keratinocytes 
were prepared after staining with 0.05 % crystal violet in PBS. Growth characteristics of (a, d) HaCaT 
keratinocytes cultured in DMEM-F12/ 5% FBS; (b, e) HaCaTs and (c, f) NHEKs seeded at identical 
density when cultured in EpiLife culture medium 
As shown above, culture in EpiLife enables HaCaT keratinocytes to adopt growth 
characteristics and a morphology which more closely approximates the primary cell 
strain. To confirm that the observed morphological changes were related to de-
differentiation of the HaCaT cell line, expression of representative differentiation 
markers was measured during adaptation to low calcium conditions. 
As keratinocytes emerge from their stem cell precursors, they enter into a 
differentiation program as they migrate from the basal layer to the outer epidermal 
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layers. During this process, keratinocytes undergo numerous structural changes 
initiated by synthesis of differentiation-dependent marker proteins. Well 
established keratin markers for differentiation include keratins 5 and 14 in the basal 
layer, and keratins 1, 10, 6 and 16 in suprabasal layers of the epidermis. Loricrin and 
involucrin are expressed in the spinous layer, followed by filaggrin and 
transglutaminase in the granular layer (456). During terminal differentiation, the 
~400 kDa profilaggrin polyprotein is dephosphorylated and rapidly cleaved by 
serine proteases to form monomeric filaggrin (37 kDa), which binds to and 
condenses the keratin cytoskeleton and thereby contributes to the cell compaction 
process that occurs during formation of the epidermal cornified layer (453). 
Figure 3:8  De- differentiation of HaCaT keratinocytes in low calcium conditions 
TP53-mutated (HaCaT) keratinocytes were cultured for 30 days (4 weeks) in low-calcium, RPMI 
medium. Cell extracts were prepared weekly and differentiation marker proteins were detected by 
immunoblotting. Actin indicates protein loading.   
In this investigation, cytokeratin 10 was used as a marker for early stage, filaggrin 
for intermediate stage, and involucrin for late stage differentiation. HaCaTs 
underwent a duration-dependent shift in involucrin, cytokeratin 10 and filaggrin 
expression during the initial 30 days of growth in low calcium conditions. After 4 
weeks of adaptation, involucrin expression decreased by 30%, filaggrin expression 
decreased 10-fold and cytokeratin 10 was halved [Figure 3:8].  
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Figure 3:9  Effect of growth medium on differentiation marker expression in keratinocytes 
Protein was extracted from untreated subconfluent HaCaT keratinocytes cultured in DMEM-F12 or 
EpiLife and used to compare differentiation marker expression with normal keratinocytes. 
Cytokeratin 1 (a), cytokeratin 10 (b), filaggrin (c), and involucrin (d) expression in HaCaT 
keratinocytes grown in DMEM-F12 or EpiLife was quantitated relative to expression in NHEKs. (e): 
Representative immunoblots of lysates from keratinocyte cells in their basal (unstimulated) state are 
shown for reference. Values represent mean expression relative to NHEKs from 3 independent 
experiments (± SD) and significant differences are represented as *, ** and ***; with p < 0.05, p < 
0.01 and p < 0.001 respectively. Differences in expression between HaCaTs in DMEM-F12 and EpiLife 
were analysed by 1-way ANOVA with Bonferroni post-test and are indicated as # (p < 0.05).  
A quantitative analysis of filaggrin, involucrin and cytokeratin expression was 
performed to compare the effect of growth medium on differentiation markers. 
HaCaTs grown in DMEM have 4-fold lower cytokeratin 1 [Figure 3:9(a)], 4.5-fold 
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greater expression of cytokeratin 10 [Figure 3:9(b)], 10-fold higher filaggrin [Figure 
3:9(c)] and 3-fold higher involucrin [Figure 3:9(d)] when compared to normal 
keratinocytes grown in EpiLife.  
Conversely, after adaptation to EpiLife, cytokeratin 10 and filaggrin expression in 
HaCaTs decreased to a level comparable to NHEKs [Figure 3:10 (b, c, e)]. 
Cytokeratin 1 expression was not altered in adapted HaCaTs [Figure 3:10 (a, e)], and 
although involucrin was still expressed in these cells, a significant reduction was 
observed [Figure 3:10 (d, e)]. This analysis demonstrates that adaptation to EpiLife 
has restored expression of filaggrin and cytokeratin 10 in HaCaT keratinocytes to a 
level comparable with primary keratinocytes. Although expression of involucrin in 
post-adapted HaCaTs remained higher than NHEKs, it was significantly reduced 
when compared to pre-adapted HaCaTs. 
Although the NHEK samples in this study produced strong cytokeratin 1 and 
profilaggrin expression, the cells used for immunoblotting were harvested at a high 
confluence. NHEKs used in future experiments were used at lower seeding density, 
restoring cytokeratin 1 and profilaggrin expression in NHEK cells to a level which 
was analogous to post-adapted HaCaTs. Overall, differentiation marker expression 
demonstrates that growth of HaCaT keratinocytes in low calcium, serum free 
conditions allows the cell line to adopt a phenotype that correlates more closely 
with primary keratinocytes. 
HaCaT keratinocytes cultured in defined medium undergo calcium-dependent 
changes in differentiation marker expression, although unlike normal keratinocytes, 
they retain their proliferative properties (452). HaCaT is a spontaneously 
immortalised cell line which is commonly used for in vitro studies due to its ease of 
growth in culture. However many investigators culture HaCaT keratinocytes in high 
calcium conditions and also supplement with bovine serum. The potential to 
influence the HaCaT phenotype by culture medium conditions is particularly 
important to studies which utilise the HaCaT cell line for preclinical investigations, 
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as treatment-based outcomes are dependent on the gene expression profile of the 
cell line used. 
Consequently, HaCaT keratinocytes used in this study were cultured in reduced 
calcium, serum-free media to allow for more accurate comparisons to be made 
with primary keratinocytes during experimentation. The following results describe 
differences in the target gene expression profile of unstimulated primary cultured 
keratinocytes (NHEK) and the HaCaT cell line following adaptation to EpiLife. 
p53 is overexpressed in HaCaT keratinocytes 
As a transcription factor, p53 operates by binding to a canonical response element 
proximal to the transcriptional start site of target genes. This consensus sequence 
contains two tandem repeats of the RRRCWWGYYY motif separated by a 0-13 bp 
spacer region (R=purines; W=adenine/thymine; Y=pyrimidines) (40). In normal cells, 
wild-type p53 is synthesised in the cytoplasm, then assembled into dimers which 
are transported in the nucleus and assembled into tetramers at DNA binding sites 
for transcription. p53 binds to DNA in its tetrameric form (40, 414). Mutations to 
the C-terminal domain interfere with tetramerisation and alter the conformation of 
the nuclear export signal (71). This inhibits nucleocytoplasmic shuttling and reduces 
transcriptional activation (459). However, the majority of cancer–associated p53 
mutations are found in the core domain and predominantly impair DNA binding 
affinity and/or protein conformation and stability (69).  
p53 mutations cause genetic instability and polyploidy by 3 distinct mechanisms: 
Firstly, through loss of its tumour suppressor function; secondly by competitive 
inhibition of wild-type p53 targets; and thirdly through impaired cell cycle 
checkpoint control and inhibition of DNA repair pathways (78). These properties are 
exacerbated in cells with heterozygous p53 mutations (such as the HaCaT cell line). 
P53 haplo-insufficiency drives cancer formation in Li Fraumeni syndrome, and has a 
stronger effect on p53-mediated transrepression (in genes such as survivin) than 
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complete gene inactivation (73). When both mutant and wild-type p53 proteins 
accumulate at high concentration, inactive heterotetramers are formed that inhibit 
the formation of functional wild-type tetramers (42, 80, 81). 
This attenuation of the tumour-suppressive property of p53 in the hemizygous 
phenotype increases tumorigenicity and metastatic potential, and contributes to 
chemotherapeutic resistance and poor treatment outcomes for patients (80).  
Figure 3:10  Basal p53 Expression and Acetylation Profile 
Protein and total RNA was extracted from untreated subconfluent primary human (NHEK) and p53-
mutated (HaCaT) keratinocytes. Expression of p53 mRNA was determined by qRT-PCR, acetylation 
and expression of total p53 protein was assayed by immunoblotting. All results are expressed 
relative to NHEK, and are expressed as mean ± SD, with p<0.05 (*); p<0.001 (***), using paired 
student’s T-test for statistical analysis.  
Consistent with NMSC samples (460), HaCaTs have 15% lower p53 mRNA 
expression and have over 3 times the cellular p53 protein content when compared 
to normal keratinocytes, (Figure 3:10; p<0.001). However although p53 is 
overexpressed in this cell line, acetylation of its active site residues is suppressed 
(Figure 3:10; p<0.05). 
In addition to canonical functions of the p53/response element interaction, p53 
functions as a transcriptional repressor at non-canonical DNA binding sequences. 
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Genes with a repressive p53 response element typically have alterations to the 
decamer motif (45), and p53-mediated transcriptional repression appears to 
regulate genes which are anti-apoptotic, regulate cell cycle checkpoint control and 
differentiation or senescence (44).  
BCL-2 and Survivin are key proteins involved in cell death and survival signalling. 
Both are negatively regulated by wild-type p53 (461, 462), and are overexpressed in 
skin cancer (463, 464). When compared with NHEKs, expression of survival markers 
BCL-2 and BIRC5/Survivin in untreated HaCaTs is approximately 10-fold higher 
(Figure 3:11; p<0.001).  
Figure 3:11  Overexpression of survival markers in p53-mutated keratinocytes 
BCL-2 and BIRC5/Survivin mRNA expression in primary (NHEK) and p53-mutated (HaCaT) 
keratinocytes was determined by Taqman qRT-PCR. All results are expressed relative to NHEK, and 
are expressed as mean ± SD, with p<0.001 (***), using paired student’s T-test for statistical analysis.  
In conjunction with unlimited replicative potential in HaCaTs (398), overexpression 
of BCL-2 and Survivin contributes to the enhanced survival characteristics 
demonstrated by this cell line in culture. 
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3.4 DISCUSSION 
The intention of this chapter has been to describe the process utilised to prepare, 
identify and characterise the phenotypic properties of the p53-mutated HaCaT 
keratinocyte cell line. In order to generate a model with p53 mutational status as its 
primary variable, HaCaT cells were adapted to growth in identical culture conditions 
as the keratinocytes used as a wild-type control, and the ORF of p53 isoform 1 was 
sequenced. To test the assumption that HaCaT mutations alter p53 expression and 
the transcriptional activity, p53 mRNA and protein expression were measured, and 
acetylation of p53 of lysine residue 382 was analysed in HaCaT and NHEK cells. 
Additionally, expression of BCL-2 and Survivin in NHEKs and HaCaTs was compared 
to assess the impact of p53 mutations on p53-DNA binding for p53 transcriptional 
repression targets. This chapter demonstrates some of the p53-specific phenotypic 
alterations in the HaCaT cell line which contribute to its precarcinogenic properties.  
Use of in vitro systems to analyse and model cellular responses is standard practice 
in the fields of toxicology and clinical therapeutics. Findings from these studies 
shape our understanding of disease processes and inform animal studies and 
human clinical trials. Culture media is a critical mediator of keratinocyte phenotype, 
and therefore choice of growth conditions and the potential to influence cellular 
responses should be considered prior to conducting any in vitro investigation which 
utilises keratinocyte cell lines. Our investigations demonstrate that HaCaT 
keratinocytes can be successfully adapted to low calcium, serum-free growth 
environment following extended culture in high calcium and serum. When grown in 
these conditions, differentiation marker expression and morphology of HaCaTs 
shifts to approximate the profile measured in normal keratinocytes. 
Mutations affecting the p53 gene of the HaCaT cell line were identified, and the 
location of these mutations in exons 5 and 8 confirmed by sequencing. An 
accumulation of p53 protein without a concomitant up-regulation of p53 mRNA in 
this cell line indicates that post-translational control of p53 expression is impaired. 
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Additionally, p53 acetylation is suppressed and p53-regulated anti-apoptotic 
markers BCL-2 and Survivin are overexpressed in HaCaTs, providing evidence of 
aberrant regulation of p53-mediated activation and DNA binding in this cell line. Of 
the HaCaT mutations, the H179Y mutation affects its zinc binding ligand, altering 
transactivation of p53; and both R281W and R282W mutations affect the major 
groove DNA binding domain (465). 
HaCaT is a human keratinocyte cell line which is extensively used as an in vitro 
model to investigate keratinocyte cell physiology. Although this cell line was derived 
from a physiologically normal human skin source, both p53 alleles bear mutations 
and have undergone further cytogenetic changes after escaping replicative 
senescence. Additionally, cell lines which have adapted to survive in in vitro cell 
culture conditions develop properties which are phenotypically different from cells 
in vivo, and after >70 population doublings, the HaCaT cell line is no exception. Our 
model system was designed to minimise exogenous influences on growth and 
survival in culture so that the endogenous influence of p53 mutations on 
keratinocyte phenotype could be measured without the confounding effects 
presented by media composition.  
In this chapter, the hypothetical framework for future experiments was defined by 
characterising the effect of p53 mutations in HaCaT keratinocytes on the p53 
expression profile. Here we have determined that the HaCaT cell line has genotypic 
and phenotypic features which are consistent with precarcinogenic changes 
observed during the earliest stages of skin cancer initiation. Additionally, by 
standardising culture conditions for the growth of keratinocyte cell lines, media-
dependent effects are minimised, and this enables our conclusions to be based on 
genotypic features of the keratinocytes used in experiment. 
129 | 
Chapter 4 - 
SIRT1 Modulates MicroRNA Processing Defects in 
p53-Mutated Human Keratinocytes 
Chapter 4 
4.1 ABSTRACT 
Together with p53, the NAD-dependent lysine deacetylase SIRT1 and the microRNA 
miR-34a form a feedback loop which self-regulates SIRT1 expression and modulates 
p53-dependent responses. In addition to its well-described role in mediating 
transcriptional responses to genotoxic stress, p53 may also regulate microRNA 
processing and maturation. RNAi, miRNA target site blocking oligonucleotides and 
small molecule inhibitors were used to explore the functional relationship between 
p53, SIRT1 and miR-34a, and the influence of p53 and SIRT1 on microRNA 
biogenesis and maturation in primary (NHEK) and p53-mutated (HaCaT) 
keratinocyte cells.  
Mature miR-34a decreased in p53-suppressed NHEK cells, whereas ablation of 
SIRT1 reduced the primary transcript (pri-miR-34a). When either SIRT1 expression 
or activity was inhibited in combination with p53 ablation, pri-miR-34a levels 
increased and mature miR-34a levels decreased. Under these same conditions, 
additional p53-regulated microRNAs (miRs 16-1/15, 145 and 107) also failed to 
mature. In HaCaT cells, primary microRNA transcripts for miR-16-1/15, miR-145 
miR200c/141 and miRNA-107, but not miR-34a, were approximately 8-fold higher 
than in NHEK cells. However, the levels of mature microRNA sequences in HaCaT 
cells were only 1.5-2 fold higher (miR-16-1, miR-145), unchanged (miR-107) or 
decreased (miR-200c/141, miR-34a) compared to NHEK cells.  
These results demonstrate that characteristic UV-induced TP53 mutations interfere 
with efficient microRNA biogenesis. Furthermore, SIRT1 functions in combination 
with p53 to establish microRNA expression patterns in human keratinocytes.  
Much of the work in this chapter forms the basis of a manuscript published in the Journal of 
Dermatological Science:  
SIRT1 Modulates MicroRNA Processing Defects in p53-Mutated Human Keratinocytes, 2014, J 
Dermatol Sci, 74:142-9 http://dx.doi.org/10.1016/j.jdermsci.2014.01.008 (466). 
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4.2 INTRODUCTION 
The transcription factor p53 has multiple tumour suppressor functions in the cell, 
including regulation of cell cycle progression, cell growth, DNA damage response 
and apoptotic signalling (467). Activation of p53 protein is influenced quantitatively 
and qualitatively by post-translational modifications which stabilise protein 
expression and facilitate DNA binding, and include phosphorylation, acetylation, 
methylation, ubiquitinylation, sumoylation and neddylation (48, 54). Acetylation of 
C-terminal lysine residues inhibits ubiquitin-mediated proteolysis, increases DNA 
binding affinity, and induces transcription of p53 regulatory targets (50-52). Post-
translational modifications selectively affect p53-responsive promoter association 
and recruitment of transcriptional co-activators (43, 468-470), ultimately producing 
an analogue, rather than digital, transcriptional outcome in the cell. Mild p53 
activation promotes cell cycle arrest and DNA repair (471), whereas increased 
induction of activated p53 triggers apoptotic signalling and cell death (54, 63, 472). 
Additionally, p53-mediated transcriptional repression influences stress responses 
by negative regulation of anti-apoptotic/pro-survival proteins. Impaired expression 
or functional activity of p53, therefore, drives carcinogenesis by interfering with 
endogenous p53-mediated responses to stress.  
MicroRNAs are key regulators of downstream effectors of p53-dependent 
responses (473). As such, microRNAs maintain the functional integrity of the 
genome and acts as a tumour suppressor during exposure to carcinogenic stressors 
(149). Consequently, the widespread nature of p53 mutations in cancer has hinted 
at a relationship between p53 activity and microRNA biogenesis which precipitates 
and reinforces many of the changes to cellular biochemistry during carcinogenesis 
(149). During microRNA biogenesis, primary nuclear transcripts (pri-miRNAs) are 
processed into 70-nucleotide precursor sequences (pre-miRNAs) for cytoplasmic 
translocation and cleavage into ~22-nucleotide fragments (mature miRNAs) prior to 
incorporation into RNA-induced silencing complexes. This process is facilitated by 
two RNaseIII enzymes – nuclear Drosha and cytosolic DICER, as well as the RNaseIII- 
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associated proteins Di George syndrome critical region 8 (DGCR8) and the DEAD 
box RNA helicases p68 and p72 (474). p53 is found to be mutated in almost every 
cancer type, including those affecting the skin (415, 475).  
The miR-34 family of miRNAs has recently emerged as an important regulatory 
component of p53-mediated signalling (476, 477), targeting substrates involved in 
cell cycle regulation and apoptosis (478). In particular miR-34a, whose expression is 
induced by p53-mediated transcriptional activation (149), regulates SIRT1 
expression by base pairing with its 3′UTR (479). SIRT1, in turn, inhibits p53 
activation through regulation of its acetylation status (201, 202). In this manner, 
SIRT1, p53 and miR-34a form a coherent feed-forward loop, referred to here as the 
p53/SIRT1/miR-34a axis, which influences cellular differentiation, senescence and 
apoptotic signalling (480-483). 
Here, p53 expression and activity were manipulated to investigate the relationship 
between the p53/SIRT1/miR-34a axis and miRNA biogenesis in normal (NHEK) and 
p53-mutated (HaCaT) human epidermal keratinocytes. Expression of primary and 
mature miRNA targets was measured in a set of p53-regulated miRNAs to 
determine how p53 and SIRT1 contribute to miRNA maturation.  
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4.3 RESULTS 
p53 and SIRT1 co-regulate miR-34a expression in human keratinocytes 
RNA interference (RNAi) was used to determine the relationship between SIRT1, 
p53 and miR-34a in normal (NHEK) keratinocytes. p53 is minimally expressed in 
normally growing keratinocytes (368) and has a half-life of < 12 minutes (484), thus 
siRNA-induced changes in unstressed keratinocytes were difficult to monitor and 
did not accurately represent knockdown efficiency in NHEKs. P53 is overexpressed 
in HaCaT keratinocytes however; so siRNA-induced ablation was easier to detect in 
this cell line. To confirm the efficacy of siRNA-induced p53 ablation during 
experiments, NHEKs were treated with a p53 expression inducer [camptothecin 
(CPT)]. P53 protein increased 6-fold in NHEKs after 24 hrs of CPT treatment, but not 
in p53-transfected cells [Figure 4:1]. 
Figure 4:1  Suppression of CPT-mediated p53 induction by RNAi in human keratinocytes 
Primary human keratinocytes (NHEKs) were transfected with a p53 siRNA targeting pool for 48 
hours, and treated with 5 µM camptothecin (CPT, black bars) for 24 hrs. p53 expression was 
determined from extracted samples by qRT-PCR and immunoblotting. Actin was used as a loading 
control for immunoblotting, and RT-PCR results were normalised to 5S rRNA. 
All data represent the mean ± SD of 3 independent experiments. Results significantly different from 
vehicle control (white bars) are represented as ***; p < 0.001 respectively.  
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Transfection of NHEK cells with p53-targeting siRNAs reduced p53 mRNA and 
protein expression by 45% [Figure 4:2(a-c); p<0.001] when compared to NHEKs 
transfected with non-targeting control siRNAs. Similarly, 48 hour transfection of 
NHEKs with SIRT1-targeting siRNAs reduced SIRT1 mRNA and protein by 60% when 
compared with the non-targeting siRNA pool [Figure 4:2 (c-e); p<0.001]. Using these 
p53- or SIRT1-specific targeting siRNA pools, we were able to selectively inhibit 
expression of either SIRT1 or p53 mRNA, with a slight reduction in SIRT1 protein 
generated by p53 knockdown [Figure 4:2 (e)].  
Figure 4:2  Co-transfection of p53 and SIRT1 in human keratinocytes 
Primary human keratinocytes (NHEKs) were transfected with p53 (right Panel) and SIRT1 (black bars) 
siRNA targeting pools. Total RNA was extracted after 48 hrs and target genes assayed by RT-PCR. 
Results were normalised to 5S rRNA, and analysed relative to samples transfected with non-
targeting control oligonucleotides (white bars).  
All data represent the mean ± SD of 3 independent experiments and are represented as *, ** and 
***; with p < 0.05, p < 0.01 and p < 0.001 respectively.  
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During combined p53/SIRT1 RNAi experiments, SIRT1 and p53 mRNA were both 
reduced in a manner comparable to p53 knockdown alone [Figure 4:2 (a & d)], 
although SIRT1 protein expression was not significantly suppressed by dual 
transfection [Figure 4:2 (c & e)].  
In order to fully evaluate the influence of combined p53 and SIRT1 knockdown on 
the SIRT1-targeting microRNA, miR-34a, we specifically quantified abundance of 
both the primary transcript and its mature sequence after processing. Our results 
showed that p53 ablation alone did not significantly alter pri-miR-34a [Figure 4:3 
(a)], but halved expression of its mature sequence [Figure 4:3 (b); p<0.001]. 
Conversely, SIRT1 knockdown halved pri-miR-34a [Figure 4:3 (a); p<0.001], but did 
not alter expression of mature miR-34a [Figure 4:3 (b)].  
Figure 4:3  p53 and SIRT1 co-regulate miR-34a maturation in human keratinocytes 
Primary human keratinocytes (NHEKs) were transfected with p53 (right Panel) and SIRT1 (black bars) 
siRNA targeting pools. Total RNA was extracted after 48 hrs and target genes assayed by RT-PCR. 
Results were normalised to 5S rRNA, and analysed relative to samples transfected with non-
targeting control oligonucleotides (white bars).  
All data represent the mean ± SD of 3 independent experiments and are represented as *, ** and 
***; with p < 0.05, p < 0.01 and p < 0.001 respectively.  
With combined p53 and SIRT1 transfection, pri-miR-34a expression in NHEKs 
increased by 30% [Figure 4:3 (a); p<0.001], but the mature miR-34a transcript did 
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not increase in a corresponding manner, and instead was depleted by 60% [Figure 
4:3 (b); p<0.001].  
Impaired post-transcriptional processing of miR-34a in p53 mutated 
keratinocytes 
To investigate the implications of our results in cancers with p53-inactivating 
mutations, SIRT1 was ablated in the p53-mutated keratinocyte cell line, HaCaT, 
using an identical siRNA transfection protocol as for NHEKs with dual p53 and SIRT1 
knockdown. Abundance of p53, SIRT1, and miR-34a targets was measured using 
qRT-PCR and immunoblotting. 
Figure 4:4 SIRT1 knockdown suppresses miR-34a in p53-mutated keratinocytes 
SIRT1 was transiently ablated in p53-mutated keratinocytes (HaCaTs) with a SIRT1 siRNA targeting 
pool (black bars). Total protein and RNA was extracted after 48 hrs and target protein and mRNA 
expression assayed by immunoblotting or RT-PCR. Actin was used as a loading control for 
immunoblotting, and RT-PCR signals were normalised to 5S rRNA. Results were analysed relative to 
samples transfected with non-targeting control oligonucleotides (white bars). 
All data represent the mean ± SD of 3 independent experiments and are represented as *, ** and 
***; with p < 0.05, p < 0.01 and p < 0.001 respectively.  
Knockdown of SIRT1 in the p53-mutated HaCaT cell line suppressed total p53 
protein and increased relative p53 acetylation [Figure 4:4; p<0.01]. Additionally, 
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although the miR-34a precursor was induced in SIRT1-inhibited HaCaTs, expression 
of its mature sequence was down-regulated [Figure 4:4; p<0.05]. This experiment 
demonstrates that acetylation capacity in the DNA binding domain is not impaired 
by p53 mutations in HaCaT keratinocytes, and that pri-miR-34a transcription is 
effectively induced by p53 acetylation during SIRT1 ablation. However p53 
mutations in this cell line suppress processing of the primary transcript to its 
mature miR-34a sequence.  
A directed block of the miR-34a binding site enhances SIRT1 expression in human 
keratinocytes 
Our knockdown experiments have shown that both overexpression of SIRT1 and 
depletion of miR-34a are features of p53 mutations in the HaCaT cell line. Since 
SIRT1 is a well characterised target of miR-34a, the next step was to test the 
assumption that overexpression of SIRT1 in keratinocytes is related to altered miR-
34a-mediated regulation. Target site blocking experiments were designed to 
measure cellular responses which are influenced by this relationship by interfering 
with miR-34a:SIRT1 mRNA binding. Based on the current understanding of miR-34a-
mediated regulation of SIRT1 expression (479), our assumption was that inhibition 
of the interaction between miR-34a and SIRT1 at the target site would prevent 
microRNA-mediated degradation of SIRT1 mRNA, and promote its translation into 
SIRT1 protein.  
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Figure 4:5 Schematic of Target site masking experiment 
LNA-modified oligonucleotides were designed to bind the miR-34a/SIRT1 target binding site within 
the SIRT1 3′UTR.These miR-34a:SIRT1 TSB oligonucleotides were used to interrogate cellular 
responses to miR-34a-mediated regulation of SIRT1 expression during p53-mediated signalling.  
To confirm the relationship between miR-34a levels and SIRT1 expression, 
oligonucleotides were designed to specifically block the miR-34a complementary 
binding site within the 3′ UTR of the SIRT1 mRNA [Figure 4:5].  
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Figure 4:6  Effective SIRT1 target site masking in human keratinocytes 
Primary human (NHEK) and p53-mutated (HaCaT) keratinocytes were transfected with 50 nM of a 
directed miR-34a:SIRT1 target site blocking (TSB) or mismatched control (MM Control) LNA-modified 
oligonucleotide pool. SIRT1 mRNA, SIRT1 protein, p53 protein expression and p53 acetylation was 
measured by qRT-PCR or immunoblotting after 72 hrs, and the effect of target site masking analysed 
relative to the mismatched control treatment. Protein loading was standardised using actin and PCR 
values were normalised using 5S rRNA as a control gene.  
Results were analysed by paired t test; (** p<0.01; ***; p<0.001; n=3). 
LNA-modified miR-34a:SIRT1 target site blocking oligonucleotides (TSB) were 
introduced into NHEK or HaCaT keratinocytes using RNAiMAX as a delivery system. 
The efficacy of miR-34a:SIRT1 target site masking was confirmed by assaying 
increases in SIRT1 expression following introduction of the miR-34a:SIRT1 target 
site blocking oligonucleotides. 
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After 72 hrs of treatment with 50 nM miR-34a:SIRT1 TSB oligonucleotides, SIRT1 
mRNA expression in NHEK or HaCaT cells had increased significantly when 
compared to SIRT1 mRNA expression in keratinocytes treated with the same 
concentration of a mismatched control LNA-modified oligonucleotide pool [Figure 
4:6; p<0.001]. Additionally, SIRT1 protein increased in TSB-treated NHEK and HaCaT 
cells after 72 hrs in addition to the accumulation of SIRT1 mRNA [Figure 4:6; 
p<0.01]. To confirm that SIRT1 mRNA is accumulating as a consequence of post-
transcriptional stabilisation following the miR-34a:SIRT1 target site block rather 
than from cell stress-mediated transcriptional up-regulation, p53 protein 
expression and activation was assayed in treated cells.  
No change in p53 acetylation or expression was measured in TSB-treated cells for 
either NHEK or HaCaT cells [Figure 4:6] therefore changes in SIRT1 expression 
resulting from a miR-34a:SIRT1 target site block are not related to p53-mediated 
transactivation.    
Although the HaCaT genome is considered to be stable, mutations to the miR-34a-
coding domain or to the 3′end of the SIRT1 gene could potentially be responsible 
for the altered regulation of SIRT1 by miR-34a observed in the HaCaT cell line. 
Target site blocking experiments in HaCaTs produced results consistent with 
findings in NHEKs, indicating that the interactions between miR-34a and the SIRT1 
mRNA binding site in this cell line had not been compromised by extended growth 
in culture.  
When miR-34a expression was assayed in these experiments, blocking the SIRT1 3′ 
UTR miR-34a target site produced a 50% up-regulation of the primary miR-34a 
transcript [Figure 4:6; p<0.001], and suppressed mature miR-34a expression [Figure 
4:6; p<0.001]. Taken together, these results demonstrate that the miR-34a:SIRT1 
binding site is effectively blocked with 50 nM of LNA-modified oligonucleotides. 
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Primary and mature miR-34a is differentially expressed by modulating p53 
activity and expression 
The role of p53 and SIRT1 in miR-34a expression and biogenesis was further 
explored by altering p53 and SIRT1 activity using pharmaceutical agents.  Wild-type 
p53 is minimally expressed in unstressed cells (estimated between 25 - 200  103 
molecules per cell, depending on the cell line) (485). P53 expression is suppressed 
by proteasomal degradation via the E3 ubiquitin ligase MDM2 (486, 487).  
Figure 4:7  Nutlin up-regulates p53 in wild-type, but not p53-mutated human keratinocytes 
Primary (NHEK) or p53-mutated (HaCaT) keratinocytes were treated with 10 µM Nutlin-3a for 24 
hours. Expression of p53 (total protein) and p53 acetylated at lysine 382 [Acetyl p53(K382)] was 
measured by immunoblotting cell lysates. Densitometric data was analysed relative to vehicle 
controls, using actin to normalise protein loading. 
All data represent mean ± SEM of 3 independent experiments. Results significantly different from 
vehicle are represented as ***; with p < 0.001.  
Acetylation of p53 during cellular stress causes p53 protein to accumulate by 
dissociation of MDM2 from its p53 binding site (32). To increase p53 expression for 
our investigations, we used Nutlin-3a, a pharmaceutical MDM2 inhibitor. Nutlin-3a 
was developed for targeted chemotherapy in cancers which retain wild-type p53 
(488, 489), however its efficacy as a p53 status-specific cancer therapy has been 
disappointing in clinical trials to date (490). 
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Nutlin-3a can reveal tumour-related changes in p53 signalling and induce 
senescence in fibroblasts by up-regulating the miR-34 family of microRNAs (491, 
492). As miR-34a is one of the microRNA targets in this study, Nutlin-3a was an 
attractive choice for p53 induction during experiments. Firstly, the impact of Nutlin-
3a on p53 expression and acetylation in keratinocytes was analysed by 
immunoblotting. Cellular p53 protein accumulated 4-fold and relative p53 
acetylation increased 3-fold in NHEKs [Figure 4:7; p<0.01] however p53 protein and 
acetylation in HaCaT cells was unaffected by Nutlin-3a [Figure 4:7].  
Figure 4:8  Nutlin up-regulates miR-34a in wild-type, but not p53-mutated human keratinocytes 
Primary (NHEKs; left panel) and p53-mutated (HaCaT; right panel) keratinocytes were treated with 
10 µM Nutlin (black bars). Total RNA was extracted after 24 hrs and expression of target genes was 
assayed by RT-PCR. Results were normalised to 5S rRNA, and analysed relative to vehicle controls 
(white bars).  
All data represent the mean ± SD of 3 independent experiments and are represented as *, ** and 
***; with p < 0.05, p < 0.01 and p < 0.001 respectively.  
When p53 protein content in basal (untreated) NHEK and HaCaT keratinocytes was 
compared (Chapter 3; Fig 11) a 5-fold higher level of constitutive p53 was measured 
in the HaCaT cell line. This finding appears to be a consequence of a functional and 
structural change to the mutant p53 protein in HaCaTs which impedes 
ubiquitinylation and/or proteolytic breakdown. Thus p53 in HaCaT keratinocytes is 
maximally expressed in the intracellular environment, and is resistant to MDM2 
inhibition by Nutlin-3a. 
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Furthermore, an increase in the cellular content of activated p53 with Nutlin 
treatment in NHEK cells was associated with a 4-fold induction of miR-34a [Figure 
4:8; p<0.001]. Conversely, mature miR-34a expression was unaltered in Nutlin-
treated HaCaTs, although expression of its primary sequence was slightly elevated 
[Figure 4:8; p<0.05]. These data demonstrate that enhanced acetylation, but not 
up-regulation, of p53 protein is associated with induction of miR-34a. Additionally, 
relative SIRT1 protein expression was not significantly different in Nutlin-treated 
keratinocytes for either NHEKs or HaCaTs [Figure 4:8].   
Induction of p53 acetylation by treatment with a SIRT1 inhibitor 
To confirm the relationship between SIRT1 and miR-34a expression explored in 
earlier results, the SIRT1 inhibitor EX-527 was used to increase the level of p53 
activation by promoting acetylation without altering the expression of p53.  
Figure 4:9  Induction of p53 acetylation by SIRT1 inhibition in human keratinocytes 
SIRT1 activity in primary (NHEK) or p53-mutated (HaCaT) keratinocytes was inhibited with 1 µM EX-
527 for 24 hours. Expression of p53 (total protein) and p53 acetylated at lysine 382 [Acetyl 
p53(K382)] was measured by immunoblotting cell lysates. Densitometric data was analysed relative 
to vehicle controls, using actin to normalise protein loading. 
All data represent mean ± SD of 3 independent experiments. Results significantly different from 
vehicle are represented as *, ** and ***; with p < 0.05, p < 0.01 and p < 0.001 respectively.  
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Here, the effect of SIRT1 inhibition on p53 in keratinocytes was determined by 
immunoblotting using the acetylation of p53 at lysine 382 [Acp53(K382)] as a 
marker for SIRT1 catalysis. EX-527 increased p53 acetylation without a concomitant 
up-regulation of p53 protein for both cell cultures. EX-527-mediated induction of 
p53 acetylation in HaCaTs was significantly greater than for NHEKs [3-fold vs 2-fold; 
Figure 4:9]. 
Co-immunoprecipitation experiments were performed to further define the 
relationship between EX-527, SIRT1 activity and p53 acetylation. EX-527 enhanced 
the association between p53 and SIRT1 protein in NHEK and HaCaT cells [Figure 
4:10; 6-fold for NHEK; 4-fold for HaCaT] after 24 hours of treatment. This 
experiment demonstrated that an association between p53 and SIRT1 persists with 
EX-527 treatment, and supports a catalytic mechanism for SIRT1 inhibition by EX-
527 which indicates that EX-527 permits SIRT1-substrate binding (p53 in this study), 
but blocks substrate release.  
Also, p53:SIRT interactions are not impeded by p53 mutations in the HaCaT cell line, 
as the relative increase in p53:SIRT1 association during EX-527 treatment is not 
significantly different than for wild-type (NHEK) keratinocytes [Figure 4:10].  
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Figure 4:10 Association between p53 and SIRT1 in EX-527 treated keratinocytes 
SIRT1 was inhibited in Primary human (NHEK) and p53-mutated (HaCaT) keratinocytes with 1 µM EX-
527 for 24 hr. Protein was extracted in NP-40 lysis buffer and p53-SIRT1 protein complexes purified 
by immunoprecipitation using p53 as the target antigen. Co-association of SIRT1 with p53 was 
determined by immunoblotting and densitometric signal normalised to the input (raw lysate) signal. 
The effect of SIRT1 inhibition on co-association between p53 and SIRT1 was calculated relative to 
vehicle control and analysed by paired t-test. Values represent the mean (± SD) from 3 independent 
experiments and significant differences are shown as * (p < 0.05). 
Colocalisation of p53 and SIRT1 has been measured by others (201, 202, 493); 
however these investigations have been conducted using SIRT1 and p53 
overexpression vectors and in tumour-derived cell lines. This study has confirmed 
this intracellular relationship between SIRT1 and p53 in keratinocytes using 
experimental conditions without off-target effects associated with plasmid 
insertion. 
Altogether, EX-527 treatment experiments demonstrate that SIRT1 deacetylase 
activity suppresses p53 transactivation in keratinocytes by managing acetylation of 
its C-terminal lysine residues. Additionally, EX-527 generates differential responses 
in target cells depending on their p53 mutational status, and may therefore be 
useful as a p53-activating therapy in cancers with a p53 mutation profile similar to 
HaCaTs.  
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Figure 4:11  miR-34a-mediated regulation of SIRT1 is impaired in p53 mutated keratinocytes 
Primary (NHEKs; left panel) and p53-mutated (HaCaT; right panel) keratinocytes were treated with 1 
µM EX-527 (black bars). Total protein and RNA was extracted after 24 hrs and target protein or 
mRNA expression assayed by immunoblotting or RT-PCR. Actin was used as a loading control for 
immunoblotting, and RT-PCR signals were normalised to 5S rRNA. Results were analysed relative to 
vehicle controls (white bars). 
All data represent the mean ± SD of 3 independent experiments and are represented as *, ** and 
***; with p < 0.05, p < 0.01 and p < 0.001 respectively.  
Mature miR-34a was induced in SIRT1-inhibited NHEK cells [Figure 4:11; p<0.01], 
although expression of the primary transcript was not altered. For the SIRT1-
inhibted HaCaT cell line, however, an increase in p53 acetylation was associated 
with induction of pri-miR-34a but expression of the mature miR-34a transcript was 
suppressed [Figure 4:11; p<0.001]. Moreover, SIRT1 protein doubled in HaCaT cells 
treated with EX-527, whereas SIRT1 expression was not altered by SIRT1 inhibition 
in NHEK cells. 
Taken with earlier results, these data show that p53 and SIRT1 are both critical to 
the maintenance of miR-34a expression in keratinocytes. Impaired maturation of 
the pri-miR-34a primary transcript appears to explain an overexpression of SIRT1 
protein measured in the HaCaT cell line, which is augmented during p53 activation. 
To further model the effect of p53 insufficiency on miR-34a-mediated regulation of 
SIRT1 expression in HaCaTs, p53 was ablated in NHEKs prior to 24 hrs of EX-527 
treatment to inhibit SIRT1 activity.  
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P53 expression and SIRT1 activity regulate miR-34a biogenesis in keratinocytes 
In this experiment, when SIRT1 was inhibited in p53-ablated keratinocytes, SIRT1 
protein increased in association with a suppression of mature miR-34a [Figure 4:12; 
p<0.01], however accumulation of SIRT1 protein following SIRT1 inhibition was not 
as pronounced in p53-ablated keratinocytes as it was for HaCaTs.  
This outcome may have occurred as an off-target consequence of transfection 
stress in the model system. Nonetheless, SIRT1 inhibition produced a pattern of 
miR-34a dysregulation in p53-ablated NHEK cells consistent with the p53-mutated 
HaCaT cell line, i.e.- impaired miR-34a maturation which was associated with 
increased SIRT1 protein expression. 
Figure 4:12 SIRT1 inhibition suppresses miR-34a in p53-ablated human keratinocytes 
Primary human keratinocytes (NHEKs) were transfected with Non-targeting oligonucleotides (left 
panel) or p53 (right panel) siRNA targeting pools. After 24 hr knockdown, SIRT1 was inhibited with 1 
µM EX-527 (black bars). p53 and SIRT1 protein expression, and pri-miR-34a or miR-34 expression 
was assayed by immunoblotting or RT-PCR, respectively. Actin was used as a loading control for 
immunoblotting, and RT-PCR signals were normalised to 5S rRNA. Results were analysed relative to 
vehicle controls (white bars). 
All data represent the mean ± SD of 3 independent experiments and are represented as *, ** and 
***; with p < 0.05, p < 0.01 and p < 0.001 respectively.  
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To further evaluate the impact of the p53/SIRT1/miR-34a axis on microRNA 
biogenesis, expression of several mature microRNAs was compared with their 
primary transcripts in NHEK cells transfected with p53 targeting siRNAs alone, EX-
527-treatment alone, or both p53 siRNA and EX-527 treatment. For this purpose, 
we selected a small group of microRNAs with multiple gene targets which are key 
regulators of cell cycle control, differentiation and survival, and which included 
microRNAs miR-16-1/15, miR-145, miR-200c/141 and miR-107, all of which are 
established transcriptional targets of p53 (149). p53 knockdown reduced expression 
of the primary transcript for miRs 16-1 and 200c [Figure 4:13 (a); p<0.001], and 
increased expression of mature miR-107 [Figure 4:13 (b); p<0.05]. Inhibition of 
SIRT1 in NHEKs up-regulated microRNA expression for all mature transcripts [Figure 
4:13 (d)]; and expression of the primary transcript increased for miRs 34a, 145 and 
200c [Figure 4:13 (c)].  
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Figure 4:13  p53 knockdown blocks microRNA maturation in SIRT1-inhibited human keratinocytes  
Primary human keratinocytes (NHEKs) were transfected with a p53 siRNA targeting pool and/or 
treated with 1 µM EX-527 for 24 hours. Expression of primary (left panels) and mature (right panels) 
microRNAs was determined by RT-PCR using Taqman probes. Results were normalised using 18S 
rRNA and U6 snoRNA. Panels a & b: p53 ablation alone; Panels c & d: SIRT1 inhibition; Panels e & f: 
Combined effect of p53 knockdown and SIRT1 inhibition. 
All data represent the mean ± SD of 3 independent experiments. Results significantly different from 
samples treated with non-targeting oligonucleotides and/or vehicle (white bars) are represented as 
*, ** and ***; with p < 0.05, p < 0.01 and p < 0.001 respectively. 
Treatment of p53-ablated NHEKs with EX-527 produced a more generalised 
response pattern, with an up-regulation of the primary transcript and suppression 
of the mature sequence observed in all microRNAs tested [Figure 4:13 (e & f)], with 
the exception of the primary miR-200c transcript.  
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Figure 4:14  p53 mutations block microRNA maturation in SIRT1-inhibited human keratinocytes 
Panels a & b: Analysis of microRNA expression in basal (unstimulated) p53-mutated keratinocytes 
(HaCaTs) relative to expression measured in unstimulated primary keratinocytes (NHEKs). Panels c & 
d: Primary and mature microRNA expression in HaCaT keratinocytes treated with 1µM EX-527 for 24 
hrs. Expression of primary (left panels) and mature (right panels) microRNAs was determined by RT-
PCR using Taqman probes. Results were normalised using 18S rRNA and U6 snoRNA. 
All data represent the mean ± SD of 3 independent experiments. Results significantly different from 
vehicle (white bars) are represented as *, ** and ***; with p < 0.05, p < 0.01 and p < 0.001 
respectively.  
When HaCaT keratinocytes are grown in identical conditions, they display 
widespread alterations to their basal microRNA expression profile compared to 
NHEK cells. A 10-fold higher expression of primary transcripts was observed for all 
microRNAs tested, with the exception of pri-miR-34a [Figure 4:14 (a); p<0.001]. This 
was mirrored by overexpression of mature miRNAs 15 and 145 [Figure 4:14 (b)], 
however miR-34a and miR-141 expression was significantly lower than recorded for 
normal keratinocytes [Figure 4:14 (b); p<0.001], and miR-107 was not significantly 
different. Given our results in NHEKs transfected with p53-targeting siRNAs and co-
treated with EX-527 [Figure 4:14 (e & f)], we lastly considered the effect on SIRT1 
inhibition on microRNA maturation in HaCaT cells. Inhibition of SIRT1 in HaCaT 
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keratinocytes with EX-527 generated responses in microRNA primary transcripts 
which were consistent with, but not identical to, the expression pattern observed in 
p53-ablated and EX-527 treated NHEKs [Figure 4:14 (c); p<0.05]. Mature miR-34a 
was down-regulated; however in contrast to p53-ablated and EX-527 treated 
NHEKs, expression of mature miRs 145 and 107 increased in EX-527-treated HaCaTs 
[Figure 4:14 (d); p<0.01]. 
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4.4 DISCUSSION 
miR-34a is induced during p53 activation and has numerous downstream regulatory 
targets, of which SIRT1 is the most extensively characterised. SIRT1 expression is 
regulated at the posttranscriptional level by miR-34a-mediated binding of its 3′ 
UTR. Suppression of SIRT1 by miR-34a during cellular stress responses reinforces 
p53 transcriptional activation by enhancing C-terminal regulatory domain 
acetylation. This constitutive feedforward loop is referred to as the p53/SIRT1/miR-
34a axis [Figure 4:15]. 
Figure 4:15  Feedforward maintenance of p53 transactivation by miR-34a and SIRT1 
SIRT1 and p53 operate as a self-limiting negative feedback loop in which SIRT1-mediated 
deacetylation suppresses p53 transactivation and promotes proliferation and survival. Up-regulation 
of miR-34a interrupts this process during genotoxic stress by creating a feed-forward loop between 
p53 and SIRT1, which down-regulates SIRT1 expression and amplifies p53-mediated cell cycle control 
and apoptotic signaling. 
SIRT1 expression increases in keratinocytes with p53 mutations as a consequence of impaired 
microRNA processing. During genotoxic stress, SIRT1 overexpression blocks feedforward regulation 
of p53-mediated cell stress responses by suppressing p53 activation, causing apoptotic resistance. 
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Our results correlate with the known functional relationship between p53 and miR-
34a-mediated regulation of SIRT1 expression in other cell lines (HeLa, HEK (479); 
PC3PR (494), HUVEC (482)), and extend this functionality to the keratinocyte 
lineage. 
In keratinocytes expressing wild-type p53, inhibition of SIRT1 with EX-527 up-
regulates mature miR-34a. In p53-mutated keratinocytes, however, mature miR-
34a was down-regulated during EX-527 treatment, contributing to an accumulation 
of SIRT1 protein [Figure 4:15]. miR-34a expression is impaired in tumour samples 
derived from multiple cancer types and is attributed to numerous mutational 
causes, including deletion of Chromosome 1 and/or inactivation of TP53. Although 
both p53 alleles are mutated in the HaCaT cell line, p53 retains partial function and 
responds to 24 hr of SIRT1 inhibition by producing a 3-fold increase in acetylation. 
The primary miR-34a transcript was up-regulated in SIRT1-inhibited HaCaT 
keratinocytes, indicating that although mature miR-34a was suppressed, EX-527-
mediated p53 acetylation induces transcription of the miR-34a gene in this cell line.  
Our findings with the HaCaT cell line supports a model in which mutant p53 
interferes with the maturation of specific microRNAs when SIRT1 is inhibited. 
Interestingly, maturation of miR-145 and miR-107 was blocked in p53 
knockdown/SIRT1-inhibited NHEKs but not in SIRT1-inhibited HaCaTs. This indicates 
an alternative, non-p53 dependent mechanism such as RNA sequence editing, 
mirtron-mediated splicing and post-translational regulation of stabilization 
complexes (474, 495) may also be operating for the maturation of these two 
microRNAs in the HaCaT cell line, possibly as an adaptation for survival in cells with 
mutated p53. Two predominant theories have been proposed to explain the impact 
of p53-mediated modulation of microRNA processing in cancer: 1) p53 mediates 
RNase III activity by associating with p68 (150), and therefore mutations to p53 
suppress microRNA processing activity in Drosha and/or Dicer complexes; and 2) 
mutant p53 directly binds to and inactivates p63, inhibiting p63-mediated Dicer-1 
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expression (496). Regardless of the mechanism, regulation of Drosha and Dicer 
activity and expression is critical for ensuring microRNA biogenesis. Heterozygous 
deletion of Drosha and Dicer is known to promote cellular transformation and 
tumorigenesis in mouse models, and hemizygous loss of Dicer and/or Drosha is 
common in numerous human cancers (190, 497). The majority of microRNAs act as 
oncosuppressors, and thus downregulation of microRNAs is consistent with 
malignancy. One exception to this may be the Dicer-targeting miRNA, miR-107. Our 
investigation indicates that an increase in expression of miR-107 in p53 mutated 
cells may contribute to a pattern of impaired microRNA processing by blocking 
Dicer. High levels of miR-107 are associated with metastasis in breast cancers, and 
miR-107 is thought to induce epithelial-mesenchymal transitions by downregulating 
miR-200 family miRNAs (498, 499). In concordance with this, in p53 ablated and EX-
527 treated NHEKs, expression of miR-200c/141 was significantly decreased, and 
was also significantly reduced in the p53-mutated keratinocyte cell line.  
The activity and expression of multiple p53 transcriptional targets is regulated via 
microRNA-mediated feedback inhibition (149). miR-34a in particular is crucial to 
p53-mediated induction of pro-apoptotic signalling during cellular stress (479), and 
this property has consequences for carcinogenesis (476, 478). For example, 
acetylation performs numerous roles in signalling networks which regulate RNA 
splicing and nuclear transport (59), and it may be that SIRT1-mediated regulation of 
lysine acetylation directly regulates microRNA processor enzyme activity or 
contributes to the formation of functional signalling complexes. Further testing of 
this hypothesis is required to determine if this reflects a globalised phenomenon. 
This investigation indicates that p53 and SIRT1 work co-ordinately to regulate miR-
34a biogenesis. Although other p53-inducible miRNAs tested here generated a 
complex response pattern when exposed to alterations in p53 expression and 
acetylation, inhibition of SIRT1 activity alongside p53 ablation, either using RNAi in 
NHEK cells or in HaCaT cells with p53 mutations, consistently blocked processing of 
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the primary transcript, causing a concomitant decrease in mature microRNA 
expression. Our observations suggest that SIRT1 plays a role in maintaining and 
stabilising p53 in a form which promotes maturation of primary microRNA 
transcripts, however from these experiments alone, we cannot exclude other 
SIRT1-mediated mechanisms which may also contribute to microRNA processing.  
Findings from this study have wider implications with regards to our understanding 
of the events which predispose cells to carcinogenic change. Here we demonstrate 
that p53 and SIRT1 co-ordinately regulate microRNA biogenesis. Since p53 is the 
most frequently mutated gene in cancer, novel insights into mechanisms which 
distinguish p53-mutated cells from their healthy counterparts may facilitate 
selective targeting of malignant cells during cancer therapy. Manipulation of SIRT1 
activity influences the cellular microRNA profile in cells with reduced p53 function, 
and this knowledge has the potential to overcome chemotherapeutic resistance.
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SIRT1 Inhibition Restores Apoptotic 
Sensitivity in p53-Mutated Keratinocytes 
Chapter 5 
5.1 ABSTRACT 
Mutations to the p53 gene are common in UV-exposed keratinocytes, and 
contribute to apoptotic resistance in skin cancer. P53 acetylation is modulated, in 
part, by a complex, self-limiting feedback loop imposed by miR-34a-mediated 
regulation of the lysine deacetylase, SIRT1, and thus SIRT1 expression influences 
p53-mediated tumour suppressor activity. Additionally, expression of numerous 
microRNAs is dysregulated in squamous and basal cell carcinomas; however the 
contribution of specific microRNAs to the pathogenesis of skin cancer remains 
untested. Through use of RNAi, miRNA target site blocking oligonucleotides and 
small molecule inhibitors, this study explored the influence of p53 mutational 
status, SIRT1 activity and miR-34a levels on apoptotic sensitivity in primary (NHEK) 
and p53-mutated (HaCaT) keratinocytes.  
SIRT1 and p53 are overexpressed in p53-mutated keratinocytes, whilst miR-34a 
levels are 90% less in HaCaT cells. HaCaT keratinocytes have impaired responses to 
p53/SIRT1/miR-34a axis manipulation which culminates in resistance to 
camptothecin-induced apoptosis. Inhibition of SIRT1 activity in this cell line 
increased p53 acetylation and doubled relative cell death. p53 mutations increase 
apoptotic resistance in keratinocytes by interfering with miR-34a-mediated 
regulation of SIRT1 expression. Thus, SIRT1 inhibitors may have therapeutic 
potential for overcoming apoptotic resistance during skin cancer treatment. 
Much of the work in this chapter forms the basis of a manuscript published in Toxicology and 
Applied Pharmacology:  
Herbert et al, 2014, SIRT1 inhibition restores apoptotic sensitivity in p53-mutated human 
keratinocytes, Toxicol. Appl. Pharmacol. http://dx.doi.org/10.1016/j.taap.2014.04.001 (500). 
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5.2 INTRODUCTION 
Sun-exposed keratinocytes are particularly prone to DNA damage and thus 
adequate repair of UV-induced DNA lesions and elimination of sunburn cells 
remains an important barrier to carcinogenesis in the skin (367). These processes 
are primarily regulated by the transcription factor p53, however the TP53 gene is 
one of the most frequently mutated tumour suppressor genes in skin cancer, with 
signature UV mutations affecting p53 activity in ~ 56% of basal cell and >90% of 
squamous cell carcinomas (501). Targeting p53 mutations, therefore, may be the 
key to overcoming pre-neoplastic proliferation and resistance to cell death signaling 
in non-melanoma skin cancer (502). 
One of the hallmarks of cancer is evasion of apoptotic signalling which allows cells 
to proliferate in an uncontrolled manner (11, 12). This process is commonly related 
to loss or inactivation of the tumour suppressor p53 (35). During p53-dependent 
cell death signalling, destabilisation of the mitochondrial membrane releases 
cytochrome c into the cytoplasm which activates the Apaf-1/caspase 9 apoptotic 
pathway (predominantly via the Intrinsic Pathway) (64, 472). P53 regulates this 
process in a complex manner, through transactivation of p53-responsive genes 
coding for mitochondrial membrane proteins and downstream effectors (503). 
Notably, expression of downstream effectors is dysregulated in tumorigenic tissue 
(504, 505), and thus p53 mutations contribute to a failure of the cell death program 
to remove damaged cells when exposed to genotoxic stressors.  
p53-mediated stress responses are facilitated by microRNAs, small non-coding 
RNAs which form a complex regulatory network controlling cell survival, 
senescence, growth and death (151). These feature a suite of microRNAs, including 
the miR-34a, miR-29, and let-7 families, miR-143, miR-145 and the miR-16-1/15a 
cluster (149, 151). The miR-34 family of miRNAs have recently emerged as 
important regulators of p53-mediated responses by directly targeting its 
downstream effector genes (476). The most widely characterised member of the 
159 | 
Chapter 5 
 
miR-34 family, miR-34a, targets SIRT1, an NAD-dependent deacetylase with 
numerous functional roles as a cell stress mediator (506). miR-34a expression is 
induced by p53-mediated transcriptional activation (476), and influences SIRT1 
expression by complementary base pairing with its 3′ UTR (479). SIRT1, in turn, 
regulates p53 activity via its acetylation status (201, 202). In this manner, SIRT1, p53 
and miR-34a operate together to amplify cellular differentiation, senescence and 
apoptotic signalling (480-483). 
Global alterations to the microRNA expression profile are common in dysplastic skin 
tissue and this in turn contributes to aberrant mRNA expression patterns observed 
in basal and squamous cell carcinoma (507). Additionally, dysregulation of post-
transcriptional processing of microRNAs is thought to play a significant role in the 
mechanism of carcinogenic transformation (508), and microRNA . Despite the 
positive correlation between gain of function p53 mutations and chemotherapeutic 
resistance in squamous cell carcinoma (509), manipulation of the p53/SIRT1/miR-
34a axis in order to enhance the efficacy of pharmacotherapy for skin cancer 
treatment has not previously been studied in keratinocyte cells.  
In this chapter, activity and expression of SIRT1 and p53 was manipulated to 
differentiate apoptotic responses in wild-type and p53-mutated keratinocytes in 
order to 1) Determine if p53 mutations in the HaCaT cell line influence survival and 
sensitivity to cell death signaling; 2) Measure p53-related differences in microRNA-
mediated regulation of anti-apoptotic gene targets for keratinocytes with wild-type 
and mutated p53; and 3) Investigate whether manipulation of the p53/SIRT1/miR-
34a axis can influence sensitivity to apoptotic induction.  
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 5.3 RESULTS 
Camptothecin (CPT)-induced apoptosis is predominantly p53-dependent and has 
been extensively utilised in chemotherapy (402). Unfortunately, many tumours 
have proven resistance to CPT, in part due to the frequency of p53 inactivating 
mutations in malignant tissue (510). As such, CPT-induced apoptosis provides a 
method for studying the impact of p53 mutations on cell death and DNA damage 
signalling in this model system. PARP activity is p53 dependent and linked to DNA 
damage-induced cell death (511, 512). During apoptosis, PARP is inactivated by 
caspase-mediated cleavage into ~25 kDa and ~85 kDa fragments and is considered 
a characteristic marker for p53-dependent apoptotic signalling (513, 514). 
Since miR-34a has a well characterised role in apoptotic signal amplification (515), 
and loss of miR-34a impairs p53-mediated cell death (478), we next tested if p53 
mutations in the HaCaT cell line provide a survival advantage for precarcinogenic 
keratinocytes by comparing responses to genotoxic stressors with their wild-type 
counterparts.  
 
TP53 mutations promote apoptotic resistance in human keratinocytes 
Initially, a time course for apoptotic induction by CPT was determined by exposing 
NHEK and HaCaT cells to CPT for 6, 12, 18 and 24 hr periods, using p53 induction 
and PARP cleavage as indicators of apoptosis. As expected, primary keratinocytes 
were significantly more sensitive than p53-mutated keratinocytes to CPT-induced 
apoptosis. CPT-mediated PARP cleavage in NHEKS was associated with DNA 
damage-induced induction of p53, which doubled cumulatively with each 6 hour 
period [Figure 5:1 (b, c)] and preceded PARP cleavage by approximately 6 hours. 
Conversely, p53 did not accumulate in CPT-exposed HaCaT keratinocytes [Figure 5:1 
(b, c) ]and PARP cleavage was 3-fold lower than cleavage measured in NHEKs after 
24 hrs [Figure 5:1 (a, c)]. These observations indicated that the mutations to p53 
are impeding programmed cell death and apoptotic signaling in HaCaT cells. 
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We next investigated how p53 mutations in HaCaT cells may contribute to 
apoptotic resistance, and so quantified the expression of the p53-regulated anti-
apoptotic genes Survivin/BIRC5 and BCL2. Both Survivin and BCL2 are repressed by 
wild-type p53 during p53-induced apoptosis (461, 462).  
 
Figure 5:1 Camptothecin resistance in p53-mutated keratinocytes 
Primary (NHEK, white bars) and p53-mutated (HaCaT, black bars) keratinocytes were treated with 5 
µM camptothecin (CPT). PARP cleavage (Panel a) and p53 expression (Panel b) was measured at 6 
hour intervals during the 24 hr exposure period by immunoblotting, using actin as a loading control 
(Representative immunoblot, Panel c).   
All data represent mean ± SD of 3 independent experiments. PARP cleavage was determined by 
dividing the densitometric signal from the cleaved fraction by total PARP expression (full length + 
cleaved PARP). Results significantly different from vehicle are represented as *, ** and ***; with p < 
0.05, p < 0.01 and p < 0.001 respectively.  
 
TP53 mutations alter the cell death program in keratinocytes 
p53 negatively regulates expression of anti-apoptotic gene targets BCL-2 and 
Survivin by targeting repressive p53-binding sequences. Hence, a 6-fold induction of 
p53 in NHEKs [Figure 5:2 (a)] is associated with an 80% suppression of BCL-2 and 
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Survivin expression during 24 hrs of CPT treatment [Figure 5:2 (b & c)]. Conversely, 
BCL-2 and Survivin are up-regulated in the HaCaT cell line during CPT treatment [5-
fold for BCL2; 2-fold for Survivin; Figure 5:2 (b & c)].  
Figure 5:2  Pro-survival target expression is impaired in p53-mutated keratinocytes 
Apoptosis was induced in primary (NHEK) and p53-mutated (HaCaT) keratinocytes using 5 µM 
camptothecin (CPT) for 24 hours. Total RNA was extracted for RT-PCR analysis of p53 (Panel a), BCL-
2 (Panel b), Survivin (Panel c) expression. Values were normalised using 5S rRNA as a reference gene. 
All data represent mean ± SD of 3 independent experiments. Results significantly different from 
vehicle are represented as *, ** and ***; with p < 0.05, p < 0.01 and p < 0.001 respectively.  
Since expression of Survivin and BCL2 are both regulated by miR-34a (516, 517), we 
investigated if resistance to p53-dependent apoptosis in HaCaT cells was related to 
the changes in miR-34a expression and biosynthesis observed in Chapter 4. Pri-miR-
34a was significantly up-regulated by CPT in NHEK and HaCaT cells [Figure 5:3 (a & 
b)], however only NHEKs showed an increase in the mature miR-34a sequence 
[Figure 5:3 (a)]. BCL2 is regulated by a group of microRNAs in addition to miR-34a – 
notably the miR-15a/miR-16-1 cluster (518) – so we next asked whether p53 
mutations in HaCaTs affect expression of tumour suppressor microRNAs other than 
miR-34a. The miR-15a/miR-16-1 cluster is located within a 0.5 kilobase region of 
13q14.3, and the microRNA products, miR-15a and miR-16-1, are processed from a 
single primary transcript during p53-mediated signaling (519). Here, pri-miR-16-1 
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provides a measure of primary transcript levels, and miR-15a has been assayed to 
represent expression of the mature microRNA.  
 
Figure 5:3  Camptothecin-induced microRNA maturation is impaired in p53-mutated keratinocytes 
Apoptosis was induced in primary (NHEK, left panels) and p53-mutated (HaCaT, right panels) 
keratinocytes using 5 µM camptothecin (CPT) for 24 hours. Total RNA was extracted for RT-PCR 
analysis of microRNA sequences for miR-34a (Panels a & b), miR-16-1/miR-15a (Panels c & d), and 
miR-145 (Panels e & f) expression. For microRNA analysis, primers which were specific for either 
primary or mature sequences were used for reverse transcription and Taqman PCR assays. RN18S1 
and U6 snoRNA were used as reference genes for pri-miRNA and microRNA assays, respectively. 
All data represent mean ± SD of 3 independent experiments. Results significantly different from 
vehicle are represented as *, ** and ***; with p < 0.05, p < 0.01 and p < 0.001 respectively.  
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CPT significantly up-regulated expression of the primary transcript (pri-miR-16-1) in 
both cell cultures, however although the mature sequence (miR-15a) was 
significantly up-regulated in NHEKs [Figure 5:3 (c)], miR-15a was down-regulated in 
CPT-treated HaCaTs [Figure 5:3 (d)]. Additionally, although expression of the c-Myc 
targeting microRNA, miR-145, was up-regulated 4-fold by CPT in NHEKs, miR-145 
was down-regulated in apoptotic HaCaTs [Figure 5:3 (e & f)]. These data correlate 
with aberrant expression of anti-apoptotic microRNA targets during CPT treatment 
in the p53-mutated cell line [Figure 5:2]. 
To further explore the relationship between p53 levels with respect to apoptotic 
sensitivity in these keratiniocytes, Nutlin-3a was used to block MDM2-mediated 
proteasomal targeting, and hence degradation of the p53 protein. p53 accumulated 
4-fold in NHEKs treated with 10 µM Nutlin-3a for 24 hr [Figure 5:4 (a); p < 0.001; 
n=3], but no change in p53 content was achieved by Nutlin-3a treatment in the 
HaCaT cell line [Figure 5:4 (b)]. Notably, the 3.5-fold increase in p53 expression with 
Nutlin-3a treatment in NHEKs brings cellular p53 content to a level which correlates 
more closely with the cellular content of p53 protein measured in untreated HaCaT 
cells. When apoptosis was induced in NHEK and HaCaT cells following 30 min 
pretreatment with Nutlin-3a using CPT, p53 protein accumulated 5-fold in CPT-
treated NHEKs [Figure 5:4 (a), p<0.001], however no significant change in p53 
protein or acetylation was measured in CPT-treated HaCaTs [Figure 5:4 (b, d)]. This 
Nutlin-3a-induced increase in p53 protein was not associated with a change in 
acetylation of lysine 382 relative to total p53 protein content in NHEKs [Figure 5:4 
(c)] or HaCaT cells [Figure 5:4 (d)].  
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Figure 5:4  Keratinocytes with p53 mutations are unresponsive to Nutlin-3a treatment 
P53 was stabilised in primary (NHEK, left panels) and p53-mutated (HaCaT, right panels) 
keratinocytes with 10 µM Nutlin-3a, and apoptosis was induced with 5 µM camptothecin (CPT) for 
24 hrs. p53 expression and PARP (full length and cleaved) were detected by immunoblotting. 
Acetylated p53 (K382) (Panels a & b) and total p53 protein (Panels c & d) were analysed relative to 
vehicle controls, using actin to normalise protein loading. 
All data represent mean ± SD of 3 independent experiments. Results significantly different from 
vehicle are represented as * (p < 0.05); *** (p < 0.001). Nutlin treatment-specific differences are 
expressed as ns (not significant), and ### (p < 0.001). 
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Moreover, Nutlin-3a treatment did not significantly alter CPT-induced PARP 
cleavage for either cell line [Figure 5:5 (a, b)]. So whilst CPT treatment triggers p53-
dependent apoptosis for keratinocytes bearing either wild-type or p53 mutations, 
improving sensitivity of p53-mediated functional responses to DNA damage 
requires more than a stabilization of p53 protein. Furthermore, mutated p53 
protein in HaCaT keratinocytes is resistant to MDM2-mediated proteasomal 
targeting, and hence Nutlin-3a is ineffective for recovering p53 functional responses 
in this cell line. 
Figure 5:5 Nutlin-3a treatment does not alter PARP cleavage in camptothecin-treated keratinocytes 
P53 was stabilised in primary (NHEK, Panel a) and p53-mutated (HaCaT, Panel b) keratinocytes with 
10 µM Nutlin-3a, and apoptosis was induced with 5 µM camptothecin (CPT) for 24 hrs. PARP (full 
length and cleaved) were detected by immunoblotting and analysed relative to vehicle controls, 
using actin to normalise protein loading. 
All data represent mean ± SD of 3 independent experiments. PARP cleavage was determined by 
dividing the densitometric signal from the cleaved fraction by total PARP expression (full length + 
cleaved PARP). Results significantly different from vehicle are represented as *** (p < 0.001). Nutlin 
treatment-specific differences are expressed as ns (not significant). 
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The intended pharmaceutical use for Nutlin 3a treatment is to act as an adjuvant in 
chemotherapy by increasing cellular p53 activity (488). Notably, the efficacy of 
Nutlin-3a depends on the nature of the gene lesion targeted – in vitro and ex vivo 
studies demonstrate that retention of some wild-type p53 activity is required for 
Nutlin-3a to enhance apoptosis in cancer cells (489, 492). Additionally, the outcome 
of Nutlin-3a treatment on p53-mediated responses is dependent on treatment 
concentration and duration of exposure, as well as p53 gene status. Whilst the 
concentration used here (10 µM) was greater than the dose sufficient to increase 
p53 content and to induce cell cycle arrest in RKO and LNCaP cell lines, a higher 
concentration (20 µM) is required to induce apoptosis (520), and thus it is possible 
that the dose and duration of exposure to Nutlin-3a in this study failed to lower the 
apoptotic threshold in HaCaT cells. However, considering that p53 expression is 
unresponsive to CPT in this cell line, it is more likely that overexpression of mutant 
p53 in HaCaTs prevents Nutlin-3a from having any pro-apoptotic effect. 
 
We next considered whether manipulating SIRT1 expression levels could alter 
apoptotic sensitivity. Since regulation of SIRT1 expression is impaired in HaCaTs, 
RNAi was used to determine the relationship between SIRT1 and apoptotic signaling 
in this cell line. p53 expression was suppressed and acetylation increased slightly 
[1.5-fold; Figure 5:6 (a & b), p<0.05] when SIRT1 was ablated in HaCaTs [Figure 5:6 
(c)]. When SIRT1-ablated HaCaT cells were treated with CPT, p53 protein decreased 
further, however relative acetylation was not altered [Figure 5:6 (a, b)], and no 
change in PARP cleavage was measured [Figure 5:6 (d)].  
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Figure 5:6 SIRT1 knockdown is insufficient to overcome apoptotic resistance in keratinocytes with 
p53 mutations 
SIRT1 expression was transiently ablated in HaCaT keratinocytes using SIRT1 siRNA oligonucleotides 
(black bars) for 48 hr prior to induction of apoptosis with 5 µM camptothecin (CPT). p53 expression, 
p53 acetylation, SIRT1 expression and PARP (full length and cleaved) were detected by 
immunoblotting. Total p53 protein (Panel a), p53 acetylated at lysine 382 [p53K382] (Panel b), SIRT1 
protein (Panel c) and PARP cleavage (Panel d) were analysed relative to vehicle controls, using actin 
to normalise protein loading. 
All data represent mean ± SD of 3 independent experiments. PARP cleavage was determined by 
dividing the densitometric signal from the cleaved fraction by total PARP expression (full length + 
cleaved PARP). Results significantly different from vehicle are represented as * and ***; with p < 
0.05 and p < 0.001 respectively. The effect of SIRT1 knockdown on CPT-treated samples was 
analysed relative to treatment with non-targeting control oligonucleotides by 2-way ANOVA and is 
expressed as ns (not significant), # (p < 0.05), and ### (p < 0.001). 
 
To investigate the relationship between miR-34a-mediated regulation of SIRT1 
expression and apoptotic resistance in keratinocytes, oligonucleotides were 
designed to specifically block the miR-34a targeting site within the SIRT1 3′UTR.  
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Figure 5:7  SIRT1 protein expression is regulated by miR-34a in human keratinocytes  
Primary (NHEK, left panels) and p53-mutated (HaCaT, right panels) keratinocytes were transfected 
with oligonucleotides designed to mask the SIRT1/miR-34a target site (TSB, black bars) for 48 hr, 
after which apoptosis was induced with 5 µM camptothecin (CPT). SIRT1 expression (Panels a & b), 
and acetylation of p53 at lysine 382 (Panels c & d) was assayed by immunoblotting and analysed 
relative to vehicle control samples, using actin to normalise protein loading. 
All data represent mean ± SD of 3 independent experiments. Results significantly different from 
vehicle are represented as *, ** and ***; with p < 0.05, p < 0.01 and p < 0.001 respectively. The 
effect of target site masking on CPT-treated samples was analysed relative to the mismatched 
control treatment by 2-way ANOVA and is expressed as ns (not significant), and ### (p < 0.001).  
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Cellular SIRT1 protein accumulated following a miR-34a target site block for both 
NHEK and HaCaT cells [Figure 5:7 (a, b); p<0.05], confirming that miR-34a post-
transcriptionally regulates SIRT1 expression in wild-type and p53-mutated 
keratinocytes. SIRT1 was suppressed in CPT-treated NHEKs and HaCaTs, however 
SIRT1 did not accumulate when the miR-34a targeting site was blocked prior to CPT 
treatment [Figure 5:7 (a, b)].  
Figure 5:8  miR-34a/SIRT1 mRNA target site block reduces apoptotic sensitivity in normal, but not 
p53-mutated keratinocytes  
The SIRT1/miR-34a target site was blocked in primary (NHEK, Panel a) and p53-mutated (HaCaT, 
Panel b) keratinocytes with target site blocking oligonucleotides (TSB, black bars) or mis-matched 
control oligonucleotides (MM control, white bars) for 48 hr, after which apoptosis was induced with 
5 µM camptothecin (CPT). Immunoblots were prepared using anti-SIRT1 and anti-PARP1 antibodies, 
using actin to normalise protein loading. 
All data represent mean ± SD of 3 independent experiments. PARP cleavage was determined by 
dividing the densitometric signal from the cleaved fraction by total PARP expression (full length + 
cleaved PARP). Results significantly different from vehicle are represented as ***; with p < 0.001. 
The effect of target site masking on CPT-treated samples was analysed relative to the mismatched 
control treatment by 2-way ANOVA and is expressed as ns (not significant), and ### (p < 0.001). 
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Although relative p53 acetylation was suppressed after 24 hours of CPT treatment 
in NHEKs [Figure 5:7 (c); p<0.01], no change in acetylation was measured in CPT-
treated HaCaTs [Figure 5:7 (d)]. Additionally, the target site block did not produce a 
significant change in acetylation in CPT-induced NHEKs, however PARP cleavage 
decreased [Figure 5:8 (a); p<0.001]. No change in PARP cleavage was measured in 
the HaCaT cell line after a target site block [Figure 5:8 (b)]. 
 
SIRT1 inhibition overcomes apoptotic resistance in p53-mutated keratinocytes 
Because neither depletion of SIRT1 by RNAi nor the miR-34a/SIRT1 mRNA target 
site block were sufficient to influence p53-mediated apoptotic resistance in the 
HaCaT cell line, we lastly asked if inhibition of SIRT1 activity with EX-527 would 
increase apoptotic sensitivity. p53 acetylation was increased by 24 hr EX-527 
treatment in both cell lines [Figure 5:9 (a, b); p<0.01].  
Note that in the analysis, values for p53 acetylation are calculated relative to a 
measurement of total p53 in cells with each treatment. Thus, whilst p53 protein 
accumulated in CPT-treated NHEKs [Figure 5:9 (c); p<0.01], no change was detected 
for HaCaTs during CPT treatment [Figure 5:9 (d)] and EX-527 has increased the 
fraction of acetylated p53 in CPT treated HaCaT cells without increasing total 
protein. Conversely, EX-527 also increases p53 acetylation in NHEKs, however 
because total p53 protein is up-regulated during CPT treatment, the acetylated 
fraction (as calculated) remains unchanged. 
To determine if EX-527-mediated changes in p53 acetylation influenced CPT-
induced apoptosis, we assessed CPT- and EX-527-treated NHEK and HaCaT cells 
using markers of apoptosis (caspase 3/7 activity, PARP cleavage) and cell viability 
(ATP content). 
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Figure 5:9 p53 acetylation is enhanced in apoptotic p53-mutated keratinocytes 
SIRT1 was inhibited in primary (NHEK, left panels) and p53-mutated (HaCaT, right panels) 
keratinocytes with 1 µM EX-527, and apoptosis was induced using 5 µM camptothecin (CPT). p53 
acetylated at lysine 326 and total p53 protein were detected by immunoblotting cell lysates after 24 
hrs. Panels a & b: analysis of p53 acetylation; Panels c & d: analysis of total p53 protein. Protein 
loading was normalised using actin.  
All data represent mean ± SD of 3 independent experiments. Results significantly different from 
vehicle are represented as *, ** and ***; with p < 0.05, p < 0.01 and p < 0.001 respectively. The 
effect of SIRT1 inhibition on CPT-treated samples was analysed relative to vehicle controls by 2-way 
ANOVA and is expressed as ns (not significant), ## (p < 0.01), and ### (p < 0.001). 
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In NHEK cells, CPT treatment reduced cell viability to 30% of the vehicle treated 
population, with no change in viability recorded during EX-527 treatment in this cell 
line [Figure 5:10 (a); p<0.001]. For HaCaTs, however, viability of CPT-treated cells 
was halved by inhibition of SIRT1 [Figure 5:10 (b); p<0.001].  
 
Figure 5:10 SIRT1 inhibition overcomes apoptotic resistance in p53-mutated keratinocytes 
SIRT1 was inhibited in primary (NHEK, left panels) and p53-mutated (HaCaT, right panels) 
keratinocytes with 1 µM EX-527, and apoptosis was induced using 5 µM camptothecin (CPT). 
Viability (ATP Content) (Panels a & b), and Caspase 3/7 activity (Panels c & d) were assayed after 24 
hrs.  
All data represent mean ± SD of 4 independent experiments. Results significantly different from 
vehicle are represented as *, ** and ***; with p < 0.05, p < 0.01 and p < 0.001 respectively. The 
effect of SIRT1 inhibition on CPT-treated samples was analysed relative to vehicle controls by 2-way 
ANOVA and is expressed as ns (not significant), and ### (p < 0.001). 
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Although cell death was not altered by SIRT1 inhibition alone, caspase 3/7 activity 
doubled in NHEKs after CPT treatment [Figure 5:10 (c); p<0.001]. Additionally, a 
slight, but statistically significant increase in caspase 3/7 activity was observed for 
SIRT1-inhibited, CPT-treated HaCaTs [Figure 5:10 (d); p<0.001]. Consistent with 
these results, PARP cleavage doubled in SIRT1-inhibited HaCaT cells after 24 hours 
of CPT [Figure 5:11 (b); p<0.001], and was halved in similarly treated NHEK cells 
[Figure 5:11 (a); p<0.01].    
 
Figure 5:11 SIRT1 inhibition restores p53-dependent cell death in p53-mutated keratinocytes 
SIRT1 was inhibited in primary (NHEK, Panel a) and p53-mutated (HaCaT, Panel b) keratinocytes with 
1 µM EX-527, and apoptosis was induced using 5 µM camptothecin (CPT). PARP (full length and 
cleaved) was assayed after 24 hrs.  
All data represent mean ± SD of 3 independent experiments. PARP cleavage was determined by 
dividing the densitometric signal from the cleaved fraction by total PARP expression (full length + 
cleaved PARP). Results significantly different from vehicle are represented as *, ** and ***; with p < 
0.05, p < 0.01 and p < 0.001 respectively. The effect of SIRT1 inhibition on CPT-treated samples was 
analysed relative to vehicle controls by 2-way ANOVA and is expressed as ns (not significant), ## (p < 
0.01), and ### (p < 0.001). 
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Collectively, these data indicate that inhibition of SIRT1 modulates cell death 
signalling in a p53-dependent manner, and preferentially promotes apoptosis in 
keratinocytes with p53 mutations.  
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5.4 DISCUSSION 
HaCaT keratinocytes bear compound heterozygous mutations in each p53 allele 
which alters the activity and expression of p53 protein without complete loss of 
function (430, 431). Loss of a single functional p53 allele reduces cellular tumour 
suppressor capacity (73), and additionally, TP53 gain-of-function mutations (such as 
those found in HaCaT cells) can generate a phenotype with unique stress responses 
which promote carcinogenesis (521). By manipulating the activity and expression of 
p53 in the HaCaT cell line, we were able to uncover conditions by which this 
phenotype can be targeted to promote cell death in a differential manner. 
Apoptotic sensitivity was enhanced in HaCaT keratinocytes by increasing p53 
acetylation through inhibition of SIRT1 activity (EX-527); but not by p53 or SIRT1 
ablation (RNAi), blocking miR-34a-mediated regulation of SIRT1 (miR-34a TSB), or 
by stabilising cellular p53 protein (Nutlin-3a). 
This study provides a mechanistic link between characteristic UV-induced p53 
mutations, miR-34a insufficiency, and impaired regulation of SIRT1 expression in 
the skin. Increased SIRT1 expression is common in non-melanoma skin cancer (522). 
Consistent with this observation, SIRT1 protein accumulates in HaCaT keratinocytes 
as a consequence of failed miR-34a-mediated repression of SIRT1 at the 
translational level, culminating in reduced p53 acetylation and resistance to p53-
dependent apoptosis [Figure 5:12]. Thus inhibition of SIRT1 in this cell line restores 
apoptotic sensitivity by partially overcoming the effects of miR-34a insufficiency. 
Together, these data indicate that p53 mutations contribute to apoptotic resistance 
in HaCaT keratinocytes by altering the regulatory capacity of the p53/SIRT1/miR-
34a axis during apoptotic signaling. Whether this is a mechanism common to all 
keratinocytes with p53 mutations is yet to be determined, but the frequent 
occurrence of UV-induced p53 mutations and increased SIRT1 expression in skin 
cancers suggests it is likely to be widespread. Furthermore, low constitutive 
expression of miR-34a in p53-mutated keratinocytes supports the potential value of 
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miR-34a as a prognostic marker for skin cancer diagnosis and therapeutic 
monitoring (523). 
 
 
Figure 5:12 EX-527 promotes p53-dependent apoptotic signalling in HaCaT keratinocytes   
SIRT1 accumulates in p53 mutated keratinocytes as a consequence of impaired miR-34a-mediated 
feedback regulation. Overexpression of SIRT1 and pro-survival proteins contributes to apoptotic 
resistance by suppressing p53 acetylation and inhibiting cell death signalling. 
p53 acetylation is promoted in p53-mutated keratinocytes when SIRT1 is inhibited, enabling 
suppression of anti-apoptotic gene targets. Together, these changes restore sensitivity to CPT-
induced cell death in the p53-mutated cell line. 
 
Results from this study show that microRNA-mediated regulation of programmed 
cell death is altered in the HaCaT cell line. Induction of miR-34a, miR-16-1/15a and 
miR-145 during p53-dependent apoptotic signalling is suppressed in p53-mutated 
keratinocytes, and this has consequences for regulatory control of mRNA targets. 
Specifically, down-regulation of Survivin and BCL-2 during apoptosis is dependent 
on normal p53 activity. Aberrant microRNA expression is widespread in primary 
tumours, and is attributed to impaired post-transcriptional regulation of the 
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primary sequence (508, 524). We have previously found that p53 regulates 
biogenesis and maturation of microRNAs which have key downstream functions in 
p53-mediated signalling, and p53 mutations in HaCaTs interfere with this process 
(466). P53 modulates microRNA biogenesis by associating with the RNA helicase 
p68, which facilitates processing of the primary transcript by Drosha (150). In cells 
with mutant p53, formation of the Drosha complex is impeded, blocking processing 
of the primary microRNA transcript (152). Additionally, mutant p53 directly binds to 
and inactivates p63, inhibiting Dicer-1 expression and microRNA maturation (496). 
Basal and squamous cell carcinomas develop significant changes to the keratinocyte 
microRNA expression profile (525-527). Our results indicate that impairments to 
microRNA expression and target regulation in keratinocytes are driven by the 
dysregulating effect of p53 mutations on microRNA biogenesis and processing, and 
occur at the premalignant stage of carcinogenesis.  
Exploitation of the mutational status of p53 in cancer has been an ongoing 
chemotherapeutic strategy for many years. Loss of a single functional p53 allele 
reduces cellular tumour suppressor capacity (73), and can generate a phenotype 
with unique stress responses which promote carcinogenesis (521). Numerous 
options, including gene-based therapy, manipulation of p53 expression by 
disruption of the p53-MDM2 axis, and reactivation of mutant p53 have been 
proposed as a means for restoring apoptotic sensitivity in chemotherapy (89, 490). 
Nutlin-3a is most effective when used in combination with inhibitors of S and M 
phase entry for selective targeting of cells with insufficient p53. However, as our 
results have demonstrated [Figure 5:1 (a & b)], p53 is overexpressed and 
underacetylated in the HaCaT cell line, indicating that p53 activity is suppressed. 
Moreover, although induction of MDM2 in the HaCaT cell line is sufficient to 
decrease p53 expression (528), our results show that HaCaT keratinocytes are 
resistant to MDM2 inhibition, and consequently Nutlin-3a does not promote 
cytotoxicity in these cells.  
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Early results from clinical trials indicate that a combinatorial approach is required 
for chemotherapy to effectively overcome p53 inactivating mutations (86, 96). 
Aside from loss-of function effects, p53 mutations increase protein stability and 
cause gain-of–function effects which increase resistance to p53-based therapeutic 
agents (75, 529), and hence reactivation of mutant p53 function has emerged as a 
strategy for improving the efficacy of traditional chemotherapy (530). In cells with 
heterozygous p53 mutations such as the HaCaT cell line, mutant p53 can have a 
dominant-negative effect on any non-mutated functional p53 within the cell by 
forming functionally inactive aggregates which inhibit DNA binding (80-82). 
Additionally, p53 mutations can produce a gain-of-function phenotype which 
results from the co-association of mutant p53 with other p53 regulatory proteins 
such as p63, p73 and the acetyltransferase p300 (531). This process is particularly 
problematic for cells exposed to genotoxic stress, during which p53 protein 
accumulates and tetramerisation increases exponentially (42). Current strategies 
developed to overcome dominant-negative and gain-of-function effects of p53 
include stimulation of p53 degradation pathways, siRNA-mediated ablation of 
mutant p53 protein, blocking co-association with effector proteins, and reactivation 
of mutant p53 by restoration of wild-type function (82, 91, 92). Importantly, the 
efficacy of these approaches is highly variable because the dominant-negative 
effect of mutant p53 depends on its propensity to inactivate circulating wild-type 
p53, and this is directly related to the site of mutation (93).  
Histone deacetylase (HDAC) inhibitors have recently been suggested as adjuvants 
for p53-based chemotherapy (532). Of the numerous HDAC-targeting therapies, 
only HDAC Class III (SIRT1) inhibitors, such as Tenovin-1 are exclusively p53-
dependent (207). EX-527 is a SIRT1 inhibitor which induces conformational 
remodelling in the SIRT1 catalytic domain, and which inhibits enzyme activity by 
blocking substrate release (229). As a consequence of its p53 mutations, HaCaT cells 
express a mixture of p53 subtypes with functional anomalies affecting protein 
stability and transcriptional activation. However, some p53-dependent activity is 
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still retained in this cell line, albeit at highly suppressed levels. Based on its 
inhibitory mechanism, we postulate that EX-527 may trap mutant p53 in HaCaT 
keratinocytes by preventing its release from the catalytic domain of SIRT1. 
Removing a proportion of mutant p53 from circulation may relieve its dominant 
negative effect, and enable p53 to become transcriptionally active. This mechanism 
may also explain the discrepancy between the ability of EX-527 to increase 
apoptotic sensitivity in HaCaT cells, compared to the inability of SIRT1 knockdown 
to improve apoptotic sensitivity for HaCaTs .  
p53 mutations in keratinocytes attenuate p53-dependent stress responses by 
blunting functional control of the p53/SIRT1/miR-34a axis. Defective miR-34a 
processing has widespread implications for cellular processes regulated by SIRT1 
activity, there is some evidence that inhibiting SIRT1 sensitises pre-cancerous cells 
to apoptosis (533). Although loss of miR-34a alone does not appear to be oncogenic 
(534), impaired miR-34a-mediated regulation of p53 responses appears to be a 
hurdle which must be overcome to promote the efficacy of p53-based 
chemotherapy. Our results have wider chemotherapeutic potential as a treatment 
strategy in skin cancer. Up-regulation of cellular SIRT1 expression and inhibition of 
miR-34a processing in keratinocytes with p53 mutations causes apoptotic 
resistance and attenuation of p53-dependent stress responses when compared to 
wild-type cells. These changes may be overcome, in part, by synthetic SIRT1 
inhibitors. By manipulating the activity of p53 with EX-527 in the HaCaT cell line, we 
were able to uncover conditions by which this phenotype can be targeted to 
promote cell death in a p53-dependent manner. Results from this investigation 
demonstrate the need for further investigation to explore the value of SIRT1 
inhibition in the design of targeted chemotherapeutic regimens in tumours with 
p53-mutated genotypes. 
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Sodium Arsenite Modulates Histone Acetylation 
at the miR-34a Gene Promoter 
Chapter 6 
6.1 ABSTRACT 
Expression of the histone deacetylase SIRT1 is altered in solid tumours and 
haematological malignancies; however its role in arsenic-induced pathology is 
unknown. In this investigation, the effect of arsenic on epigenetic regulation of the 
histone deacetylase SIRT1, and its targeting microRNA, miR-34a, was monitored in 
primary (NHEK) and p53-mutated (HaCaT) human keratinocytes. Arsenic produced 
dose-dependent responses in NHEK and HaCaT cells, increasing metabolic activity at 
concentrations ≤ 5 µM and causing cell death at higher concentrations. In NHEK 
cells, these changes were associated with concomitant shifts in SIRT1 expression 
and acetylation of histone H4 at lysine 16 (H4K16) and after 24 hours, 0.5 µM 
arsenic increased p53 and SIRT1 occupancy at SIRT1 and miR-34a gene promoters 
and chromatin remodelling at the miR-34a gene. HaCaT keratinocytes, however, 
were resistant to arsenic-induced toxicity and did not display H4K16 acetylation 
changes or p53 recruitment at gene promoter regions after arsenic treatment.  
Here we show that arsenic alters epigenetic regulation of SIRT1 expression in NHEK 
cells by modulation of SIRT1 activity and structural reorganisation of the chromatin 
at the miR-34a gene promoter. Conversely, HaCaT keratinocytes are resistant to 
arsenic toxicity, and appear to have altered structural organisation of the chromatin 
at gene promoters. Taken together, this investigation demonstrates that arsenic 
modulates SIRT1-mediated responses to cellular stress in human keratinocytes. 
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6.2 INTRODUCTION 
Investigations within the past decade have demonstrated that arsenic influences 
the pattern of histone acetylation, methylation and phosphorylation in exposed 
cells, and these changes are associated with altered gene expression (535). These 
studies indicate that arsenic toxicity disrupts the regulatory function of chromatin 
remodelling complexes, and specifically, the activity of histone modifying proteins. 
Exposure to arsenic increases oxidative DNA damage and disrupts regulatory 
control over signal transduction and redox homeostasis (536). Additionally, arsenic 
exposure causes genomewide posttranslational histone modifications, particularly 
those associated with looser chromatin structures (537).  
Carcinogenic changes to the epigenome can contribute to genomic instability and 
mutational DNA damage, and cultured cells undergo genome-wide restructuring of 
the epigenome with arsenic exposure. These changes appear to impair cellular 
stress responses such that the genotoxic damage imposed by carcinogens is 
enhanced, and sustained across replicative generations.  
Histone deacetylases (HDACs) are particularly important regulators of chromatin 
conformation. Acetylation of the ε-amino group of lysine residues neutralises the 
positive charge of histone proteins, reducing DNA-binding affinity and loosening the 
chromatin structure (106, 538). This open configuration provides accessibility for 
transcriptional regulators at gene promoters (102, 539), and the DNA repair 
machinery during the DNA damage response (108). Additionally, bromodomain-
binding proteins such as HDACs associate with acetylated histone lysine residues, 
enabling selective targeting of transcriptional regulators and chromatin remodelling 
complexes to gene promoter regions (119). Thus the role of HDACs is to suppress 
gene transcription and to promote a non-permissive/condensed conformation in 
chromatin by removal of histone acetyl residues (540, 541). Destablisation of 
chromatin causes genetic instability and increases the risk of mutational damage 
(542). Consequently, HDACs protect the genome against mutational damage by 
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establishing global chromatin environments and stabilising the structural integrity 
of the genome. 
Acetylation and deacetylation of histone H4 at lysine 16 is a mark which is 
associated with genomewide changes in chromatin condensation and the patterns 
of transcriptional activation and repression (540, 543, 544). H4K16 is a substrate of 
the NAD-dependent lysine deacetylase SIRT1 (226, 261), and thus changes in the 
expression and activity of SIRT1 may be associated with genomewide shifts in 
acetylation of this mark (176, 545). Our hypothesis is that arsenic exposure induces 
histone posttranslational modifications by disrupting the regulatory function of 
SIRT1 and these changes alter cellular stress responses to arsenic toxicity by 
impairing regulation of tumour suppressor genes.  
Arsenic-induced epigenetic changes are thought to promote the mutagenic damage 
which leads to carcinogenic transformation. Here, in vitro cell culture of non-
immortalised (primary) human keratinocytes was used to investigate the 
epimutagenic properties of arsenic exposure. Acetylation of histone H4 and 
micrococcal nuclease accessibility were used as biomarkers for epigenetic effects, 
and expression of SIRT1 and miR-34a genes was used as an endpoint. 
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6.3 RESULTS 
Metabolic activation by sublethal arsenic exposure is affected by p53 status and 
SIRT1 activity.  
Assays were performed to determine the effect of short-term arsenic exposure on 
cellular metabolic activity in keratinocytes with wild-type p53 (NHEK), and 
keratinocytes bearing p53 mutations (HaCaT). The role of SIRT1 in regulating 
cellular responses to arsenic stress was investigated by specific inhibition of SIRT1 
activity with EX-527.  
Using the alamarBlue® assay as a fluorometric measure of cellular metabolic 
activity, we found that arsenic generates concentration-dependent toxicity in NHEK 
and HaCaT keratinocytes, with significant cell death occurring after exposure at 
higher concentrations (> 10 µM) [Figure 6:1 (a & b)]. HaCaT keratinocytes are 
resistant to cell death at higher arsenic concentrations, producing an IC50 of ~60 µM 
As(III) after 24 hours of exposure [Figure 6:1 (b)], as opposed to an IC50 of < 20 µM 
for NHEKs [Figure 6:1 (a)]. These data correlate with the LD50 values determined for 
NHEK and HaCaT cells by other investigators using the MTT assay and by the 
Neutral Red assay (546-549). Inhibition of SIRT1 enhanced the toxicity of arsenic at 
higher concentrations, resulting in a lowering of the IC50 [Figure 6:1 (a & b)]. These 
data indicate that SIRT1 performs a protective function in keratinocytes during 
cellular stress, as shown by the shift in IC50 with EX-527 treatment.  
Resozurin reduction was elevated in both cells lines when treated with arsenic at 
concentrations ≤ 5 µM for 24 hours [Figure 6:1 (a & b)]. When keratinocytes are 
exposed to sublethal concentrations of arsenic, expression of glutathione-related 
genes and antioxidant enzymes increase in response to reactive oxygen species 
production (548-551), and thus an increase in metabolic activity measured in 
arsenic-exposed keratinocytes during this experiment represents an increase in 
cellular reducing power. For the HaCaT cell line, this up-regulation of metabolic 
activity at submicromolar arsenic concentrations was suppressed significantly by 
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EX-527 treatment [Figure 6:1 (b)]. Thus it appears that in p53-mutated 
keratinocytes, aberrant constitutive expression of antioxidant enzymes, and 
overexpression of SIRT1 enhances metabolic responses to environmental toxicant 
exposure. 
Figure 6:1  Effect of SIRT1 on arsenic toxicity in human keratinocytes 
Primary (NHEK, Panel a) and p53-mutated (HaCaT, Panel b) keratinocytes were treated for 24 hours 
with arsenite [As(III)], and assayed for relative viability using resozurin reduction as a determinant of 
metabolic activity. SIRT1 was inhibited by treatment with 1 µM EX-527 during the 24 hr exposure 
period. 
All data represent mean ± SD of 4 independent experiments. Cell-specific differences were analysed 
by 2-way ANOVA with Bonferroni post-tests, represented as # (p<0.05), ## (p<0.01), ### (p<001). 
IC50 values were determined using non-linear regression. 
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These data show that cellular responses to As(III) are dose-dependent, therefore to 
further characterise the effect of arsenic on p53/SIRT1/miR-34a axis activity, p53 
activation and expression, induction of SIRT1, and miR-34a expression was 
measured in arsenic-exposed keratinocytes. 
Arsenic modulates SIRT1 and p53 gene expression in keratinocytes 
By measuring mRNA and protein expression in NHEKs exposed to a range of arsenic 
concentrations over a 24 hour time frame, we found that p53 expression was 
induced 2-fold by arsenic at submicromolar concentrations, and p53 mRNA was 
down-regulated in cells exposed to > 5 µM As(III) [Figure 6:2 (a)].  
Figure 6:2 Dose-dependent p53 and SIRT1 expression in human keratinocytes treated with arsenic 
The effect of As(III) on p53 (Panel a) and SIRT1 expression (Panel b) was detected by qRT-PCR and 
immunoblotting, using 5S rRNA to normalise qRT-PCR results and actin to normalise protein loading.  
All data represent mean ± SD of 3 independent experiments. Results significantly different from 
vehicle are represented as * and ***; with p < 0.05 and p < 0.001 respectively.  
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Arsenic exposure increased SIRT1 protein 6-fold at sub-lethal concentrations, 
peaking at 0.5 µM [Figure 6:2 (b)]. SIRT1 mRNA, however, was not altered by 
arsenic at lower concentrations, and was up-regulated at doses ≥ 20 µM [Figure 6:2 
(b)]. SIRT1 protein was not increased in NHEKs exposed to arsenic at concentrations 
higher than 5 µM, so based on these findings, the sublethal dose of arsenic (0.5 µM) 
which induced accumulation of SIRT1 protein was used for future experiments.  
Arsenic up-regulates miR-34a gene expression in keratinocytes 
In order to fully evaluate the relationship between SIRT1 mRNA and arsenic 
exposure, expression of the SIRT1-targeting microRNA, miR-34a, was measured 
using primers targeting the precursor sequence, pri-miR-34a. Exposure to 
submicromolar concentrations of As(III) triggered a slight, but significant up-
regulation of miR-34a after 24 hrs [Figure 6:3; p < 0.05], whereas treatment with > 5 
µM As(III) induced > 10-fold increase in miR-34a abundance [Figure 6:3; p < 0.001].  
Figure 6:3  Induction of miR-34a in human keratinocytes treated with arsenic 
Primary (NHEK) human keratinocytes were treated with arsenite [As(III)] for 24 hr. The effect of 
As(III) on pri-miR-34a expression was detected by qRT-PCR, using 5S rRNA and U6 snoRNA to 
normalise qRT-PCR results.  
All data represent mean ± SD of 3 independent experiments. Results significantly different from 
vehicle are represented as * and ***; with p < 0.05 and p < 0.001 respectively.  
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Taken together, these data show that p53, SIRT1 and miR-34a (the p53/SIRT1/miR-
34a axis) influence cellular responses to arsenic in a dose-dependent manner. At 
submicromolar concentrations, arsenic up-regulates p53, inducing a 2-fold increase 
in miR-34a transcription. At concentrations greater than 5 µM, a different response 
pattern emerges, and this is associated with cellular toxicity rather than metabolic 
activation. miR-34a is a well-characterised regulator of apoptotic signalling (476), 
and thus a 10-fold upregulation of miR-34a correlates with arsenic-induced cell 
death measured in toxicity assays at concentrations >5 µM [Figure 6:1 & Figure 6:3]. 
In oxidative conditions, SIRT1 is regulated by microRNA-targeted degradation of its 
mRNA (552, 553). Here we show that p53 is activated in keratinocytes exposed to 
arsenic in the 0.1-1 µM range, inducing a 2-fold increase in miR-34a expression. 
Paradoxically, SIRT1 protein accumulates in keratinocytes exposed to 
submicromolar concentrations of arsenic without a concomitant increase in SIRT1 
mRNA. Arsenic is believed to inhibit ubiquitin E3 ligase activity (554-556), altering 
protein levels by interfering with targeted proteolysis (557). Consistent with this 
evidence, our findings suggest that sublethal concentrations (≤ 5 µM) arsenic blocks 
proteolytic degradation of SIRT1 in human keratinocytes. 
Histone H4 is hyperacetylated by arsenic exposure in normal, but not p53 mutated 
human keratinocytes  
Next, whole cell lysates of As(III)-treated cells were analysed to determine if 
modulation of SIRT1 expression by arsenic influences acetylation of histone H4 at 
lysine 16 (H4K16) in keratinocytes.  
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Figure 6:4 Histone acetylation in arsenic-treated keratinocytes is p53-dependent 
Primary (NHEK) and p53-mutated (HaCaT) human keratinocytes were treated with arsenite [As(III)] 
and protein was extracted after 24 hours according to protocols outlined in Chapter 2. The effect of 
As(III) on histone H4 acetylation at lysine 16 was detected by immunoblotting. Protein loading was 
normalised using actin and acetylation was calculated relative to total H4 expression.  
All data represent mean ± SD of 3 independent experiments. Results were analysed by 2-way ANOVA 
and values significantly different from untreated, passage matched controls are represented as ***; 
with p < 0.001.  
Treatment with 0.5 and 1 µM As(III) increased acetylation of the SIRT1 substrate 
H4(K16) in NHEK cells [Figure 6:4; p < 0.001]. Taken with results from Figure 6.2, 
these data indicate that SIRT1 activity is also inhibited by arsenic exposure.  
P53 is recruited to SIRT1 and pri-miR-34a gene promoters during arsenic 
exposure 
Both SIRT1 and miR-34a have p53 response elements in their gene promoters (479). 
In each case, the p53 response element identified in other studies was situated 
within upstream CpG islands (515, 558).  
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Figure 6:5 Pri-miR-34a and SIRT1 Regulatory Features 
The Ch1p36 primary transcript (pri-miR-34a) is processed from exons 1 and 2 form to pre-miR-34a, 
which generates the loop-stem precursor to mature miR-34a (Panel a). Mature miR-34a inhibits 
translation of SIRT1 by complementary pairing to the SIRT1 primary transcript at its 3′ UTR (Panel b).  
These criteria were used to select suitable nucleotide sequences responsible for 
p53-dependent transcriptional regulation. Pri-miR-34a expression is regulated by a 
CpG island upstream from exon 1 which contains a p53 response element [Figure 
6:5 (a)]. SIRT1 transcription is also regulated by an upstream p53 response element 
and a CpG island which spans the transcription start site (TSS) [Figure 6:5 (b)]. 
For promoter remodelling experiments, 2 loci within each gene promoter were used 
for analysis, and a third region was used as a control locus – upstream of the gene 
promoter for the miR-34a gene, and within the 3`UTR for SIRT1 [Figure 6:6].  
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Figure 6:6  Diagrammatic representation of gene loci for ChIP primers in SIRT1 and pri-miR-34a 
genes. 
NHEK and HaCaT cells were treated for 24 hours with 0.5 µM As(III) and analysed for 
changes in p53 binding to its target recognition sequence in SIRT1 and pri-miR-34a 
genes using chromatin immunoprecipitation (ChIP) coupled to RT-PCR. After 24 hrs 
of arsenic exposure, p53 is recruited to SIRT1 and miR-34a promoter regions in 
NHEK cells [Figure 6:7 (a & c)]. In the HaCaT cell line, no significant change in p53 
recruitment was measured for miR-34a and SIRT1 promoter regions [Figure 6:7 (b & 
d)]. 
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Figure 6:7 Recruitment of p53 to SIRT1 and pri-miR-34a gene loci during arsenic exposure 
Crosslinked chromatin was isolated from normal (NHEK) and p53-mutated (HaCaT) keratinocytes 
treated with As(III) for 24 hrs and p53-associated chromatin was captured with antibody-bound 
magnetic beads. Occupancy at the SIRT1 (Panels a and b) and pri-miR-34a (Panels c and d) promoter 
loci was analysed by quantitative PCR relative to input DNA. Isotype matched IgG-bound beads were 
used as a control for immunoprecipitation, and 3′ or upstream primer loci were used as PCR 
controls.  
All data represents the mean ± SD from three independent experiments with * (p < 0.05), ** (p < 
0.01) and *** (p < 0.001) respectively. 
We have previously found that TP53 mutations in HaCaT keratinocytes generate 
structural and functional defects which alter responses to genotoxic stress (Chapter 
5). Taken together with Chapter 5 findings, these experiments demonstrate that 
arsenic induces p53-mediated transcriptional activation, and this response is 
impaired in the HaCaT cell line. 
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Figure 6:8 Arsenic-Induced Acetylation of H4[AcK16] in Human Keratinocytes 
Crosslinked chromatin was isolated from normal (NHEK) keratinocytes treated with As(III) for 24 hrs 
and chromatin associated with SIRT1 or histone H4 acetylated at lysine 16 was captured with 
antibody-bound magnetic beads. Occupancy at SIRT1 (Panels a amd c) and pri-miR-34a (Panels b and 
d) promoter regions were analysed by quantitative PCR relative to input DNA. Isotype matched IgG-
bound beads were used as a control for immunoprecipitation, and 3′ or upstream primers were used 
as PCR controls.  
All data represents the mean ± SD from three independent experiments with * (p < 0.05), ** (p < 
0.01) and *** (p < 0.001) respectively. 
Next we asked if arsenic exposure influences remodelling of the chromatin at these 
promoters. First we looked at acetylation of lysine 16 in histone H4, as this mark is 
the predominantly characterised nuclear SIRT1 substrate. Additionally, SIRT1 
occupancy at the same loci was assayed to determine the relationship between 
H4K16 acetylation and SIRT1 recruitment in arsenic-exposed NHEK cells. H4K16 
acetylation in NHEK cells treated with the 0.5 µM concentration of arsenic increased 
4-fold at the p53 RE within the SIRT1 promoter and 30-fold at the p53 RE within the 
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miR-34a promoter after 24 hours [Figure 6:8 (a & c)]. In arsenic-exposed HaCaT 
cells, however, acetylation of H4K16 at the SIRT1 and miR-34a promoters did not 
change during this time frame [Figure 6:8 (b & d)]. 
Finally, experiments were performed to determine if these changes in histone 
acetylation were associated with changes in chromatin condensation. 
Analysis of chromatin accessibility by RT-PCR (ChART) 
To test whether the changes we have seen are associated with chromatin 
remodelling, a MNase sensitivity assay was performed on the SIRT1 and miR-34a 
promoters in arsenic-exposed NHEK and HaCaT keratinocytes. The Rhodopsin gene 
was used as a control in these experiments. 
In NHEK cells, a 3-fold increase in MNase accessibility across the miR-34a promoter 
was measured after 24 hrs arsenic exposure [Figure 6:9 (a)]. This correlates with the 
increase in acetylation of the H4K16 mark measured for the miR-34a target during 
arsenic exposure [Figure 6:8(c)], and indicates that this gene has undergone 
promoter-wide chromatin remodelling. For the SIRT1 promoter, no change in 
MNase accessibility was measured for arsenic-treated NHEKs [Figure 6:9 (c)], 
regardless of the change in histone acetylation [Figure 6:8 (c)]. For HaCaT cells, 
however, a slight, but significant decrease in accessibility was measured across both 
the miR-34a and SIRT1 promoter regions after arsenic treatment [Figure 6:9 (b & 
d)]. For both cell lines, the Rhodopsin gene was resistant to MNase digestion during 
arsenic exposure [Figure 6:9 (e & f)]. 
These data demonstrate that induction of miR-34a expression in NHEK cells is 
associated with structural remodelling at the miR-34a gene promoter during low-
dose arsenic exposure.  
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Figure 6:9 Arsenic alters the pattern of chromatin condensation in human keratinocytes 
Primary human (NHEK) and p53-mutated (HaCaT) keratinocytes were treated with 0.5 µM As(III) for 
24 hours. Chromatin was digested with micrococcal nuclease and DNA fragments were assayed for 
accessibility at pri-miR-34a (Panels a and b), SIRT1 (Panels c and d), and Rhodopsin (Panels e and f) 
gene promoters by ChART-PCR using nucleosome-spanning primers. Results were normalised using 
undigested input DNA. 
All data were analysed relative to vehicle controls by pairwise t-test and represent the mean ± SD 
from three independent experiments with ns (not significant); ** (p < 0.01) and *** (p < 0.001). 
No structural change was detected in the region of the SIRT1 gene assayed in this 
experiment, and although H4K16 acetylation increased 4-fold during arsenic 
exposure, the change was not sufficient to influence nucleosomal positioning.  
197 | 
Chapter 6 
Collectively, these data suggest that for NHEKs, chromatin of the SIRT1 promoter is 
in a poised, or transcriptionally ready state. During arsenic exposure, pri-miR-34a 
becomes primed by acetylation of H4K16 and chromatin remodelling at its 
promoter, facilitating transcriptional activation. This epigenetic pattern correlates 
with SIRT1 inhibition. To further determine the relationship between SIRT1 activity 
and chromatin structure, acetylation of H4K16 and MNase accessibility was assayed 
at target gene promoters after SIRT1 activity was inhibited using EX-527. 
Arsenic-mediated SIRT1 inhibition loosens chromatin by H4 hyperacetylation 
Inhibition of SIRT1 caused a 6-fold increase in acetylation of histone H4 at lysine 16 
for the pri-miR-34a gene [Figure 6:10 (a)], and a 4-5 fold increase in acetylation for 
the SIRT1 gene after 24 hours [Figure 6:10 (c)]. These results were associated with a 
doubling in MNase accessibility for the pri-miR-34a promoter [Figure 6:10 (b)], and 
a slight increase in accessibility for the SIRT1 promoter after 24 hours [Figure 6:10 
(d)]. Taken together, ChIP and ChART results demonstrate that EX-527-induced 
hyperacetylation of H4K16 is associated with chromosomal loosening, and that 
inhibition of SIRT1 activity increased acetylation of this histone mark in 
keratinocytes with wild-type p53. Next, to determine how arsenic affects SIRT1 
occupancy at gene promoter loci, SIRT1 ChIP was performed in arsenic-treated 
NHEK and HaCaT cells.   
SIRT1 occupancy increased for all loci at both genes (4-fold in the case of pri-miR-
34a, and ~3-fold for SIRT1) in the NHEK cell strain [Figure 6:11 (a & c)], and a slight 
increase was measured for 2 of the SIRT1 loci and locus 1 of the pri-miR-34a gene in 
the HaCaT cell line after 24 hours of arsenic treatment [Figure 6:11 (b & d)]. 
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Figure 6:10  SIRT1 inhibition enriches acetylation of H4 at lysine 16, increasing chromatin accessibility 
SIRT1 activity was inhibited in Primary human (NHEK) keratinocytes with 1 µM EX-527 for 24 hours. 
Panels a & c: Crosslinked chromatin associated with histone H4 acetylated at lysine 16 was captured 
with antibody-bound magnetic beads. Occupancy at pri-miR-34a and SIRT1 gene promoters was 
analysed by quantitative PCR relative to input DNA. Isotype matched IgG-bound beads were used as 
a control for immunoprecipitation, and upstream or 3′ primers were used as PCR controls.  
Panels b & d: Chromatin was digested at 22 °C for 5 min with micrococcal nuclease and DNA 
fragments were assayed for accessibility at pri-miR-34a and SIRT1 gene promoters by PCR using 
nucleosome-spanning primers. Results were normalised using undigested input DNA. 
All data were analysed relative to vehicle controls represent the mean ± SD from three independent 
experiments with * (p < 0.05), ** (p < 0.01) and *** (p < 0.001) respectively. 
Acetylation of the H4K16 mark increased in NHEKs treated with either EX-527 or 
arsenic, despite the fact that SIRT1 occupancy increased at gene loci during arsenic 
exposure. Taken together, these results demonstrate that arsenic increases H4K16 
acetylation by altering SIRT1 activity and not by suppressing recruitment. 
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Interestingly, these changes were associated with chromatin remodelling of the 
miR-34a gene promoter, but not for the SIRT1 gene promoter. 
Figure 6:11 SIRT1 ChIP 
Crosslinked chromatin was isolated from normal (NHEK) keratinocytes treated with As(III) for 24 hrs 
and chromatin associated with SIRT1 was captured with antibody-bound magnetic beads. 
Occupancy at SIRT1 (Panels a amd c) and pri-miR-34a (Panels b and d) promoter regions were 
analysed by quantitative PCR relative to input DNA. Isotype matched IgG-bound beads were used as 
a control for immunoprecipitation, and 3′ or upstream primers were used as PCR controls.  
All data represents the mean ± SD from three independent experiments with * (p < 0.05), ** (p < 
0.01) and *** (p < 0.001) respectively. 
Additionally, the pattern of chromatin regulation was altered in HaCaT keratinocytes 
when compared to NHEKs, such that this cell line responded differently to arsenic-
induced changes in SIRT1 activity. To investigate the nature of chromatin 
remodelling in arsenic-exposed HaCaTs, the level of chromatin condensation at pri-
miR-34a and SIRT1 gene promoters was compared in untreated NHEK and HaCaT 
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cells [Figure 6:12]. Interestingly, the HaCaT genome was more sensitive to MNase 
digestion than that of the primary keratinocyte cell strain, indicating that HaCaT 
cells have a constitutively lower level of chromatin condensation at the miR-34a and 
SIRT1 gene promoters [Figure 6:12]. This is particularly evident for the miR-34a 
promoter, which measured 2.5-fold higher MNase accessibility in HaCaT cells when 
compared to NHEKs.  
Figure 6:12 Chromatin repatterning in HaCaT keratinocytes 
Primary human (NHEK, white bars) and p53-mutated (HaCaT, black bars) keratinocytes were grown 
in 100 cm2 culture plates at a cell density of 75%. Chromatin was extracted and MNase-digested 
DNA fragments were assayed for accessibility at SIRT1, pri-miR-34a and Rhodopsin gene promoters. 
Results were normalised using undigested input DNA. HaCaT MNase accessibility data were analysed 
relative to accessibility in NHEKs by pairwise t-test and represent the mean ± SD from three culture 
populations with ns (not significant); and *** (p < 0.001). 
Results from this analysis indicate that the chromosomal landscape in the HaCaT 
cell line is significantly different than primary keratinocytes, and therefore the 
impact of epigenetic modifiers on the genes tested is altered. Thus in contrast to 
the increase in chromatin accessibility measured in NHEK cells [Figure 6:9 (a)], 
arsenic treatment causes chromatin to be condensed in the HaCaT cell line [Figure 
6:9 (b, d)].  
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6.4 DISCUSSION 
In this study, we show that arsenic modulates SIRT1 and miR-34a expression in a 
dose-dependent manner, and influences chromatin condensation at the miR-34a 
promoter by altering histone H4 acetylation at lysine 16 (H4K16). When primary 
keratinocytes are exposed to arsenic, a genomewide increase in acetylation of 
H4K16 occurs, causing chromosomal loosening at the pri-miR-34a promoter, 
however this observation was not recorded for the p53 mutated HaCaT cell line.  
For NHEK and HaCaT cells, arsenic increased metabolic activity at sublethal doses 
after 24 hrs, and this response was more pronounced for HaCaT cells than for 
NHEKs. Arsenic exposure disrupts mitochondrial membrane integrity (559, 560), 
increases cellular ROS (550, 551), causes chromosomal instability (559, 561), and 
oxidative DNA damage (562). Redox-regulating genes are induced in response to 
short-term arsenic exposures (548, 563), and conceivably, this enhances cellular 
reducing capacity and is responsible for increasing resozurin reduction in 
keratinocytes exposed to submicromolar doses of arsenic. Arsenic exposure causes 
extensive mutational damage to the mitochondrial genome (564) and increases 
glucose usage by inducing glycolysis (315). Changes attributed to mitochondrial 
damage are features of arsenic-induced Bowen’s disease (565), and this mechanism 
is thought to trigger a metabolic switch from oxidative to glycolytic energy 
pathways (the ‘Warburg effect’) which provides a selective growth advantage for 
precarcinogenic cells during transformation (12, 352). 
This investigation demonstrates that arsenic exposure suppresses SIRT1-mediated 
deacetylation of target substrates (p53 and histone H4) in human keratinocytes. 
SIRT1 activity is inhibited by numerous mechanisms, including microRNA inhibition, 
NAD depletion and oxidative posttranslational modifications (566), and bears 
cysteine residues which are particularly sensitive to oxidants and aldehydes (567). 
Arsenic is well known for its affinity for sulfhydryl groups in cysteine residues (568, 
569); therefore SIRT1 is likely candidate for modification during arsenic exposure. 
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SIRT1 maintains mitochondrial biogenesis and control over cellular energy 
metabolism by regulating AMP-activated protein kinase (AMPK) and PCG-1α 
expression (570-572). Consequently, decreased SIRT1 expression is associated with 
loss of mitochondrial function and increased oxidative stress (566). 
During genotoxic stress, SIRT1 is recruited to DNA strand breaks during the DNA 
damage response and plays a key role in regulating accessibility of DNA repair 
enzymes to the DNA by coordinating the process of chromatin remodeling (219). 
Consistent with the findings of other groups, (573, 574) our results demonstrate 
that arsenic exposure disturbs the structural arrangement of chromatin by 
interfering with histone deacetylase activity in exposed keratinocytes. The process 
of DNA repair is a complex one, and evidence indicates that histone deacetylases 
function late in the DNA damage response, presumably to reestablish the more 
condensed structure of facultative heterochromatin (575-577). Thus disruption of 
SIRT1 activity at sites of arsenic-induced DNA damage has the capacity to prevent 
chromatin from condensing following DNA repair. Results from this investigation 
suggest that arsenic toxicity has the potential to promote mutational damage by 
suppressing SIRT1-mediated chromatin remodeling. 
Regulation of the epigenetic landscape is a critical requirement for the maintenance 
of genomic integrity. Genomic instability is a well-established hallmark of cancer 
(11), however the relationship between aberrant regulation of chromatin structure 
and cancer promotion is currently a matter of some debate (578). Impaired 
chromosomal remodelling during cellular replication and/or DNA damage and 
repair processes are thought to promote tumorigenesis through the acquisition of a 
diverse set of spontaneous mutations which enable neoplastic cells to adapt to 
their environment (578-580). As a carcinogen, arsenic appears to act in a manner 
consistent with this hypothesis. Arsenic does not interact directly with the DNA in a 
manner such as direct carcinogens, although it can introduce intranuclear 
conditions by which mutagenesis is more likely. These include induction of oxidative 
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DNA damage (288, 289), impaired DNA repair activity, disruption of mitotic spindle 
formation during replication (581-584), aneuploidy (290), and microsatellite 
formation.  
During this investigation we have provided evidence showing that arsenic produces 
changes which are consistent with modulation of a key epigenetic regulator (SIRT1), 
and which alters the pattern of histone marks and chromatin condensation at the 
miR-34a promoter such that the gene is transcriptionally ready. Consistent with our 
results, Somji et al. have shown that arsenic transformation modifies the metal 
response element of the metallothionein 3 gene promoter such that the chromatin 
displays a poised pattern of histone marks (585). Whether these changes persist 
with extended exposure, and whether SIRT1 inactivation by arsenic plays a role in 
the promotion of keratinocyte transformation is unclear. 
We also found here that p53-mutated keratinocytes (HaCaT cells) are resistant to 
arsenic-induced cell death, and acetylation of the H4K16 mark does not increase at 
gene promoters with arsenic exposure. This finding appears to contradict 
conclusions made regarding the effect of arsenic as an inhibitor of SIRT1 activity in 
NHEK cells. However, differences in the epigenetic regulatory machinery of HaCaTs 
may account for altered responses to arsenic when compared to NHEKs. Expression 
of SIRT1 is 3-fold higher in the HaCaT cell line, and the chromosomal architecture at 
gene promoters is more sensitive to MNase digestion. Moreover, stress-related 
gene expression in the HaCaT cell line appears to be higher than primary 
keratinocytes during arsenic-induced or UV-induced toxicity (548, 586). However it 
must be noted that these studies compared cells which were cultured in different 
growth media [keratinocyte growth media for NHEKs; RPMI or DMEM for HaCaT 
cells].  As we have shown in Chapter 3, physiological responses of HaCaT cells are 
sensitive to growth media, and HaCaT phenotype is more comparable to NHEKs 
when cultured in keratinocyte growth medium. 
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In Chapter 5, we demonstrated that HaCaTs are resistant to camptothecin-induced 
apoptosis and this appears to be augmented by SIRT1. Thus the effect of arsenic as 
an inhibitor of SIRT1 activity (as observed in NHEK cells) is less potent in the HaCaT 
cell line as a result of its greater intracellular SIRT1 protein level and antioxidant 
defense capacity. In the next chapter, , an extended treatment period was used to 
measure changes in the pattern of gene expression and DNA methylation with low-
dose arsenic exposure to test whether arsenic-induced modifications to SIRT1 and 
miR-34a genes were sustained in NHEK cells over time. 
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Chapter 7 
 7.1 ABSTRACT 
Arsenic is an environmental contaminant which generates significant health issues 
for populations with chronic exposure. Human populations exposed to arsenic 
through drinking water are at risk of developing numerous pathologies of the skin, 
including hyperkeratosis, hyperpigmentation and carcinoma. Recent investigations 
show that histone deacetylase and DNA methyltransferase activity are altered by 
arsenic exposure and this appears to promote cellular transformation. The purpose 
of this investigation was to investigate the epimutagenic properties of arsenic in 
keratinocytes using an in vitro cell culture model. Acetylation of histone H4 
progressively increased over 70 days in arsenic-exposed populations, whilst a loss of 
promoter methylation was observed across the miR-34a gene promoter during this 
timeframe. Experiments conducted in the previous chapter demonstrated that 
SIRT1 expression is up-regulated in keratinocytes which are exposed to 0.5 µM 
arsenic over short-term time frames. Results presented in this chapter further 
reveal that enhanced expression of SIRT1 in arsenic-treated keratinocytes is 
reversed during extended exposure by widespread epigenetic remodelling to SIRT1 
and miR-34a gene promoters, which up-regulates miR-34a expression, enhances 
feedback regulation of SIRT1, and suppresses transactivation of the SIRT1 
promoter.  
Primary human keratinocytes did not escape replicative senescence during the 
course of this experiment, although keratinocyte cell lines with impaired functional 
p53 have been successfully transformed by others using the same arsenic 
concentration within a 10 week period. We show here that hyperacetylation of 
histone proteins and reorganisation of promoter methylation are associated with a 
dysregulated pattern of SIRT1 and miR-34a expression, and these features are part 
of a wider landscape of altered epigenetic regulation in arsenic-exposed 
keratinocytes.  
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7.2 INTRODUCTION 
Of all the organ systems, the skin is particularly sensitive to arsenic toxicity, either 
from systemic or topical exposures (587). Arsenite binds proteins bearing sulfhydryl 
moieties in thiol-rich proteins such as keratins (588, 589), and consequently, has a 
tendency to accumulate in keratinocytes of the epidermal layer of the skin (590). 
Arsenic toxicity produces a pathological profile which is characterised by 
hyperproliferation, dysplasia, presence of apoptotic cells and hyperpigmentation. 
Unlike UV-induced skin lesions, arsenic-induced hyperkeratotic skin lesions affect 
multiple sites across the epidermis and develop into non-melanoma skin cancers 
(NMSC) which are more aggressive than those triggered by sun exposure alone 
(287). Consequently, uncovering the mechanisms driving arsenic-induced 
carcinogenesis is a priority for development of strategies to reduce disease risk for 
exposed populations.  
So far, most evidence indicates that arsenic does not directly interact with DNA and 
this contributes to a classification of arsenic as an indirect carcinogen in humans 
(283). The mutagenic potential of arsenic is thought to derive from oxidative DNA 
damage, clastogenic damage, and mitogenic stress (316, 562, 591, 592). In addition, 
arsenic exposure interferes with numerous regulatory processes which maintain 
genomic fidelity, including the DNA repair machinery and those responsible for 
epigenetic imprinting (582, 583, 593-596). As our understanding of carcinogenesis 
has evolved, cancer has been redefined as a disease of impaired epigenetic gene 
regulation in addition to DNA sequence mutations (178). The DNA methylome is 
maintained by DNA methyltransferases (DNMTs), which target position 5 of 
cytosine bases in CpG dinucleotides (597, 598). Cytosine methylation influences 
chromatin condensation and accessibility of regulatory elements to gene 
promoters, thus providing an additional layer of control over gene expression (599). 
In healthy cells, the majority of methylated CpG dinucleotides in the genome are 
part of non-coding tandem repeat sequences (LINEs, SINEs and LTRs) (100). In 
contrast, concentrated CpG regions associated with gene-regulatory domains (CpG 
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islands) are predominantly unmethylated (600). This pattern of DNA methylation 
shifts during carcinogenesis such that cancer cells develop genomewide DNA 
methylation abnormalities (601, 602), and these changes alter patterns of gene 
expression, increase mutational rates (603) and contribute to chromosomal 
instability (170, 604).  
Arsenic exposure induces well-documented genomewide methylation changes in 
exposed individuals (376, 605), and is also known to alter the methylation status of 
cultured cells in vitro (396). Consistent with methylation patterns from cancer 
genomes, these studies show that arsenic exposure causes gene-associated 
hypermethylation of CpG islands and genomewide hypomethylation of repetitive 
sequences (357). A loss of methylation at non-CpG sites during cancer progression 
appears to be linked to redistribution of the epigenetic regulatory machinery and a 
concomitant increase in de novo methylation at promoter-associated CpG islands 
(170, 174, 606). Although a causative link has not been conclusively demonstrated, 
it is widely understood that this hypomethylation/hypermethylation process occurs 
concurrently during chemical carcinogenesis, as a consequence of alterations in the 
distribution of polycomb repressive group complexes across the chromatin and 
impaired DNA methyltransferase activity (607).This global loss of 5-methylcytosine 
in the genome also increases the rate of mutational damage (9, 13) and increases 
microsatellite instability (608). Along with alterations to microRNA expression (389), 
these studies provide growing evidence for a relationship between arsenic-induced 
epigenetic dysregulation and cancer. Whether these changes are derived from, or 
drive the process of arsenic-induced carcinogenic transformation is unclear.  
SIRT1 is a lysine deacetylase which has a key role in regulating cellular responses to 
chronic stress. In addition to its role in modulating histone acetylation, SIRT1 
facilitates CpG methylation during DNA damage, by recruiting DNMT3B to sites of 
DNA base oxidation and strand breaks (609, 610), and by modulating DNMT1 
activity (611). SIRT1 expression is controlled by the microRNA miR-34a (479); 
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however miR-34a expression is frequently suppressed in cancer (478). Inactivation 
of the region of Chromosome 1 coding for the miR-34 gene (1p36.22) is associated 
with CpG hypermethylation in many cancers (612-616). Additionally, SIRT1 is 
overexpressed in cancer subtypes, including acute myeloid leukemia (617), 
hepatocellular carcinoma (618), prostate cancer (619), and non-melanoma skin 
cancer (522). SIRT1 regulates differentiation and senescence in normal 
keratinocytes (620-622), and suppresses epithelial-to-mesenchymal transition in 
breast cancer (623, 624); however the role of SIRT1 in arsenic-induced skin cancer 
has not previously been investigated. 
Here, primary human keratinocytes were exposed to a sub-lethal concentration of 
arsenic continuously over a period of 10 weeks in order to generate epigenetic 
changes associated with carcinogenesis. DNA methylation analysis demonstrated 
arsenic-induced hypomethylation of the miR-34a promoter associated with up-
regulation of its coding microRNA.   
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 7.3 RESULTS 
Human keratinocytes enter senescence after 10 weeks in culture 
Normal human epidermal (NHEK) keratinocytes at passage 2 were grown in 75 cm2 
flasks from an initial population of 5  105 cells and allowing an overnight settle 
prior to addition of the treatment medium. When the flasks had reached 75-85% 
confluence (approximately once per week), the cells were detached using TrypLE 
dissociation reagent (Invitrogen, Carlsbad, CA, USA), rinsed in Epilife and counted 
using a Haemocytometer. Harvested cells were seeded at a standard density of 5  
103 cells per square centimetre into a new 75 cm2 culture flask, and the remaining 
harvested cells washed in PBS. Seeding medium was replaced with EpiLife growth 
medium containing 0.5 µM arsenic the following day. Untreated NHEK cells grown in 
EpiLife were harvested concurrently as passage matched controls. 
 
Figure 7:1 Effect of arsenic on keratinocyte growth in culture 
Primary human keratinocytes (NHEK) were cultured for 10 weeks in EpiLife Keratinocyte growth 
medium into which had been added arsenite [As(III)] to a final concentration of 0.5 µM. The effect of 
arsenic on growth characteristics of keratinocytes in culture was determined using a cell count of 
cells stained with the vital dye, Trypan Blue performed at each passage. An untreated passage-
matched population of NHEKs grown under identical conditions was used as a reference. Panel a: 
Total cells ( 105); Panel b: Percentage non-viable cells. 
 
The harvested NHEKs were pelleted in aliquots of 1  106 cells and stored at −80°C 
until use. This experiment was repeated twice, for at least 10 weeks on each 
occasion, and similar results were obtained with each population 
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Primary keratinocytes reached a peak replicative capacity in culture at 20 days, 
declining rapidly thereafter. These data correlate with the growth characteristics of 
keratinocytes documented by others (450, 625). Arsenic suppressed growth of 
cultured keratinocytes during the initial 20 days of culture, after which a 
subpopulation continued to divide in a manner consistent with untreated 
keratinocytes [Figure 7:1 (a)]. Total cell yield was reduced by arsenic exposure, with 
the arsenic-treated population generating approximately 20  106 cells from the 
initial 500000 cell sample at the conclusion of the 70 day experiment, whereas 
keratinocytes growth in culture without arsenic generated approximately 27  106 
cells in total. This observation was mirrored by the percentage of non-viable cells 
counted each week, with 30-35% dead cells measured during weeks 4-6 in the 
arsenic-exposed population, compared with a background yield of 10-15% dead 
cells in the non-exposed population [Figure 7:1 (b)]. 
Analysis of promoter methylation in arsenic-exposed keratinocytes 
Until this study, the arsenic-induced modulation of SIRT1 and pri-miR-34a gene 
regulation has not been documented in depth, and so whether their promoter 
regions would be influenced by arsenic was unknown. Considering the effect of 
arsenic on mitochondrial function and energy metabolism, SIRT1 expression and 
activity was expected to change with extended exposure to arsenic. Based on 
results obtained from Chapter 6 experiments, we concluded that arsenic exposure 
suppresses SIRT1 deacetylase activity, and de-condenses chromatin in the miR-34a 
gene promoter, leaving the region susceptible to posttranscriptional remodeling 
factors. Here, primary human keratinocytes were exposed to arsenic for 60 days to 
induce arsenic-induced methylation changes at the target loci. A short region (190 
bp) of the SIRT1 promoter between the p53 response element and the transcription 
start site (TSS) was targeted for analysis [Figure 7:2(a)]. Likewise, the regulatory 
domain of the pri-miR-34a promoter directly upstream of the p53 response element 
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was analysed by bisulfite sequencing [Figure 7:2(b)]. Potential regions for 
methylation analysis were identified using parameters outlined in Chapter 2. 
Figure 7:2 Targets for Methylation Analysis 
Diagrammatic representation of regulatory domains for miR-34a (Panel a) and SIRT1 (Panel b) gene 
sequences with regions targeted for methylation analysis are annotated. Ticks indicate CpG 
dinucleotides, CpG islands are marked as blue, p53 binding sites are circled. The downstream region 
of each gene sequence has been omitted for clarity. 
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High Resolution Melt Curve Analysis (HRM) was used to screen arsenic-exposed 
NHEKs for methylation changes in the SIRT1 and pri-miR-34a promoter regions to 
indicate if further analysis by sequencing was warranted. HRM is a technique which 
screens for variations in sample gene sequences by identifying differences in the 
melting properties of heterogeneous DNA sequences. Here, methylated and 
unmethylated cytosine residues were differentiated by bisulfite conversion and 
identified using difference plots derived from melt curves. Relative methylation of 
sample DNA was assessed by comparison with standards of known percentage 
methylation.  
 
Figure 7:3 Melt Curve Analysis, 60 day arsenic exposure in keratinocytes 
Bisulfite-converted DNA from arsenic-exposed keratinocytes was amplified using SIRT1 and pri-miR-
34a bisulfite primers (Panels a & c), and high resolution melting was performed with MeltDoctor 
HRM Reagents. Melt curves were analysed and difference plots generated from the data using High 
Resolution Melt Software v3.0 (Applied Biosystems, Foster City, CA, USA). Standard curves 
generated from fully methylated and unmethylated control gDNA are included for reference (Panels 
b & d). 
 
After 70 days of arsenic exposure, the SIRT1 difference plot from untreated NHEK 
control cells correlated with the 2.5% methylation standard, and the plot from 
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arsenic treated cells showed a further 5-6% increase in methylation status 
compared to untreated control [Figure 7:3 (a, b)]. For the pri-miR-34a locus, arsenic 
treatment produced a more marked change in percent methylation, with ~100% 
methylation in untreated keratinocytes, and >10% methylation in arsenic-treated 
keratinocytes at the target region [Figure 7:3 (c, d)]. These results support our 
hypothesis that arsenic alters methylation of the pri-miR-34a upstream regulatory 
region, and show that methylation changes at this locus can be detected by a 
relatively simple technique (HRM) within a 9-10 week experimental time frame. 
  
Arsenic alters SIRT1 and pri-miR-34a gene expression in keratinocytes by 
repatterning promoter methylation  
Cytosine methylation in the promoter regions of SIRT1 and pri-miR-34a genes was 
measured in NHEK cells which were cultured for 10 weeks in EpiLife Keratinocyte 
growth medium into which had been added arsenite [As(III)] to a final concentration 
of 0.5 µM. Methylation was analysed from the DNA of population samples extracted 
at weeks 1, 5, 9 and 10 by direct sequencing of bisulfite-modified target genes. 
Percentage cytosine methylation was determined manually for each CpG within the 
region from the sequencing trace, and results analysed using a BiQ Analyser 
software program (413). The effect of As(III)-mediated epigenetic repatterning of 
the SIRT1 and pri-miR-34a promoter on expression of target genes was analysed 
using qRT-PCR. For this experiment, only one replicate was obtainable, and so 
results are presented without statistical analysis due to time constraints.  
When compared to untreated, passage matched controls, arsenic increased CpG 
dinucleotide methylation in the SIRT1 promoter at 2 CpG sites in the first 5 weeks, 
and at two more CpG sites after a further 4-5 weeks of treatment [Figure 7:4 (a)]. 
Across the pri-miR-34a promoter region tested, CpG dinucleotides were 
predominantly methylated in untreated control keratinocytes, and methylation 
status remained constant during the 10 week exposure period [Figure 7:4(b)]. In 
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arsenic-treated keratinocytes, methylation progressively decreased, with distal 
changes occurring within the first week of treatment and proximal CpGs being 
affected after 9-10 weeks [Figure 7:4(b)].  
 
Figure 7:4 Aberrant DNA methylation of specific loci is associated with altered gene expression 
during extended arsenic exposure 
Primary human keratinocytes were cultured in medium containing 0.5 µM As(III) continuously for a 
period of 10 weeks. Genomic DNA was extracted each week for bisulfite conversion and sequencing 
of SIRT1 (Panel a) and pri-miR-34a (Panel b) PCR fragments. Sequences were analysed for changes in 
cytosine methylation using BiQ Analyser v2.00 (413) using the ClustalW (626) algorithm, and the 
dataset converted into a graphical format (black circles > 50% methylated; white circles < 50% 
methylated).qRT-PCR was performed from single RNA extracts using primers for SIRT1 (Panel c) and 
pri-miR-34a (Panel d). 
 
Promoter methylation repatterning in arsenic-treated NHEKs correlated with 
duration-dependent shifts in SIRT1 and miR-34a expression. For untreated NHEKs, 
SIRT1 mRNA expression did not alter dramatically during the 10 week timeframe, 
whereas SIRT1 expression was suppressed more than 10-fold with exposure to 
arsenic [Figure 7:4 (c)]. Conversely, pri-miR-34a increased almost 100-fold after 10 
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weeks of arsenic exposure and was down-regulated in untreated controls [Figure 
7:4 (d)].  
These data demonstrate a relationship between arsenic-induced changes in 
promoter methylation and altered expression of SIRT1 and miR-34a in 
keratinocytes. Considering that the NHEK cell strain consists of a heterogenous 
population of keratinocytes, it is most likely that the results presented in Figure 7.4 
are a consequence of arsenic-mediated selection pressure. Thus the result is a 
generalized representation of methylation changes which may indicate that cells 
with certain methylation states have preferentially survived throughout the course 
of the experiment, rather than indicating that arsenic is directly responsible. 
Nonetheless, many investigators have demonstrated a causal relationship between 
arsenic exposure and alterations in the DNA methylation profile during in vitro 
experiments and in population studies. A more detailed method of methylation 
analysis using clonal sequencing would be able to detect population-based changes 
in the sample; however this technique was beyond the scope of this investigation. 
To further ascertain the relationship between promoter hypermethylation, altered 
SIRT1 expression and chromatin remodelling, p53 expression and acetylation of 
histone H4 at lysine 16 was measured in arsenic-exposed keratinocytes. 
Arsenic-mediated hyperacetylation of histone H4 in human keratinocytes 
Although SIRT1 expression was up-regulated in arsenic-treated NHEKs when 
compared to untreated controls for the initial 24 days of the treatment period, 
relative expression of SIRT1 protein decreased over time after the initial up-
regulation observed with 1 day exposure to As(III) [Figure 7:5(a)]. 
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Figure 7:5 Arsenic alters SIRT1/miR-34a axis regulation during prolonged exposure in keratinocytes 
Normal keratinocytes were continuously cultured in media containing 0.5 µM As(III) over a period of 
10 weeks. Protein and RNA were extracted during the 10 weeks of treatment (n=2). SIRT1 protein 
(Panel a), p53 protein (Panel b) and acetylation of histone H4 at lysine 16 (H4AcK16; Panel c) was 
measured by immunoblotting. Protein loading was normalised using actin, and qRT-PCR data was 
normalised using 5S rRNA as an internal control gene. Acetylation was calculated relative to 
expression of histone H4. 
 
Consistent with this observation, arsenic-mediated up-regulation of p53 expression 
was only sustained during the first 3 weeks of the experiment [Figure 7:5(b)]. 
Furthermore, relative acetylation of H4K16 progressively increased to become 5-
fold higher in NHEKs after 24 days when compared to cells cultured in arsenic-free 
media over the same time period [Figure 7:5(c)] 
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7.4 DISCUSSION 
SIRT1 is a critical mediator of physiological processes which regulate lifespan and 
ageing, predominantly by maintaining epigenetic control over gene expression (220, 
627). In keratinocytes, up-regulation of SIRT1 redirects cellular signalling programs 
towards differentiation, and down-regulation of SIRT1 promotes senescence (620, 
621). Additionally, miR-34a expression is known to increase during senescence, and 
this is associated with a down-regulation of SIRT1 protein (482).. Sirtuin expression 
is down-regulated in hyperkeratotic lesions from arsenic exposed individuals (628) - 
a result which is consistent with our findings in keratinocytes exposed to arsenic 
over 10 weeks. Paradoxically, other groups have shown that SIRT1 is overexpressed 
in skin cancer (522, 629), and when taken with our results, this disparity in the 
SIRT1 expression profile indicates that arsenic induces carcinogenic transformation 
in keratinocytes via a mechanism which differs from UV-induced skin cancer. 
Regulation of the histone code and patterns of DNA methylation are inextricably 
linked, and cooperate to dynamically manage chromatin condensation. When 
keratinocytes were exposed to arsenic in our experiments, histone H4 was 
hyperacetylated at lysine 16 and CpG dinucleotides were demethylated at the pri-
miR-34a promoter, resulting in a reorganisation of the chromatin structure and an 
increase in miR-34a expression. In recent years, clinical trials and in vitro studies 
have shown that arsenic transformed cells develop widespread histone 
modifications which are associated with changes to the DNA methylation profile 
(373, 535). For the most part, cells exposed to arsenic over extended time periods 
have hypermethylated and phosphoacetylated histone residues (355, 382, 630, 
631), and methylation of CpG dinucleotides decreases (360, 396).  
Histone modifications precede DNA methylation in the initiation and consolidation 
of tumour suppressor silencing (130). Our data show that as exposure time 
progresses, As(III)-induced histone modifications are replaced by a DNA 
methylation pattern which reinforces epigenetic regulation of gene expression in 
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keratinocytes. Specifically, keratinocytes exposed to arsenic underwent progressive 
shifts in the pattern of SIRT1 and pri-miR-34a promoter methylation which were 
associated with concurrent changes in SIRT1 and miR-34a gene expression. 
Further to our findings that epimutagenic properties of arsenic are related to 
impaired regulatory function of epigenetic modifiers such as SIRT1, arsenic 
exposure increases oxidative stress and alters cellular availability of redox cycling 
intermediates such as glutathione (549, 632). The epigenome is significantly 
modified when cells are exposed to oxidative stress (633, 634), a process which 
directly inhibits SIRT1 (567), and also indirectly suppresses activity by limiting 
cofactor availability. Here, functional activity of epigenetic modifying enzymes is 
influenced by reduced abundance of NAD+, which supplies PARP and SIRT1, Acetyl 
CoA, which supplies histone acetyltransferases, and S-adenosyl methionine (SAM) 
which supplies DNA methyltransferases (DNMTs) (221, 384, 635). 
Mechanistically, DNA methylation changes associated with arsenic exposure have 
been attributed to competition for methyl group donors by methyltransferases 
(369, 535). This hypothesis is supported by in vitro studies demonstrating 
concurrent SAM insufficiency and inhibition of DNMT activity in cells treated with 
arsenic (360). This theory has been questioned as arsenic biotransformation by 
methylation is minimal in most tissues with the exception of the liver (636). An 
alternative mechanism proposes that glutathione synthesis during oxidative stress 
redirects cellular stores of homocysteine from pathways which recycle DNMT 
cofactors, such as SAM (373, 374). However, inhibition of DNMT in arsenic exposed 
cells has been shown to occur independently of SAM concentration (360). 
Nonetheless, arsenic exposure disrupts DNMT activity and expression (637), and 
causes a generalised loss of DNA methylation in arsenic-exposed keratinocytes 
(396).  
Impairments to DNA methyltransferase activity cause disruptions to maintenance 
methylation during cell division (171, 638, 639), and increases cancer susceptibility 
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by destabilizing the genome (290). Furthermore, altering the activity of Polycomb 
Repressive Group (PRG) complexes enables de novo DNA methyltransferases 
DNMT3a and DNMT3b to methylate exposed gene promoters (126). Consequently, 
inhibition of PRG protein expression and DNMT activity by arsenic causes shifts in 
the pattern of DNA methylation (360, 371, 396). In accordance with this model, 
others have found that transformation of BALB/c 3T3 cells by extended exposure to 
0.5 µM As(III) activates PRG proteins BMI1 and Suz12, and these changes were 
associated with suppression of p16INK4A and p19ARF expression (640). Our results 
support a model in which arsenic suppresses PRG-mediated gene repression and 
disrupts established patterns of histone acetylation by disrupting SIRT1 activity 
[Figure 7:6].  
 
 
Figure 7:6 Arsenic alters patterns of DNA methylation by blocking SIRT1 activity. 
SIRT1 is recruited to methylation sites as part of polycomb repressive group (PRG) complexes 2 and 
4 where it associates with and regulates EZH2, EED, Suz12 and DNMT1 (180). As part of this gene 
repressive complex, SIRT1 induces chromatin condensation by deacetylating histone H4 at lysine 16 
(H4K16) and maintains DNA methylation patterns by recruiting and activating DNA 
methyltransferase 1 (DNMT1).  
Key: As(III) – arsenite; DNMT1 - DNA methyltransferase 1; EED – embryonic ectoderm development 
protein; EZH2/SUV3-9 – Enhancer of Zeste Homologue 2; MeCP2 – Methyl CpG binding protein 2; 
Suz12 – suppressor of zeste 12; RbAp46 & 48 – retinoblastoma binding proteins 46 & 48. 
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Moreover, our experimental findings provide evidence that arsenic is causing 
significant disruptions to the epigenetic machinery in a manner which is 
independent of p53 inactivation. In accordance with our investigations in Chapter 5, 
p53 must not only be expressed, but also be activated by an external (or internal) 
stressor for p53-dependent cellular processes (such as cell cycle arrest or survival 
signaling) to occur (641). It is no coincidence, then, that genes with aberrant DNA 
methylation in arsenic-exposed individuals are predominantly part of the p53 
tumour suppressor network (605). However, cultured cells are responding to 
numerous stress signals which compound the effect of any carcinogenic insult (such 
as arsenic, as in our study), and which promote a low-level transactivation of p53 
(642). Wild-type p53 expression is required for cells to enter mitotic arrest and 
apoptosis during arsenic exposure (643, 644). 
In vitro models of oncogenic transformation are difficult to interpret for a variety of 
reasons – amongst which is the confounding influence of the cellular growth 
environment in culture. Our results indicate that cellular replication is suppressed 
by arsenic in culture, and that exposure to arsenic alone is not sufficient to induce 
cancerous change in primary keratinocytes. Whilst other groups have performed 
extended arsenic treatment experiments in culture, the cell lines used in these 
studies are derived from immortalized or pre-malignant sources (HaCaT (645, 646)), 
are transformed with hTERT (SAEC (647)), adenovirus-12 SV40 (BEAS-2B (648), 
UROtsa (649)) or HPV 18 (RWPE-1 (650, 651)), which, although enabling long-term 
growth in culture, may produce results that are non-representative of arsenic-
induced carcinogenesis in vivo. Genes regulating G1 to S phase transition are down-
regulated and genes promoting cell cycle arrest are up-regulated in NHEKs exposed 
to arsenic for 24 hour periods (547). However this expression profile does not 
persist in hyperkeratotic skin lesions, which show enhanced expression of genes 
promoting G1/S and G2-M phase transition (628). In general, SIRT1 expression 
decreases and acetylation of the SIRT1 histone substrate, histone H4 at lysine 16 
(H4K16) increases with age (111), and is associated with higher-order remodelling 
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of the genome (544). Genomewide remodelling of higher-order chromatin structure 
occurs during keratinocyte differentiation (652), however H4K16 is hypoacetylated 
in senescent cells (621, 653, 654). 
Since we found that primary keratinocytes were not transformed by extended 
arsenic treatment, it would be useful to determine if the epigenetic remodelling we 
measured during this experiment had altered keratinocyte susceptibility to 
transformation by other carcinogens such as UV exposure. The nature of arsenic-
mediated transformation has not been fully defined, despite its classification as a 
known carcinogen by the International Agency for Research on Cancer (IARC) (283). 
Inorganic arsenic has been variously described as a non-genotoxic carcinogen, an 
indirect carcinogen or a co-carcinogen, and although exposure induces oxidative 
DNA lesions and alters oncogene expression (288, 289, 655), to our knowledge 
arsenic-mediated transformation has only been achieved in immortalised cell lines. 
Acquisition of transformational changes by keratinocytes treated with arsenic was 
difficult to detect from our results, as data from this study represents population-
wide outcomes rather than an analysis of isolated colonies. Primary keratinocytes 
rapidly enter mitotic senescence when cultured on plastic; however when exposed 
to an initiating carcinogen, individual cells may acquire changes which confer 
resistance to replicative senescence. As part of a wider population in culture, the 
population phenotype is only affected if clonal expansion of transformed cells is 
more rapid than their untransformed counterparts. This had not occurred at the 
end of the 70 day exposure period in our investigation. HaCaT keratinocytes have 
been successfully transformed within this time frame by other investigators (646, 
656), and based on these in vitro transformation studies, we anticipated that 
extended growth in the presence of arsenic would alter the growth pattern of 
primary keratinocytes, and that arsenic would generate epigenetic changes which 
enabled cells to overcome senescence during the course of the experiment. As this 
did not appear to be the case for arsenic-exposed NHEKs, our interpretation is that 
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co-carcinogens such as UV produce the initiating event (such as inactivation of p53) 
which is necessary for arsenic-mediated oncogenic transformation in keratinocytes.
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General Discussion 
SIRT1 is a novel pharmaceutical target which mediates the cell’s adaptive responses 
to chronic stress. Current research suggests that SIRT1 activation is protective for 
individuals who are under biological stress or lack adequate homeostatic regulatory 
capacity but does not alter the health of already healthy individuals. On a cellular 
level, SIRT1 differentially targets diseased cells within a mixed population (such as 
found in tumour tissue) by enhancing redox and metabolic homeostasis, 
suppressing inflammatory signalling and improving responses to genotoxic damage 
and DNA repair. Consequently, SIRT1 protects against age-associated diseases and 
mediates cellular responses to genotoxins. 
Arsenic toxicity causes numerous cellular defects and triggers carcinogenesis 
through a non-genotoxic mechanism which is poorly defined. Dysregulated 
maintenance of epigenetic imprinting promotes shifts in gene expression patterns 
which are associated with tumour development. This thesis explored a primary 
hypothesis that aberrant SIRT1 activity mediates the epigenetic events which 
initiate and promote arsenic-induced skin cancer. Additionally, since mutations to 
p53 are associated with overexpression of SIRT1 in skin cancer, this study also 
investigated the role of the p53/SIRT1/miR-34a axis during cell death signalling. 
The main experimental findings in this thesis are summarised below: 
Firstly, we established that p53 mutations in HaCaT keratinocytes increase SIRT1 
expression by suppressing miR-34a-mediated regulatory control. These properties 
formed the basis for an in vitro model of dysregulated p53/SIRT1/miR-34a axis 
activity which is consistent with precarcinogenic changes observed in squamous cell 
carcinoma. 
By transiently manipulating p53 and SIRT1 expression, we demonstrated that SIRT1 
functions in combination with p53 to establish microRNA expression patterns in 
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human keratinocytes. Characteristic UV-induced TP53 mutations in HaCaT cells 
interfere with efficient biogenesis and maturation of a select group of microRNAs 
which regulate responses to genotoxic stress. As a result, expression of 
downstream microRNA-targeted mRNAs is poorly controlled in HaCaTs, causing 
overexpression of pro-survival proteins such as SIRT1. Up-regulation of cellular 
SIRT1 expression and inhibition of miR-34a processing suppresses p53 activation 
and contributes to apoptotic resistance in p53-mutated keratinocytes. Most 
importantly, by treating HaCaT keratinocytes with a pharmaceutical SIRT1 inhibitor, 
EX-527, we were able to enhance apoptotic sensitivity in this cell line by improving 
relative p53 acetylation.  
Having characterised the role of p53/SIRT1/miR-34a axis activity in wild-type and 
pre-carcinogenic keratinocytes, we then tested the effect of arsenic on epigenetic 
regulation of SIRT1 and miR-34a gene promoters. Arsenic exposure over a 24 hr 
time frame alters the pattern of chromatin condensation by increasing histone H4 
acetylation at lysine 16. These changes are consistent with inhibition of a key 
epigenetic regulator (SIRT1). Culture in arsenic-containing media for > 10 weeks did 
not induce sufficient phenotypic change to cause measureable transformation of 
cultured primary keratinocytes in this study; however the pattern of DNA 
methylation shifted in the regulatory promoter regions of SIRT1 and miR-34a genes 
and was associated with altered mRNA and protein expression. These data support 
our primary hypothesis, and correlate with evidence that PRG proteins (such as 
SIRT1) play a key role in arsenic-mediated transformation (640). 
Future Directions 
SIRT1 inhibition has wide chemotherapeutic potential as a treatment strategy in 
skin cancer. Our investigations into p53/SIRT1/miR-34a axis activity were 
performed using HaCaT keratinocytes, and therefore conclusions about the effect 
of SIRT1 inhibition on apoptotic sensitivity in keratinocytes presented in Chapters 4 
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& 5 are only relevant in the context of the p53 mutations found in this cell line. 
Since TP53 alleles in the HaCaT cell line bear characteristic UV-induced mutations at 
commonly altered codons, it may be possible to expand the interpretation of our 
results in the context of other cancers with p53 mutations. Suppression of 
oncogenic proliferation by the SIRT1 inhibitor Tenovin-1 has recently been 
demonstrated in melanoma cell lines (629), and so to confirm the efficacy of EX-527 
as an adjuvant for skin cancer therapy it would be useful to repeat our experiments 
using keratinocyte cell lines derived from epidermal squamous cell carcinomas. 
Further investigation is needed to explore the value of SIRT1 inhibitors in the design 
of targeted chemotherapeutic regimens for tumours with p53-mutated genotypes. 
Future work in this area would be to track epigenetic changes in other key 
oncogenes/tumour suppressors using arsenic exposure in vitro as a model for 
carcinogenic transformation. Additionally, measurement of serum miRNA may be 
an alternative biomarker of arsenic toxicity in exposed populations. Ultimately, if 
we determine the significance of an epigenetic mode of action for arsenic-induced 
cancer, we could unlock the potential to block the transition of transformed cells 
between stages (particularly at the promotion stage, during which carcinogenesis is 
reversible) with epigenetic modulators or RNA interference therapy. This not only 
has implications for the prevention of cancer in arsenic-exposed populations, but 
also for our understanding and treatment of carcinogenesis as a multi-faceted 
disease. 
Limiting Factors 
A major limiting factor during this investigation was the lack of a high-throughput 
technique for measuring SIRT1 activity. Although a number of multiplate assays 
designed to quantitate SIRT1 deacetylase activity are commercially available at 
present [ENZO Life Sciences, Catalogue # BML-AK555; Sigma-Aldrich, Catalogue # 
CS1040; Cayman Chemical Company, Catalogue # 10010991; Upstate (Millipore), 
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Catalogue # 17-10090; AbCam, Catalogue # ab156065], the accuracy of these assays 
was a matter of debate when this study commenced. As a rule, SIRT1 activity assays 
use a fluorescent probe attached to a modified peptide containing an acetylated 
lysine residue as an indicator. Several groups had revealed that these fluorescent 
probes acting as assay substrates were influencing SIRT1 activity (657). Since then, 
SIRT1 activity assays have been redesigned with luminescent indicators and are less 
prone to interference [Perkin-Elmer, Promega]. Retesting of SIRT1 activity in 
treated keratinocytes would be useful to confirm the inhibitory effect of arsenic in 
Chapter 6. Nonetheless, as the luciferase-bound substrate used in commercially 
available SIRT1 activity assays is a modified p53 peptide sequence containing an 
acetylated lysine residue, our results are still valid as we have used a comparable 
marker for SIRT1 activity (relative acetylation of p53 at lysine 382) to base our 
experimental conclusions - albeit using a semi-quantitative detection technique 
(immunoblotting).  
As discussed in Chapter 1 [Table 1.6], the Km for lysine deacetylation by SIRT1 is 
substrate-specific; therefore assays which use a p53 peptide sequence as a marker 
may not provide an accurate representation of SIRT1 activity throughout the cell. 
Future enzymatic assays would be more sensitive and specific if they used an 
alternative marker [i.e. measure the formation of 2′-O-Acetyl-ADP-Ribose from NAD 
by nicotinamide cleavage and ADP-ribose transfer to acetate (212, 232, 233) to 
measure SIRT1 activity.  
Conclusion 
In conclusion, this thesis has demonstrated the importance of efficient 
p53/SIRT1/miR-34a axis activity for protection of the skin from genotoxic insults, 
and that prolonged arsenic exposure impairs epigenetic regulation of SIRT1 and 
miR-34a gene expression in a duration-dependent manner. Aberrant miR-34a-
mediated regulation of SIRT1 expression promotes carcinogenic transformation in 
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human keratinocytes, and consequently we demonstrated that manipulation of 
SIRT1 activity is sufficient to overcome apoptotic resistance with the p53-mutated 
HaCaT cell line. Finally, these data reveal novel insights into mechanisms which 
distinguish cells with p53 mutations from their healthy counterparts, and provides 
evidence which supports the use of SIRT1 inhibitors as a strategy for selective 
targeting of malignant cells during cancer therapy. 
230 | 
Supplementary Material 
Supplementary Material 
LIST OF BUFFER STOCK SOLUTIONS 
Cell Culture 
Dulbecco's Phosphate Buffered Saline [Calcium/Magnesium Free] 
Components g/L (10X) Molarity (1X) 
KCl 2 2.7 mM 
KH2PO4 (anhydrous) 2 1.5 mM 
NaCl 80 136.9 mM 
Na2HPO4 (anhydrous) 11.5 8.9 mM 
Hank's Balanced Salt Solution [Calcium/Magnesium Free] 
Components g/L (10X) Molarity (1X) 
KCl 4 5.33 mM 
KH2PO4 (anhydrous) 0.6 0.44 mM 
NaCl 80 138 mM 
Na2HPO4 (anhydrous) 0.4788 0.3 mM 
D-glucose 10 5.6 mM 
Phenol red (sodium salt) 0.11 0.03 mM 
NaHCO3 (add to 1X solution) 0.35 (1X) 4 mM 
Immunoprecipitation 
Immunoprecipitation Lysis Buffer 
Tris-HCl (pH 7.5) 50 mM 
EDTA 1 mM 
Na3VO4 0.5 mM 
β-mercaptoethanol 0.10% 
Triton X-100 1% 
NaF 50 mM 
Sodium pyrophosphate 5 mM 
β-glycerophosphate 10 mM 
PMSF 0.1 mM 
Add Protease Inhibitor Cocktail before use 
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Immunoblotting 
Tris Buffered Saline Tween-20 [TBST] 
 Components Quantity (1) 
Tris HCl (7.6)  20 mM 
NaCl 150 mM 
Tween-20 0.10% 
  SDS-PAGE Running Buffer 
 Components Quantity (1) 
Tris HCl (8.3) 25 mM 
Glycine 190 mM 
SDS 0.10% 
  SDS-PAGE Transfer Buffer [Towbins Buffer] 
Components Quantity (1) 
Tris HCl (8.5) 25 mM 
Glycine 0.2 M 
Add 10% methanol to 1X solution prior to use 
  RadioImmunoPrecipitation Assay [RIPA] Cell Lysis Buffer 
Components Quantity (1) 
Tris-HCl (pH 8.0) 50 mM 
NaCl 150 mM 
NP-40 1% (v/v) 
Sodium deoxycholate 0.5% (w/v)  
SDS 0.1% (w/v) 
Glycerol 10% (v/v) 
Add Protease and Phosphatase Inhibitors at time of use 
  Laemmli Sample Buffer  
 Components Quantity (1) 
Tris HCl (6.8) 62.5 mM 
SDS 2% (w/v) 
Glycerol 10% (v/v) 
*DTT or BME 50 mM 
Bromophenol Blue 0.01% (w/v) 
*Add at time of use 
  
  
233 |  
 
Supplementary Material 
ChIP 
Nuclear Lysis Buffer (ChIP) 
Component Concentration 
Tris.HCl (pH 8.0) 50 mM 
EDTA 10 mM Add Protease Inhibitor Cocktail before use 
SDS 1% 
Dilution Buffer (ChIP) 
Component Concentration 
Tris.HCl (pH 8.0) 16.7 mM 
NaCl 167 mM Add Protease Inhibitor Cocktail before use 
EDTA 1.2 mM 
Triton X-100 1% 
Low Salt Buffer (ChIP) 
Component Concentration 
Tris.HCl (pH 8.0) 20 mM 
SDS 0.10% 
NaCl 150 mM 
EDTA 2 mM 
Triton X-100 1% 
High Salt Buffer (ChIP) 
Component Concentration 
Tris.HCl (pH 8.0) 20 mM 
SDS 0.10% 
NaCl 500 mM 
EDTA 2 mM 
Triton X-100 1% 
LiCl Buffer (ChIP) 
Component Concentration 
Tris.HCl (pH 8.0) 10 mM 
Igepal 1% 
LiCl 250 mM 
EDTA 1 mM 
Sodium Deoxycholate 1% 
Elution Buffer (ChIP) 
Component Concentration 
SDS 1% 
NaHCO3 100 mM 
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PARP Sample Buffer 
PARP Sample Buffer 
 Component Quantity (1) 
Tris HCl (6.8)  62.5 mM 
Urea 6 M 
Glycerol 10% 
SDS 2% 
Bromophenol Blue 0.00% 
B-mercaptoethanol 5% 
 
 
Staining 
Coomassie Blue Gel Stain Destaining Solution 
0.05% (w/v) Coomassie blue R-250 20% (v/v) ethanol 
40% (v/v) ethanol 0.5% (v/v) acetic acid 
5% (v/v) acetic acid 
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RANGE FINDING AND TOXICITY 
Measuring and comparing the effect of p53 mutations on apoptotic sensitivity is 
complicated by many factors, including 1) method of induction; 2) duration of 
exposure; 3) endpoint targets; and 4) assay parameters. 
Initial screening tests were designed to determine conditions of dose and duration 
which induce measurable apoptotic changes, and which are able to discriminate 
differences in apoptotic sensitivity between NHEK and HaCaT cells. 
Figure vii  Range Finding - Apoptosis Inducers 
Primary (NHEK) (●) and p53-mutated (HaCaT) (□) keratinocytes were seeded into 96 well 
microplates at 5000 cells/well and allowed to recover overnight prior to camptothecin (CPT) 
treatment. Cellular activity was assayed by measuring resozurin reduction after 24 (Panel a), or 48 
(Panel b) hours of exposure. The fluorimetric signal was normalised to unseeded media-only control 
wells, and results were analysed as a percentage of the signal from the untreated control 
population. 
All data represent mean ± SEM of 4 independent experiments. Significant differences between cell 
lines are represented as *** (p < 0.001).  
After 24 hrs, metabolic activity increased by 20% in NHEKs exposed to 
submicromolar CPT, however metabolic activity was not altered by CPT in HaCaTs 
under the same conditions [Figure i]. CPT-induced genotoxic damage induces 
mitochondrial reducing proteins – hence metabolic activity increases. An altered 
metabolic response to stress indicates that the HaCaT cell line has undergone a 
partial shift in its cellular respiration. Additionally, duration of exposure to CPT 
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influences its toxicity in both cell lines as the DNA damaging effect of 
Topoisomerase I inhibition is S-phase specific (658, 659); therefore greater 
cytotoxicity is measured after 48 hr [Figure i]. 
In order to discriminate between live, apoptotic and necrotic cells using the caspase 
3/7 assay, the signal was normalised using results from co-treated cell proliferation 
assays.  As keratinocytes are prone to detachment with cytotoxicity, some signal 
loss occurred using the CyQUANT assay due to the removal of detached cells with 
the treatment medium as part of the protocol. Thus this assay could not be reliably 
used to discriminate between healthy and apoptotic cells after CPT treatment 
[Figure ii (a)]. The ATPLite protocol did not require any removal of medium, and so 
was a better prospect for normalisation of the Apo-ONE assay [Figure ii(b)]. 
Figure viii Normalisation of Caspase 3/7 activity by ATPLite and CyQUANT viability assays 
Primary keratinocytes (NHEKs) were seeded into microplate wells at 5,000 cells/well and treated 
with 5 µM CPT for 24 hr. Cell number was determined using CyQUANT and ATPLite viability assays 
(Panel a), and analysed using pairwise t-tests. Apoptosis was detected using the Apo-ONE caspase 
3/7 activity assay (Panel b) according to the manufacturer’s instructions, and normalised to cell 
number using both viability assays. The effect of CPT on caspase 3/7 activity in NHEKs was analysed 
from 4 independent populations relative to untreated vehicle controls using pairwise t-tests. 
Significant differences are represented as p<0.001; ***; or ns, not significant.  
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TRANSIENT TRANSFECTION OF PRIMARY KERATINOCYTES 
RNA interference (RNAi) is a posttranscriptional regulatory mechanism which uses 
complementary base pairing of ~21 nucleotide length small interfering RNAs 
(siRNA) to a target mRNA sequence. RNA oligonucleotides are processed by DICER 
into smaller fragments before the siRNA antisense strand is then loaded into an 
RNA-induced silencing complex (RISC) for recognition and degradation of the target 
mRNA sequence. Synthetic siRNAs utilise the endogenous cellular RNAi machinery 
to specifically act upon a target mRNA sequence for degradation.  
RNAi experiments use cationic lipid, viral vector or electroporation techniques to 
deliver siRNAs across cell membranes, and most typically achieve a transient 
reduction in gene expression – however the production of stable transfectants is 
also possible (660). As an investigative technique, RNAi experiments are complex to 
interpret due to problems with cellular toxicity, interferon-mediated responses and 
off-target phenotypic effects (661-664). Knockdown of a gene with a targeting 
siRNA depends on both transfection efficiency (siRNA complex uptake) and 
reduction in gene expression/target protein activity. As these are highly variable 
between tissues, each RNAi experiment requires that the transfection conditions 
are optimised specifically to cater for specific cell lines (665). In order to determine 
the impact of arsenic on the SIRT1-p53-miR-34a axis, we first developed a model to 
characterise the axis in our cell cultures. 
Cultured primary human keratinocytes are difficult to transfect with high efficiency 
(666). Transfection efficiency can be improved with removal of hormonal 
supplements from the transfection medium (667) or with nucleofection (668). Opti-
MEM medium is normally recommended as a transfection diluent by the 
Lipofectamine2000 manufacturer (Invitrogen, Life Technologies); however this 
product induces senescence in keratinocytes as a consequence of its calcium 
content (1.8 mM). For this study, siRNA-Lipofectamine2000 complexes were 
prepared in unsupplemented EpiLife growth medium without added antibiotics and 
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added directly to the culture plates. Transfection was carried out at 37°C and 5% 
CO2 in a humidified incubator. After 3 hours, keratinocyte supplement solution was 
added to each well and the plates returned to the incubator. 
For each cell culture, a range of doses was tested according to the manufacturer’s 
instructions to determine tolerance to the cationic lipid in transfection solution. 
Relative toxicity was measured using AlamarBlue reagent and the dose which 
generated >80% viability was chosen as optimal for transfection. OnTARGET pool 
siRNA pellets were resuspended in 1X siRNA buffer [20 mM KCl, 6 mM HEPES (pH 
7.5), 0.2 mM MgCl2] to generate 20 µM stock solutions which were stored at −80°C. 
Prior to use, stock solutions were diluted to 5 µM in siRNA buffer, and then 
dissolved in the appropriate volume of transfection medium. A matrix of controls 
and a range of siRNA doses were tested using the transfection protocol outlined 
below. After 24 hours, mRNA was extracted and tested for knockdown of the target 
by RT-PCR. Knockdown of mRNA >80% represented optimal transfection. 
 
Figure ix Lipofectamine2000 toxicity in primary and p53-mutated keratinocytes 
Primary (NHEK) and p53-mutated (HaCaT) keratinocytes were seeded into 96 well microplates at 
5000 cells/well and allowed to recover overnight prior to Lipofectamine treatment. Cellular activity 
was assayed by measuring resozurin reduction after 5 (○), or 24 () hours of exposure. The 
fluorimetric signal was normalised to unseeded media-only control wells, and results were analysed 
as a percentage of the signal from the untreated control population. 
All data represent mean ± SEM of 4 independent experiments.  
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First, to optimise the volume of Lipofectamine2000, toxicity was assayed in NHEK 
and HaCaT cells by introducing Lipofectamine2000 (0-1.25 µl/well) to the culture 
medium of cells growing in 96 well culture plates and testing cell viability by 
AlamarBlue assay after 5 hr and 24 hr of incubation. Exposure to 
Lipofectamine2000 was more toxic for NHEKs than for HaCaT keratinocytes, 
reducing cell viability to 80% at volumes >0.25 µl/well, and viability did not 
significantly decrease over time for either cell culture [Figure iii]. Using these results 
and scaling up the volume for transfection in 6 well culture plates, 5 µl/well was 
determined to be optimal for effective siRNA delivery with minimal toxicity. 
siRNA concentration was titrated to find the optimal concentration for knockdown 
by treating NHEK and HaCaT keratinocytes with 5, 25 and 50 nM of ON-TARGET 
siRNA mix and measuring expression of the targeted mRNAs at 48hr and measuring 
protein expression at 72 hr incubation. Ablation of target mRNAs improved for both 
cell cultures when siRNA concentration increased. HaCaT keratinocytes had a higher 
knockdown efficiency than NHEK cells [Figure iv].  
For the NHEK cell strain, SIRT1 mRNA was reduced from 55% (5 nM) to 35% (50 nM) 
and p53 mRNA from 60% (5 nM) to 39%. In HaCaTs, SIRT1 mRNA decreased from 
52% (5 nM) to 14% (50 nM), and p53 mRNA decreased from 15% (5 nM) to 5% 
(50nM) when compared to expression in cells transfected with equivalent 
concentrations of a non-targeting siRNA pool [Figure iv]. Whilst knockdown by 50 
nM of siRNA in HaCaTs was >80%, depletion of SIRT1 and p53 was unsatisfactory 
with this concentration of siRNAs in NHEK cells.  
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Figure x SIRT1 and p53 siRNA transfection optimisation in human keratinocytes 
Primary (NHEK) and p53-mutated (HaCaT) human keratinocytes were transfected with 5, 25 or 50 
nM of SIRT1 or p53 siRNA oligonucleotide pools. SIRT1 mRNA and p53 mRNA expression was 
measured by RT-PCR after 48 hrs, and SIRT1 or p53 ablation was analysed relative to transfection 
with equal concentrations of a non-targeting oligonucleotide pool. Values were normalised using 5S 
rRNA as a control gene.  
Next, the siRNA concentration was increased to 100 nM in the NHEK cell strain in an 
attempt to improve knockdown efficacy. Although SIRT1 further decreased [35% → 
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18%; Figure v] with the increase in siRNA concentration, suppression of p53 only 
improved by 10% at 100 nM siRNA [39% → 29%; Figure v].  
Figure xi Transient knockdown of SIRT1 and p53 with 100 nM siRNA targeting pools in primary 
human keratinocytes 
Primary human keratinocytes (NHEK) were transfected with 50 or 100 nM of SIRT1 or p53 siRNA 
oligonucleotide pools. SIRT1 mRNA and p53 mRNA expression was measured by RT-PCR after 48 hrs, 
and SIRT1 or p53 ablation was analysed relative to transfection with equal concentrations of a non-
targeting oligonucleotide pool. Values were normalised using 5S rRNA as a control gene.  
For our study, Lipofectamine2000 (Invitrogen, Life Technologies) was initially used 
as an siRNA delivery system; however NHEKs transfected using Lipofectamine2000 
demonstrated morphological changes consistent with an increase in toxicity. Based 
on this observation, an alternative cationic delivery system, RNAiMAX (Invitrogen, 
Life Technologies), was used to decrease the risk of stress-induced off-target 
interference in NHEK cells. RNAiMAX reduced toxicity during transfection and 
improved siRNA delivery, enabling transfection with 10 nM siRNA and achieving a 
percentage reduction in target gene expression which was comparable to that 
achieved with 100 nM siRNA using Lipofectamine2000 as a delivery system. 
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TARGET SITE MASKING BY LNA-MODIFIED OLIGONUCLEOTIDES 
Overexpression vectors (either plasmid or viral) are classically used to manipulate 
gene expression by increasing copy number. However insertion of these vectors 
into a proliferating cell line is fraught with similar issues as for RNAi – i.e. off-target 
expression changes, toxicity, and inconsistent stability. Considering the sensitivity 
of NHEKs to transfection during knockdown experiments, alternative approaches 
for up-regulating gene expression were adopted.  
Figure xii Titration of delivery dose for effective miR-34a:SIRT1 target site masking 
Primary human keratinocytes (NHEK) were transfected with 10 nM, 25 nM or 50 nM of a directed 
miR-34a:SIRT1 target site blocking (TSB) or mismatched control (MM Control) LNA-modified 
oligonucleotide pool. SIRT1 mRNA, was measured by qRT-PCR, and the effect of target site masking 
analysed relative to the mismatched control treatment. Values were normalised using 5S rRNA as a 
control gene. Results were analysed by paired t test; with * (p<0.05; n=3). 
SIRT1 expression is modulated by a suite of posttranscriptional and 
posttranslational regulatory mechanisms, including those directed by non-coding 
RNAs. The consensus opinion is that miR-34a binding to the SIRT1 3′UTR promotes 
mRNA degradation and blocks protein translation (479). In addition to SIRT1, miR-
34a regulates numerous targets within the cell. Although others have used siRNA-
based techniques to investigate miR-34a-mediated gene regulation, miR-34a 
inhibitors potentially impact numerous cellular processes and therefore this 
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technique is non-specific from a mechanistic point of view. With this in mind, we 
designed oligonucleotides to competitively inhibit the SIRT1 mRNA binding site 
targeted by miR-34a. This approach allowed us to determine the role of the 
SIRT1/miR-34a regulatory axis during genotoxic stress in a more specific manner. 
The efficacy of miR-34a:SIRT1 target site masking was confirmed by assaying SIRT1 
expression following introduction of the miR-34a:SIRT1 target site blocking 
oligonucleotides. During a 48 hour treatment period, effective miR-34a:SIRT1 
binding site masking was achieved with 50 nM of LNA-modified oligonucleotides 
[Figure vi]. This concentration was chosen for use in future experiments, and a total 
exposure time of 72 hours was used to enable detection of accumulated SIRT1 
protein in NHEK cells. 
IMMUNOPRECIPITATION 
To perform these experiments, two methodologies were used – first, 
immunocomplexes were captured using SIRT1 antibodies, prior to western blotting 
with p53-targeting antibodies; and alternatively, p53 antibodies were used for 
immunoprecipitation, with associated SIRT1 in the precipitate detected by 
immunoblotting. Both approaches were used to ensure that results were not 
affected by differences in antibody-antigen binding kinetics between the p53 and 
SIRT1 antibodies used for the experiment. Initially, immunoprecipitation was 
successful using a SIRT1 antibody [#2496, Cell Signalling Technology], however a 
p53 antibody solution [sc-98, Santa Cruz Biotechnology] failed to capture p53:SIRT1 
immunocomplexes [Figure vii]. In later experiments, an alternative p53 antibody 
[#9282, Cell Signalling Technology] was used for antigen capture, and associations 
between p53 and SIRT1 detected by Western blotting with the anti-SIRT1 antibody. 
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Figure xiii Optimisation of immunoprecipitation methodology 
 ANALYSIS OF CpG METHYLATION  
To test whether arsenic treatment influences DNA methylation patterns, 5  105 
cells were harvested after 10 weeks of arsenic exposure, washed in PBS and the 
DNA prepared for methylation analysis with a Cells-to-CpG Bisulfite Conversion Kit 
(Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s 
instructions. 
 
High Resolution Melt Curve Analysis 
Genomic DNA from treated cells was amplified with MeltDoctor high resolution 
melt (HRM) reagents (Applied Biosystems, Foster City, CA, USA) using cycling 
conditions optimized for each individual primer set used, and then subjected to 
melt curve analysis. Methylation standards were included in each experiment and 
bisulfite converted gDNA from an immortal human keratinocyte cell line grown in 
EpiLife (HaCaT) was included for comparison. Melt curve data was analysed using 
High Resolution Melt Software v3.0 (Applied Biosystems, Foster City, CA, USA).  
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HRM analysis represents an average of methylation information across the 
amplified region, and so results should be interpreted as such. Additionally, data 
are shown as a range of values rather than an absolute figure as these are 
generated from pooled sample populations. Difference plots were analysed by 
comparing percentage methylation relative to melt curve standards across each 
target region, and this information was used to predict the outcome of sequencing 
analysis. Here CpG methylation in the SIRT1 promoter progressively increased, 
whilst pri-miR-34a promoter methylation decreased with arsenic treatment [Figure 
viii]. 
Figure xiv  Melt Curve Analysis – 10 week (70 day) treatments 
Bisulfite-converted DNA from arsenic-exposed keratinocytes was amplified using SIRT1 and pri-miR-
34a bisulfite primers and high resolution melting performed with MeltDoctor HRM Reagents. Melt 
curves were analysed using High Resolution Melt Software v3.0 (Applied Biosystems, Foster City, CA, 
USA). Difference plots are represented by week (1-10).  
Control samples are represented in black, and As(III) treated samples are red. Curves generated from 
methylated and unmethylated control DNA are included for reference. 
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Analysis of Partial Methylation 
The DNA sequences of bisulfite converted samples were assayed after PCR 
amplification by Sanger sequencing using an ABI Prism 310 Genetic Analyser.  As 
these samples were obtained from heterogeneous cell populations rather than 
from individual clones, the signal trace represented a mixture of methylation states 
at each CpG locus. The ratio of mixed bases [methylated:non-methylated cytosines] 
on sequencing traces was analysed using the schematic in Figure ix.  
Figure xv Assessment of partial methylation in heterogeneous populations  
Schematic demonstrating sequencing traces obtained from populations with heterogeneous 
methylation states at CpG loci. Blue chromatogram trace represents the signal measured from 
cytosine bases, red trace represents thymine bases 
The effect of arsenic on CpG methylation in the treated population was represented 
graphically using the CLC Main Workbench application (Version 6.7.1). [Figure x; 
Figure xi]. These histograms were used to confirm the methylation output from BiQ 
Analysis of the derived sequences. Note – the data produced by BiQ analysis 
represents either non-methylation or full methylation of CpG loci. For 
homogeneous sequencing data derived from cloned samples, the cytosine of each 
locus is either 0% or 100% methylated, however the CpG loci of heterogeneous 
samples analysed here have been assigned methylation status based on <50% 
(unmethylated) or >50% (methylated) methylation of the cytosine signal. 
At the SIRT1 promoter, methylation increased for loci c, d, e, i & j; and decreased at 
locus h in arsenic-exposed keratinocytes. Moreover, specific loci (d, e, f) responded 
247 | 
Supplementary Material 
to arsenic exposure in a duration-dependent manner, however loci i & j were 
consistently methylated by arsenic treatment [Figure x]. 
Figure xvi Percentage methylation of SIRT1 promoter CpG loci in vehicle and arsenic-exposed 
keratinocytes 
Normal human keratinocytes were cultured in media containing 0.5 µM As(III) for a period of 10 
weeks. Genomic DNA was extracted at weeks 1, 5, 9 & 10 for bisulfite conversion and sequencing of 
SIRT1 PCR fragments. The sequencing trace was assessed for percentage methylation of each CpG 
dinucleotide (a-j) and represented histogrammatically.  
Methylation analysis at the miR-34a promoter was more complicated, as the 
sequence was particularly unstable during bisulfite conversion. Consequently, our 
analysis of cytosine methylation was not conclusive for all samples, and so paired 
results are presented for weeks 5, 9 & 10 only [Figure xi]. Overall, arsenic-treated 
samples had a lower percent methylation at miR-34a promoter CpG dinucleotides 
than their passage-matched controls. 
Analysis of the sequencing traces correlated with BiQ analysis of the raw data 
presented in Chapter 7. 
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Figure xvii Percentage methylation of miR-34a promoter CpG loci in vehicle and arsenic-exposed 
keratinocytes 
Normal human keratinocytes were cultured in keratinocyte growth media (Vehicle) or media 
containing arsenic (0.5 µM As(III)) for a period of 10 weeks. Genomic DNA was extracted at weeks 5, 
9 & 10 for bisulfite conversion and sequencing of pri-miR-34a PCR fragments. The sequencing trace 
was assessed for percentage methylation of each CpG dinucleotide (a-j) and represented 
histogrammatically. 
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MICROCOCCAL NUCLEASE DIGEST 
Micrococcal nuclease is a non-specific endonuclease that preferentially cleaves 
internucleosomal regions of DNA, limiting PCR amplification of digested templates 
by nucleosome-spanning primers. The principle of the micrococcal nuclease 
(MNase) assay is that silent ‘closed’ heterochromatin is more compacted than 
‘open’ euchromatin, and thus a ≥10-fold differences in enzyme activity is required 
to cleave a specific genomic sequence to the same extent (669). These differences 
in MNase accessibility can be used to assay chromosomal structure by PCR 
amplification of a target region.  
Figure xviii Optimisation of MNase Digestion Temperature 
Nuclei were isolated from NHEK cells and incubated with micrococcal nuclease at 37°C or 22°C for 
increasing digestion times. DNA was extracted according to the ChART protocol outlined in Chapter 
2, and equal concentrations were amplified for 40 PCR cycles using pri-miR-34a ChART primers. PCR 
product was run on 2% agarose gel and visualised with SYBR Safe DNA stain. 
250 | 
Supplementary Material 
 
 
To discriminate between loose and compact chromatin states, MNase activity was 
limited to enhance the assay’s specificity, and it was therefore necessary to 
empirically determine the appropriate MNase reaction conditions necessary to 
differentially analyse chromatin structure over the genomic locus of interest. This 
was achieved by using short incubation times and suboptimal reaction 
temperatures. Micrococcal nuclease activity is optimal at 37°C and DNA cutting 
most efficient with an incubation time of 20 min. By reducing reaction temperature 
to 22°C (room temperature) MNase activity was limited, allowing PCR product to be 
amplified with a digestion time of 2.5 min [Figure xii].  
Although cleavage was limited for the miR-34a target at the lower temperature, 
this result was only evident at the minimal digestion time used in the experiment. 
Next, the ability of MNase digestion to discriminate between chromatin 
condensation states of different genes was assessed by comparison with the 
amplification profile of the control gene (Rhodopsin), which was assumed to be 
inactive (and therefore condensed) in keratinocytes.  
 
Figure xix Optimisation of MNase Incubation Time 
Nuclei were isolated from NHEK cells and incubated with micrococcal nuclease at 22°C for increasing 
digestion times. DNA was extracted according to the ChART protocol outlined in Chapter 2, and 
equal concentrations were amplified for 40 PCR cycles using ChART primers targeting Rhodopsin. 
PCR product was run on 2% agarose gel and visualised with SYBR Safe DNA stain. 
251 |  
 
Supplementary Material 
 
 
Using the previously outlined incubation conditions, a drop-off in PCR product after 
end-point amplification demonstrates that MNase digestion has increased in a 
time-dependent manner [Figure xiii], with the target region completely cleaved 
after 10 minutes of enzyme activity at 22°C. When compared with results obtained 
for the miR-34a target region, which was completely cleaved after 5 min [Figure xii], 
it appears that Rhodopsin is more MNase resistant than the pri-miR-34a promoter 
region. These results indicate that the chromatin containing the region of DNA 
amplified by the Rhodopsin primers is more compacted (and less MNase-accessible) 
than the corresponding chromatin/DNA amplified by pri-miR-34a-targeting primers. 
From these data, 5 minutes of MNase digestion at 22°C proved optimal for 
differential detection of variability in chromatin structure in this study. 
 SAMPLE PREPARATION FOR ChIP 
Sample Preclearing 
Unlike protocols for immunoprecipitation with agarose beads, when using magnetic 
beads for immunoprecipitation, sample preclearing is not required and blocking the 
beads with salmon sperm DNA is not recommended (according to manufacturers’ 
protocols). Sodium butyrate is a general histone deacetylase inhibitor and is 
included in buffer solutions used for analysis of histone posttranslational 
modifications (670, 671). When samples were processed with 5 µM sodium 
butyrate in lysis buffer solutions, the isotype/IgG control templates amplified more 
strongly than the 5% input templates [Figure xiv]. 
Sodium butyrate appears to enhance binding of free DNA to the magnetic beads 
when included in buffer solutions. Background was reduced by preclearing these 
samples in the same volume of magnetic beads, however this was only partially 
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effective [Figure xiv]. Consequently, sodium butyrate was removed from lysis 
buffers to prevent background DNA from sticking to the beads. 
Figure xx Sample preclearing decreases ChIP background signal 
Crosslinked chromatin was prepared from NHEK cells isolated in buffer solutions containing 5µM 
sodium butyrate. Samples were precleared by incubation with Protein G Magnetic beads for 1 hr at 
4°C on a roller, and then incubated in IgG-bound Protein G Magnetic beads overnight at 4°C on a 
roller. Captured DNA was extracted according to the ChIP protocol outlined in Chapter 2, and 
amplified with SIRT1 and pri-miR-34a targeting primer sets for 40 PCR cycles. Equal volumes of PCR 
product were run on 2% agarose gel and visualised with SYBR Safe DNA stain. 
Input (5%) and non-cleared, IgG-incubated sample DNA was amplified for comparison. 
Analysis of Results 
To ensure that the experimental results were consistent and representative of 
arsenic-induced effects, each ChIP experiment was controlled by the following 
methods: 
• An isotype matched immunoglobulin (Ig) was used as a non-targeting
immunoprecipitation control in all experiments.
• Anti-Histone H3 ChIP was used as a positive control for enrichment [Figure
xv]
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• A non-template control was included in each PCR reaction
• RPL30 (Ribosomal Protein L30, Exon 3) was used as a constitutive gene
control. It is assumed that occupancy at the RPL30 locus is invariant
between treated samples.
• Positive (region of the gene target containing suspected locus of interest)
and negative (region of the gene target distant to locus of interest) control
loci were targeted for amplification by RT-PCR. The 3′UTR was the negative
control locus for SIRT1, and for pri-miR-34a, a region of the gene upstream
from the CpG island was used.
Figure xxi ChIP enrichment with H3(Total) antibody 
Crosslinked chromatin was prepared from NHEK cells and incubated in H3 antibody-bound Protein G 
Magnetic beads overnight at 4°C on a roller. Captured DNA was extracted according to the ChIP 
protocol outlined in Chapter 2, and amplified with TP53 and pri-miR-34a targeting primer sets for 40 
PCR cycles. Equal volumes of PCR product were run on 2% agarose gel and visualised with SYBR Safe 
DNA stain. Input (2%) and IgG-incubated sample DNA was amplified for comparison. 
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Amplification of the captured target ChIP at the non-targeting negative control 
locus was not substantially different from amplification by sample incubated with 
isotype control IgG [Figure xvi(a)], and the positive control primer set amplified the 
ChIP target sample more strongly relative to the total input samples than the 
negative control primer set [Figure xvi(b)]. This represented the occupancy at target 
promoters for the ChIP sample. 
Figure xxii Gene Target Controls for ChIP 
PCR amplification traces from As(III)-treated NHEK samples following incubation with p53 antibody-
bound Protein G Magnetic beads. Panel a: Negative control gene locus (pri-miR-34a); Panel b: 
Positive control gene locus (pri-miR-34a). 
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Endpoint ChIP-PCR 
Endpoint ChIP-PCR was performed to verify the ability of quantitative ChIP-PCR to 
differentiate between arsenic-treated samples. Equal template volumes from 
Vehicle, As(III)-treated, IgG isotype control, and 5% Input DNA were amplified for 40 
PCR cycles using Pri-miR-34a and SIRT1 ChIP primers according to the protocol 
outlined in Chapter 2 and PCR products were visualised by agarose gel 
electrophoresis. 
Figure xxiii Endpoint PCR in Arsenic-Treated Keratinocytes 
ChIP was performed on crosslinked chromatin from As(III)-treated NHEK samples using Histone H4 
acetyl K16 antibody-bound Protein G Magnetic beads. Samples were amplified for 40 cycles using 
SIRT1 and pri-miR-34a ChIP-PCR primers, and 8 µl PCR product was separated on 2% agarose 
electrophoresis gels and bands visualised by SYBR Safe staining. 
Here, visualised endpoint PCR products correlated with results calculated by 
quantitative PCR [Figure xvii].
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Publication Abstracts 
Herbert, K. J., Snow, E. T., 2012, Modulation of arsenic-induced epidermal growth 
factor receptor pathway signalling by resveratrol, Chem Biol Interact 198 (38-48) 
Arsenic (As) is both a human carcinogen and an effective anticancer drug. These 
aspects of arsenic toxicity develop as a consequence of arsenic-induced oxidative 
stress and modifications to signal pathway activity which alter gene expression. 
Resveratrol (RVL) a food antioxidant found in grapes and other fruits, exhibits anti-
carcinogenic properties by reducing oxidative stress and restoring signal pathway 
control. This study investigated the impact of RVL on arsenite [As(III)]-induced cell 
signalling in HaCaT keratinocytes by assaying phosphorylation status of epidermal 
growth factor receptor (EGFR) signalling intermediates and measuring changes in 
expression of Phase II and DNA repair biomarkers. 
As(III) exposure produced dose-dependent toxicity which was associated with 
increased activation of EGFR pathway intermediates, cSrc, Rac1 and extracellular 
signal-regulated kinases 1 & 2 (ERK1/2). Arsenic-mediated ERK1/2 activation 
negatively regulated DNA polymerase beta expression and up regulated heme-
oxygenase-1 at toxic concentrations. RVL treatment modulated As(III)-mediated 
ERK1/2 activation by shifting the balance of cSrc regulatory domain 
phosphorylation. These effects significantly altered the response of the EGFR 
pathway to growth factor-induced stimulation.  
Our research provides evidence that treatment with pharmacologically relevant 
doses of RVL influences cellular responses to As(III), largely due to RVL-mediated 
changes to Src and ERK1/2 activation. 
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Defects in p53-Mutated Human Keratinocytes, J Dermatol Sci, 74(2): 142-149. 
[Impact Factor: 3.520] 
 
Background: Together with p53, the NAD-dependent lysine deacetylase SIRT1 and 
the microRNA miR-34a form a feedback loop which self-regulates SIRT1 expression 
and modulates p53-dependent responses. In addition to its well-described role in 
mediating transcriptional responses to genotoxic stress, p53 may also regulate 
microRNA processing and maturation. Objective: This study explored the functional 
relationship between p53, SIRT1 and miR-34a, and the influence of p53 and SIRT1 
on microRNA biogenesis and maturation in primary (NHEK) and p53-mutated 
(HaCaT) keratinocyte cell lines.  
Methods: RNAi, miRNA target site blocking oligonucleotides and small molecule 
inhibitors were used to modulate activity and expression of SIRT1 and p53. Changes 
in microRNA and mRNA were analysed by qRT-PCR and protein expression was 
determined by immunoblotting.  
Results: Mature miR-34a decreased in p53-suppressed NHEK cells, whereas ablation 
of SIRT1 reduced the primary transcript (pri-miR-34a). When either SIRT1 
expression or activity was inhibited in combination with p53 ablation, pri-miR-34a 
levels increased and mature miR-34a levels decreased. Under these same 
conditions, additional p53-regulated microRNAs (miRs 16-1/15, 145 and 107) also 
failed to mature. In HaCaT cells, primary microRNA transcripts for miR-16-1/15, 
miR-145 miR200c/141 and miRNA-107, but not miR-34a, were approximately 8-fold 
higher than in NHEK cells. However, the levels of mature microRNA sequences in 
HaCaT cells were only 1.5-2 fold higher (miR-16-1, miR-145), unchanged (miR-107) 
or decreased (miR-200c/141, miR-34a) compared to NHEK cells.  
Conclusions: Our results suggest that p53 mutations interfere with efficient 
microRNA biogenesis in keratinocytes, and that SIRT1 functions in combination with 
p53 in this process.  
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Herbert, K. J., Cook, A. L., Snow, E. T., 2014, SIRT1 Inhibition Restores Apoptotic 
Sensitivity in p53-Mutated Human Keratinocytes, Toxicol Appl Pharmacol, (in press, 
available online: 12 April 2014) [Impact Factor: TAAP = 3.975] 
Mutations to the p53 gene are common in UV-exposed keratinocytes and 
contribute to apoptotic resistance in skin cancer. P53-dependent activity is 
modulated, in part, by a complex, self-limiting feedback loop imposed by miR-34a-
mediated regulation of the lysine deacetylase, SIRT1. Expression of numerous 
microRNAs is dysregulated in squamous and basal cell carcinomas; however the 
contribution of specific microRNAs to the pathogenesis of skin cancer remains 
untested. Through use of RNAi, miRNA target site blocking oligonucleotides and 
small molecule inhibitors, this study explored the influence of p53 mutational 
status, SIRT1 activity and miR-34a levels on apoptotic sensitivity in primary (NHEK) 
and p53-mutated (HaCaT) keratinocyte cell lines. SIRT1 and p53 are overexpressed 
in p53-mutated keratinocytes, whilst miR-34a levels are 90% less in HaCaT cells. 
HaCaTs have impaired responses to p53/SIRT1/miR-34a axis manipulation which 
enhanced survival during exposure to the chemotherapeutic agent, camptothecin. 
Inhibition of SIRT1 activity in this cell line increased p53 acetylation and doubled 
camptothecin-induced cell death. Our results demonstrate that p53 mutations 
increase apoptotic resistance in keratinocytes by interfering with miR-34a-mediated 
regulation of SIRT1 expression. Thus, SIRT1 inhibitors may have therapeutic 
potential for overcoming apoptotic resistance during skin cancer treatment. 
Herbert, K. J., Holloway, A. F., Cook, A. L., Chin, S. P., Snow, E. T., 2014, Arsenic 
Exposure Disrupts Epigenetic Regulation of SIRT1 in Human Keratinocytes, 
(Manuscript in Preparation) 
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Herbert K. J., Snow E. T., Modulation of Arsenic-Induced Toxicity by Resveratrol; AH 
& MRC Congress, Melbourne 2010 
Inorganic arsenic (As) is a human carcinogen; yet arsenic trioxide [As(III)] is also an 
effective anticancer drug with particular efficacy against acute promyelocytic 
leukemia. Evidence suggests induction of oxidative stress, disruption of redox 
homeostasis and activation of signal transduction pathways are responsible for 
arsenic toxicity and its anticancer activity. Resveratrol (RVL), a polyphenol found in 
red wine, has anti-carcinogenic properties that may provide chemotherapeutic 
benefits by reducing oxidative stress and restoring signal pathway control. This 
study investigated the impact of RVL on As(III)-induced toxicity by assaying 
activation of extracellular signal-regulated kinase (ERK1/2) signaling intermediates 
cSrc and Rac1; and by measuring mRNA and protein expression for heme-
oxygenase-1 (HO-1) and DNA polymerase beta (Polβ) in cultured HaCaT 
keratinocytes. Twenty hours of As(III) exposure produced dose-dependent toxicity 
which was associated with increased activation of ERK1/2 and its intermediates. 
Upstream from ERK1/2, RVL treatment modulated As(III)-mediated ERK 
pathway control by shifting the balance of cSrc regulatory domain phosphorylation, 
but did not significantly influence Rac1 activation. Arsenic-mediated ERK pathway 
activation negatively regulated Polβ mRNA expression and increased expression of 
HO-1, a Phase II xenobiotic response gene, at toxic concentrations. ERK1/2 
inhibition increased mRNA levels for both HO-1 and Polβ, while low doses of As(III) 
significantly enhanced Polβ protein expression when ERK1/2 was inhibited. Our 
research indicates that pretreatment with pharmacologically relevant doses of RVL 
induces changes to Src and ERK pathway interactions in the presence of arsenic. 
This study supports growing evidence of RVL's properties as an anti-transforming 
agent by demonstrating its ability to influence cellular growth and survival 
responses to As(III)-induced toxicity.  
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Human Keratinocytes; AH & MRC Congress, Adelaide 2012 
SIRT1 is an NAD-dependent deacetylase which influences the outcome of cellular 
stress by regulating histone-mediated chromatin remodelling and the p53-
dependent DNA damage response. As such, SIRT1 modulates key signalling 
pathways which influence carcinogenesis. SIRT1 expression is regulated by p53 
activity at the transcriptional level, and by the microRNA miR-34a at the 
translational level. Together SIRT1, p53 and miR-34a form a feedback loop which 
self-regulates p53 activation.The tumour suppressor p53 is mutated in >60% of all 
cancers, including those affecting the skin. Thus the development of 
pharmaceutical agents which differentially target cells on the basis of p53 
mutational status is of interest in the prevention and treatment of skin cancer. In 
this study, we used primary keratinocytes (neonatal human epidermal 
keratinocytes - NHEKs) and p53-mutated keratinocytes (HaCaTs) cultured in 
identical serum-free conditions to investigate the relationship between p53 
mutational status, SIRT1 activity and miR-34a processing in human keratinocytes.  
Expression of miR-34a was up-regulated by transient ablation of SIRT1 in NHEKs; 
but was suppressed by dual knockdown of SIRT1 and p53. In contrast, SIRT1 
knockdown reduced miR-34a in HaCaTs keratinocytes whilst concomitantly up-
regulating expression of its precursor transcript. This discrepancy between mature 
and precursor transcript levels was also observed after pharmaceutical SIRT1 
inhibition in both p53-ablated and HaCaT keratinocytes. Additionally, differences in 
the level of p53 expression and acetylation observed between the NHEK and HaCaT 
cell lines was partially restored by inhibiting SIRT1 in the p53-mutated cell line. 
Our results indicate that p53 haploinsufficiency impairs regulatory control of the 
SIRT1-miR-34a axis. SIRT1 inhibitors enable keratinocytes with p53 mutations to 
regulate p53 expression and relative acetylation and may therefore have 
therapeutic potential for the treatment and prevention of skin cancer.
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Herbert K. J., Cook, A.L., Snow E. T., SIRT1 Inhibition Promotes Apoptotic Sensitivity 
in p53-Mutated Keratinocytes; Breakfast SIG (Epigenetic Drugs and Toxicity), 44th 
EMGS Annual Meeting 2013, Sept 21rd-25th, Monterey – CA 
Mutations to the p53 gene are common in UV-exposed keratinocytes and 
contribute to apoptotic resistance in skin cancer. Together with p53, SIRT1 and miR-
34a form a feedback loop which self-regulates SIRT1 and modulates p53-dependent 
apoptosis. Through use of RNAi, miRNA target site blocking oligonucleotides and 
small molecular inhibitors, we explored the influence of p53 status, SIRT1 activity 
and miR-34a levels on apoptotic sensitivity in primary (NHEK) and p53-mutated 
(HaCaT) keratinocyte cell lines. This study found that mutations to p53 impair 
SIRT1/miR-34a feedback responses in keratinocytes by interfering with miR-34a 
biogenesis. When compared with NHEKs, HaCaTs had 4-fold higher SIRT1 and p53 
protein expression, and 80% lower miR-34a. Inhibition of SIRT1 with EX-527 
induced miR-34a expression in NHEKs; however in HaCaTs, the primary transcript, 
but not mature miR-34a was up-regulated by EX-527. Additionally, EX-527 
treatment caused SIRT1 protein to accumulate in HaCaTs, increasing relative p53 
acetylation. This result mirrored the effect of a targeted miR-34a-binding site block 
to the SIRT1 3′UTR in NHEKs, which induced the miR-34a primary transcript and 
increased SIRT1 expression. 
Here we provide mechanistic data which demonstrates that miR-34a-mediated 
control of SIRT1 expression regulates apoptotic sensitivity in a p53-dependent 
manner. When compared to NHEKs, HaCaTs were resistant to camptothecin-
induced apoptosis, however apoptotic sensitivity was restored by inhibiting SIRT1 in 
the p53-mutated cell line. These results indicate that using SIRT1 inhibition to 
overcome chemotherapeutic resistance in p53-mutated keratinocytes is an 
attractive adjuvant strategy for skin cancer treatment.  
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Human Keratinocytes; 6th AOCP Conference/MEPSA Annual Scientific Meeting, 
November 10rd-14th, Sydney 2013 
 
Arsenic is an environmental toxin which increases skin cancer risk for exposed 
populations worldwide, however the biomolecular mechanism remains unclear. 
Recent investigations show that histone deacetylase and DNA methyltransferase 
activity is altered by arsenic exposure and this appears to promote cellular 
transformation. Expression of the lysine deacetylase SIRT1 is altered in solid 
tumours and haematological malignancy; however its role in arsenic-induced 
pathology is unknown. In this study we investigated the effect of arsenic on 
epigenetic regulation of SIRT1 and its targeting microRNA, miR-34a in human 
keratinocytes exposed to arsenic continuously for 10 weeks.  
In whole cell lysates, acetylation of the permissive mark, histone H4 at lysine 16 
(H4K16), increased over the initial 12 days’ exposure to arsenic. Arsenic increased 
H4K16 acetylation for the SIRT1 gene promoter and decreased H4K16 acetylation at 
the miR-34a promoter. Moreover, although SIRT1 expression was induced by 
arsenic within the first 24 hrs, after 24 days SIRT1 protein was not significantly 
different in arsenic-exposed cells. With extended treatment (> 5 weeks) these cells 
showed altered sensitivity to induction by arsenic, with significant shifts in DNA 
methylation of the SIRT1 and miR-34a promoters associated with altered 
expression patterns for both genes. We have found that arsenic exposure generates 
complex temporal effects on the cellular epigenetic machinery in keratinocytes. 
Arsenic appears to alter regulation of SIRT1 expression via chromatin-mediated 
modulation of SIRT1 and miR-34a p53 promoter binding in the initial 24 hours and 
through shifts in promoter DNA methylation with extended exposure times.  
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Herbert K. J., Modeling Epigenetic Factors in Disease – A Case for Arsenic Toxicity; 
AH & MRC Congress, Melbourne 2010 
Epigenetics is an emerging field in the study of disease etiology. Chronic diseases 
are strongly associated with extensive epigenetic reprogramming, with many 
exhibiting specific histone and DNA methylation patterns, chromatin condensation 
and microRNA profiles. Epigenetic modification is thought to be stimulated by self-
maintenance and repair responses which promote cellular adaptation and 
protection in conditions of environmental stress. Unlike mutagenic change, 
epigenetic remodeling is potentially reversible. However, loss of primary imprinting 
and induction of secondary imprinting during sustained exposure to epigenetic 
modifiers is heritable in clonal cell lines. Thus, the window of opportunity for 
therapeutically reestablishing basal epigenetic profiles appears to be limited. 
Long-term arsenic exposure produces aberrant gene expression which is associated 
with global genomewide hypomethylation and focal CpG hypermethylation. 
Additionally, arsenic treatment alters the activity and expression of numerous 
proteins which are vital for epigenetic remodeling. Arsenic itself is not a direct 
mutagen, however destabilization of genomic fidelity as a result of epigenetic 
modifications may account for arsenic-induced pathogenic changes.  
Many questions about the origins and development of disease remain to be 
answered. Unfortunately, disease-related phenotypic changes are measureable 
only after their ‘silent’ genotypic onset has occurred. By monitoring arsenic-induced 
epigenetic changes as they manifest, we gain insights into the modality of 
environmental stress-induced adaptive mechanisms and how they progress to 
pathogenic responses over time.  
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Cultured Human Keratinocyte Cell Lines; MEPSA Scientific Meeting, Brisbane 2011. 
In healthy cells the tumour suppressor protein p53 coordinates cellular responses 
to genotoxic damage, and as such is considered to be the ‘guardian of the genome’. 
Consequently, functional alterations to the p53 gene and its expressional profile are 
common features in the etiology of cancer. The role of SIRT1 as a cellular stress 
response protein has recently gained interest due to its association with disease 
prevention and control of organismal ageing. Although its mode of action is 
incompletely understood, SIRT1 is thought to influence cellular growth and survival 
by modulating p53 activity. SIRT1:p53 axis responses were characterised by 
comparing p53 acetylation, relative gene expression, and cellular metabolic activity 
in wild-type and p53-mutated human keratinocyte cell lines.Basal p53 and SIRT1 
expression was elevated in p53-mutated (p53m1/m2) when compared to wild-type 
(p53+/+) keratinocytes. SIRT1 inhibition increased relative p53 acetylation 3-fold for 
both cell lines, and decreased relative association of SIRT1 with p53 by a factor of 
10. Overnight SIRT1 inhibition down-regulated p53 and SIRT1 transcription in
p53m1/m2 and increased relative premiR-34a. However, although SIRT1 inhibition 
induced p53 and SIRT1 transcription in p53+/+, p53 protein was significantly 
reduced, indicating increased protein cycling. PARP1 expression increased, and 
relative PARP1 cleavage decreased for both cell lines, although the effect of SIRT1 
inhibition was more pronounced for cells with mutated p53. Additionally, SIRT1 
inhibition decreased metabolic activity in p53m1/m2 keratinocytes, restricting cellular 
growth and proliferation in the mutated cell line.This study provides evidence that 
SIRT1 contributes to the DNA damage response by modulating p53-regulated gene 
expression. SIRT1 negatively regulates p53 activity in normally functioning 
keratinocytes; however p53 mutations influence the nature of gene expression, 
metabolic activity and SIRT1-mediated stress responses. Taken together, these 
results demonstrate the impact of p53 haploinsufficiency on the SIRT1:p53 axis in 
human skin cells. 
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Cultured Human Keratinocyte Cell Lines; UTAS Graduate Research Conference, 
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In healthy cells the tumour suppressor protein p53 coordinates cellular responses 
to genotoxic damage, and as such is considered to be the ‘guardian of the genome’. 
Consequently, functional alterations to the p53 gene and its expressional profile are 
common features in the etiology of cancer. The role of SIRT1 as a cellular stress 
response protein has recently gained interest due to its association with disease 
prevention and control of organismal ageing. Although its mode of action is 
incompletely understood, SIRT1 is thought to influence cellular growth and survival 
by modulating p53 activity.  
The SIRT1:p53 axis in cultured keratinocytes was characterised by assaying p53 
acetylation, relative gene expression, and cellular metabolic activity. Overnight 
SIRT1 inhibition increased relative p53 acetylation, however downstream responses 
differed in p53-mutated (HaCaT) and wild-type (NHEK) keratinocyte cell lines. P53 
and SIRT1 protein expression was down-regulated in SIRT1-inhibited NHEKs; whilst 
relative cellular p53 and SIRT1 mRNA levels remained steady. Paradoxically, p53 
and SIRT1 mRNA levels were significantly reduced in HaCaTs, but protein expression 
was unchanged by SIRT1 inhibition. Cellular growth and proliferation was also 
influenced by p53 status, with NHEKs showing a relative increase, and HaCaTs 
showing a relative decrease in metabolic activity with SIRT1 inhibition. 
This study provides evidence that SIRT1 contributes to the DNA damage response 
by modulating p53-regulated gene expression. SIRT1 negatively regulates p53 
activity in normally functioning keratinocytes; however SIRT1-mediated responses 
differ in p53-mutated keratinocytes, which produce altered gene expression, 
metabolic activity and regulatory responses with SIRT1 inhibition. Taken together, 
these results demonstrate the critical nature of cellular p53 status in the outcome 
of SIRT1:p53 axis responses in human skin cells.  
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Herbert K. J., Cook, A.L., Snow E. T., SIRT1 Inhibition Promotes Apoptotic Sensitivity 
in p53-Mutated Keratinocytes; 44th EMGS Annual Meeting 2013, Sept 21rd-25th, 
Monterey – CA 
Mutations to the p53 gene are common in UV-exposed keratinocytes and 
contribute to apoptotic resistance in skin cancer. Together with p53, SIRT1 and miR-
34a form a feedback loop which self-regulates SIRT1 and modulates p53-dependent 
apoptosis. Through use of RNAi, miRNA target site blocking oligonucleotides and 
small molecular inhibitors, we explored the influence of p53 status, SIRT1 activity 
and miR-34a levels on apoptotic sensitivity in primary (NHEK) and p53-mutated 
(HaCaT) keratinocyte cell lines. This study found that mutations to p53 impair 
SIRT1/miR-34a feedback responses in keratinocytes by interfering with miR-34a 
biogenesis. When compared with NHEKs, HaCaTs had 4-fold higher SIRT1 and p53 
protein expression, and 80% lower miR-34a. Inhibition of SIRT1 with EX-527 
induced miR-34a expression in NHEKs; however in HaCaTs, the primary transcript, 
but not mature miR-34a was up-regulated by EX-527. Additionally, EX-527 
treatment caused SIRT1 protein to accumulate in HaCaTs, increasing relative p53 
acetylation. This result mirrored the effect of a targeted miR-34a-binding site block 
to the SIRT1 3′UTR in NHEKs, which induced the miR-34a primary transcript and 
increased SIRT1 expression. 
Here we provide mechanistic data which demonstrates that miR-34a-mediated 
control of SIRT1 expression regulates apoptotic sensitivity in a p53-dependent 
manner. When compared to NHEKs, HaCaTs were resistant to camptothecin-
induced apoptosis, however apoptotic sensitivity was restored by inhibiting SIRT1 in 
the p53-mutated cell line. These results indicate that using SIRT1 inhibition to 
overcome chemotherapeutic resistance in p53-mutated keratinocytes is an 
attractive adjuvant strategy for skin cancer treatment.  
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in p53-Mutated Keratinocytes; 11th ICEM 2013, November 3rd-8th, Foz do Iguassu – 
Brazil 
Mutations to the p53 gene are common in UV-exposed keratinocytes and 
contribute to apoptotic resistance in skin cancer. Together with p53, SIRT1 and miR-
34a form a feedback loop which self-regulates SIRT1 and modulates p53-dependent 
apoptosis. Through use of RNAi, miRNA target site blocking oligonucleotides and 
small molecular inhibitors, we explored the influence of p53 status, SIRT1 activity 
and miR-34a levels on apoptotic sensitivity in primary (NHEK) and p53-mutated 
(HaCaT) keratinocyte cell lines. This study found that mutations to p53 impair 
SIRT1/miR-34a feedback responses in keratinocytes by interfering with miR-34a 
biogenesis. When compared with NHEKs, HaCaTs had 4-fold higher SIRT1 and p53 
protein expression, and 80% lower miR-34a. Inhibition of SIRT1 with EX-527 
induced miR-34a expression in NHEKs; however in HaCaTs, the primary transcript, 
but not mature miR-34a was up-regulated by EX-527. Additionally, EX-527 
treatment caused SIRT1 protein to accumulate in HaCaTs, increasing relative p53 
acetylation. This result mirrored the effect of a targeted miR-34a-binding site block 
to the SIRT1 3′UTR in NHEKs, which induced the miR-34a primary transcript and 
increased SIRT1 expression. 
Here we provide mechanistic data which demonstrates that miR-34a-mediated 
control of SIRT1 expression regulates apoptotic sensitivity in a p53-dependent 
manner. When compared to NHEKs, HaCaTs were resistant to camptothecin-
induced apoptosis, however apoptotic sensitivity was restored by inhibiting SIRT1 in 
the p53-mutated cell line. These results indicate that using SIRT1 inhibition to 
overcome chemotherapeutic resistance in p53-mutated keratinocytes is an 
attractive adjuvant strategy for skin cancer treatment.  
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Herbert K. J., Cook, A.L., Snow E. T., Keratinocyte Phenotype is Dictated by Culture 
Medium; 6th AOCP Conference/MEPSA Annual Scientific Meeting, November 10rd-
14th, Sydney 2013 
Growth of cells in culture is an efficient means for analysis and modelling of cellular 
responses in vitro. Findings from these investigations inform animal studies and 
human clinical trials and influence our understanding of disease processes. 
Biological activity is a product of intrinsic cellular potential and the external 
environment, whether the cell exists in vivo or in vitro.  
Extracellular environment directly influences established patterns of epigenetic 
regulation in cultured keratinocytes. In this investigation, we found that histone 
acetylation and microRNA expression were media-dependent. HaCaT keratinocytes 
cultured in a serum-free, low-calcium medium (Epilife®) displayed a less 
differentiated morphology and were more sensitive to genotoxins than those 
grown in undefined (DMEM-F12) media with added serum. In fact, HaCaT cells 
grown in Epilife® medium exhibited a phenotype much more similar to normal 
keratinocytes than those grown in DMEM-F12. Here we show that choice of culture 
media not only affects keratinocyte phenotype, but also directly influences stress 
responses by altering patterns of epigenetic regulation. Therefore growth 
conditions including choice of growth medium should be carefully considered prior 
to conducting any in vitro investigation which utilises keratinocyte cell lines.
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